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ABSTRACT
ELASTIC SCATTERING SPECTROSCOPY IN THE MANAGEMENT OF
BREAST CANCER
Elastic scattering spectroscopy (ESS) is an emerging technology capable of detecting 
malignant changes in tissue using elastic light scattering and light absorption. Pulses 
of broadband light are delivered to and subsequently collected from tissue to provide 
a spectrum. Automated spectral analysis using model based analysis (MBA) is under 
development. Potential clinical applications include ESS guided breast core biopsy, 
intra-operative assessment of SLN and tumour excision margin. This thesis explores 
various technical aspects of ESS and factors concerning spectral analysis in relation to 
the above potential clinical applications.
Chapter 5 studied the effects of ambient lighting, tissue handling (i.e. exposure in 
open laboratory conditions, submersion in saline, chilling in ice) and formaldehyde 
fixation over time on ESS. The effect of ambient light on the ESS spectra is minimal 
at intensities below lOOOlux (i.e. in indoor or laboratory), but becomes significant at 
higher light intensities (i.e. beneath an operating lamp). As for tissue handling and 
formaldehyde fixation, the changes observed in ESS spectra within the first hour 
following excision were related to the changes in oxygenation status of haemoglobin. 
Otherwise, no other changes occurred during this period. However, prolonged 
formaldehyde fixation (beyond 4 hours) resulted in significant changes.
The first part of Chapter 6 investigated the factors influencing the sensitivity and 
specificity of spectral analysis in differentiating ESS spectra of normal and metastatic 
axillary lymph nodes. By improving the correlation between ESS spectra and 
histology, sensitivity and specificity increased to 88-90% and 91-96% respectively 
from the previously reported sensitivity of 57% and specificity of 85%. The second 
part of Chapter 6 is a comparative study of ESS and touch imprint cytology (TIC). 
Based on 89 sentinel lymph nodes, both ESS and TIC identified 6 out of 8 nodes with 
metastasis giving equal sensitivities of 75%. Specificity was 93% for ESS and 100% 
for TIC.
In Chapter 7, a grid system was used to correlate ESS spectra to the precise histology 
with the percentage of malignant replacement in breast tissue. Spectral analyses using 
MBA were performed with different training sets, and showed increasing sensitivity 
to differentiate normal and malignant breast ESS spectra with increases in the 
percentage of malignant breast tissue (specificity 0.74):
Sensitivity 0.56 0.72 0.60 0.90 0.87
In conclusion, ex-vivo ESS spectra are relatively stable and reproducible within 1 
hour of excision irrespective of different tissue handling techniques. Sensitivity and 
specificity of spectral analysis is dependent on accurate correlation between ESS 
spectra and histology, and the amount of replacement by malignant tissues.
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Chapter 1 Diagnosis of Breast Cancer and Recent Advances
1.1 Introduction
In 2002, 1151298 women worldwide were diagnosed with breast cancer accounting 
for 23% of all female cancers excluding non-melanoma skin malignancies1. Over this 
period, 410712 deaths were attributed to breast cancer1. Survival in the western world 
has improved since the early 1990s. This was primarily due to diagnosis at earlier 
stages and better treatment.
A definitive diagnosis of breast cancer requires direct histological evidence of breast 
cancer cells from within the lesion concerned. Historically, excision breast biopsy 
(EBB) has been the diagnostic procedure of choice. However, EBB is not a definitive 
surgical procedure for breast cancer because it does not necessarily achieve complete 
excision margins and it does not provide the axillary lymph node status. Therefore, 
further surgery is required.
The current strategy in the diagnosis of breast cancer is to use non-operative methods. 
The advantage of such methods is to enable clinicians and patients to plan surgical 
management as a single definitive operation. Additional advantages and 
disadvantages are outlined in Table 1.1.
In the United Kingdom, patients with breast cancer present either with symptoms, 
such as a breast lump, to the breast clinic or without symptoms through the National 
Health Service Breast Screening Programme (NHSBSP). In both cases, non-operative
- 14-
diagnosis of breast cancer is based on triple assessment (TA) consisting of clinical 
examination, imaging and pathological evaluations.
Table 1.1: Advantages and disadvantages o f non-operative diagnosis o f  breast
cancer comvared to excision breast biopsy
Diagnosis with simple tests Error in diagnosis may lead to overtreatment or delay in making the correct diagnosis
Cheap compared with EBB Occasional complications
Avoids excision breast biopsy in some cases and 
allows treatment of cancers at a planned operation
Requirement o f skilled personnel with additional 
cost o f training
Performed as an outpatient procedure
Avoidance o f frozen section
Reduction o f patient uncertainty and anxiety
Low complication rate compared with EBB
(Modified from Table 1: Non-operative diagnostic subgroup of the National 
Coordinating Group for Breast Screening Pathology: Guidelines for non-operative 
diagnostic procedures and reporting in breast cancer screening. NHSBSP Publication, 
Sheffield, 20012)
1.2 Triple Assessment
TA is the current diagnostic procedure of choice for breast diseases. For symptomatic 
patients, TA consists of clinical examination followed by mammography and finally 
pathological evaluation. This is to ensure that any vascular injuries and haematomas
- 15-
do not compromise the interpretation of mammography. For asymptomatic patients, 
TA begins with mammography, and proceeds once an abnormality is found.
TA is positive if any one of its 3 components is positive and negative if all 3 
components are negative. In women over the age of 35 years, the diagnostic accuracy 
of TA for breast cancer is over 95%3'6.
1.3 Clinical Examination
Despite advances in imaging technologies, clinical examination plays an important 
role in the diagnosis of breast cancer. It is comprised of a detailed visual inspection 
for skin and nipple changes, asymmetry and dimpling, followed by a systematic 
palpation of the breasts, axillae and supraclavicular fossae for discrete lumps. In 
women presenting with nipple discharge, the subareolar area should be massaged to 
provoke secretion.
The main goal of clinical examination is to identify palpable lesions and to 
differentiate normal physiological nodularity from discrete lumps. The latter require 
mandatory evaluation to exclude breast cancer. Clinical examination requires trained 
staff and is subject to inter-observer variation. Sensitivity ranges between 48% and 
69% and specificity ranges between 85% and 99%7. Clinical examination can be 
unreliable in women below the age of 35 with a sensitivity of 37% in predicting breast 
cancer . The uses of oral contraceptives and hormone replacement therapy can 
increase breast nodularity thereby affecting clinical interpretation.
- 16-
1.4 Imaging
The principal imaging modality used in breast cancer diagnosis is mammography. The 
role of ultrasonography (US) is increasing particularly in cases where mammography 
is equivocal. Other imaging modalities include magnetic resonance imaging (MRI) 
and nuclear medicine imaging.
1.4.1 Mammography
Since the 1960’s, mammography has played an important role in the diagnosis of 
breast cancer. Mammography can be used for both screening and diagnosis. Screening 
mammography aims at detecting breast cancer at the asymptomatic stage. Diagnostic 
mammography provides diagnostic evaluation of a specific area within the breast 
when a clinical abnormality such as a lump or a screening abnormality has been found. 
Both screening and diagnostic mammograms are usually taken in 2 perpendicular 
views, lateral and craniocaudal. Additional views at different angles can be taken for 
more accurate images of a suspicious area.
Mammography is based on the principle that various types of breast tissue have 
different x-ray densities, which can be utilised to produce a grey-scale image of the 
breast. High-density tissues such as calcifications and dense glandular tissues appear 
white whilst low-density tissues such as fatty tissue appear black. To achieve optimal 
quality, adequate compression of breasts is required to separate overlapping structures, 
to decrease the amount of radiation and to obtain sharp images9.
During interpretation of mammograms, radiologists identify specific features, which 
are associated with breast cancer. These include the shapes, margins and density of
- 17-
lesions and microcalcifications. Mammograms are usually reported with a description 
of findings and a diagnostic category, such as the Breast Imaging Reporting and Data 
System (BIRADS) (Table 1.2)10.
Table 1.2: Breast Imaging Reporting and Data System (BIRADS) categories
0 Inconclusive Additional mammography views required
1 Negative No mammographic abnormality present
2 Benign Benign findings, no short-interval follow-up required
3 Probable benign finding Findings with high probability of being benign, biopsy recommended
4 Suspicious finding Findings not characteristic of malignancy but requires biopsy
5 High suggestive of malignancy High probability of breast cancer
In general, the sensitivity and specificity of mammography for diagnosing breast 
cancer in symptomatic patients ranges between 72% and 94% and between 75% and 
94% respectively11. For breast screening, performance is measured by the rates of 
invasive and in-situ cancers detected, the benign excision breast biopsy per 1000 
women screened (false positive), and recall for assessment. The overall false negative 
rate for screening mammography is approximately 10%. The performance of 
NHSBSP in the UK between 1999 and 2000 are illustrated in Table 1.312.
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Table 1.3: Performance o f  NHSBSP between 1999 and 2000
Parameters Standard* Aeh ie \ eda t l  Achieved
screen**
Invasive cancers 
per 1000 women
>3.6 (>4% for 
subsequent screen)
5.0 4.4
In-situ cancers per 
1000 women 20.4 to ^ .0
1.7 1.14
Benign biopsies 
per 1000 women
<3.6 (<4 for 
subsequent screen)
2.7 0.7
Recall rate (%) <7% 8.3 3.9
(Figures from Tables 3 & 4: NHS Cancer Screening Programmes: Breast Screening 
programme annual review 2001. NHSBSP Publication, Sheffield, 2001 p. 14-1512. 
*Standard set by NHSBSP, **Results achieved by NHSBSP after one round of 
screening mammography per woman screened, ***Overall result achieved including 
repeat mammography and additional views)
In general, the diagnostic accuracy of mammography for breast cancer depends on 
several factors: (1) operator skills of the radiographer in positioning the breast, (2) 
interpretation skills of the radiologist, (3) high breast density, (4) scarring secondary 
to previous surgery, radiotherapy and chemotherapy to breast and (5) breast implants. 
High breast density is the main patient factor for reducing the diagnostic accuracy of 
mammography. This is because non-calcified breast cancers have a similar x-ray 
density to normal fibroglandular breast tissue13. Hence, mammography is not as 
effective in younger pre-menopausal women, those who are pregnant or lactating, and 
those on hormone replacement therapy.
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In patients with a discrete palpable breast lesion, mammography contributes little to 
the diagnosis, which should be pathological. However, the role of mammography in 
this situation is to determine the extent of the cancer and to detect occult synchronous 
cancers within the ipsilateral or contralateral breast. Additional uses of mammography 
include stereotactic localisation of impalpable tumours or lesions prior to surgery and 
regular post-operative follow-up of breast cancer patients.
1.4.2 Recent advances in mammography
Recent advances in mammography include digital mammography, Computer-aided 
detection and diagnosis (CADD), Digital Tomosynthesis and Contrast Digital 
Mammography.
Digital mammography is one of the most important advances in mammography. 
Similar to standard mammography, x-rays are used to generate images of the breast. 
Instead of a film, a 50mm by 50mm phosphor screen is used to detect the x-rays 
leaving the breast and to convert them into light. The latter is transferred through a 
fibre optic reducer to a charged coupled device (CCD) detector. A typical CCD 
measures 25mm by 25mm with a 1024 by 1024 pixel matrix giving a 0.05mm 
resolution per pixel. The CCD converts the incident light into a digitised signal, which 
can be displayed onto a computer monitor or stored.
The main advantage of digital mammography is that contrast and density can be 
adjusted after image acquisition, thus allowing visualisation of subtle details such as 
spiculations at the margin of small breast cancers and granular calcifications in low 
grade ductal carcinoma in-situ (DCIS). So far, digital mammography has shown
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equivalent spatial resolution to conventional film mammography. Therefore, digital 
mammography has the potential to improve breast cancer detection whilst reducing 
additional exposures due to under or over-exposure of films.
In the largest published study to date, Lewin et al. compared the performance of 
digital mammography and conventional film mammography in a screening setting14. 
Screening mammograms were performed both on conventional and digital 
mammography systems. 42 cancers were detected in 6736 paired examinations. 9 
cancers were detected solely on digital mammography, 15 solely on conventional 
mammography and 18 were detected on both. The difference was not statistically 
different partly due to the small patient numbers and the relatively low numbers of 
cancers detected through breast screening. However, there were significant reductions 
in recall and biopsy rates with digital mammography (799 vs 1007).
Currently, the Digital Mammographic Imaging Screening Trial is on going. It has 
49,528 women enrolled. Each participant had both digital and conventional 
mammography at the time of enrolment and a follow-up mammogram one year later. 
Closed to further enrolment since 2003, the results are awaited.
Additional advantages of digital mammography include (1) improved contrast 
between dense and non-dense breast tissue, (2) faster image acquisition (<1 minute), 
(3) easier image storage through picture archiving and communication systems, (4) 
transmission of images over internet i.e. teleradiology and (5) the provision of a 
platform for further advances such as CADD, tomosynthesis and contrast medium 
mammography.
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The disadvantages of digital mammography are the cost of the system and the lack of 
convincing evidence that it improves breast cancer detection. The costs and benefits 
involved will decide whether this technology becomes part of routine practice.
CADD is a recent development in mammography. The objectives of CADD are to 
identify radiological features associated with breast cancer through computer vision 
and to systematically analyse these features using computer algorithms such as 
artificial intelligence to provide an output, thereby improving the diagnostic accuracy 
and performance of mammography. To achieve computer vision, all mammographic 
images must first be in a digital format either by digitisation of conventional 
mammographic films or acquired directly by digital mammography. This is followed 
by a processing stage, which enhances important image features whilst suppressing 
those of little interest. Individual images are subsequently divided into various areas 
by the process of segmentation, which are ready for analysis.
Currently, only two systems, R2 ("Image Checker", R2 Technology, Los Altos, 
California, USA) and CADx ("Second Look", CADx Medical Systems, Quebec, 
Canada) are commercially available for computer-aided detection (CAD). In a recent 
prospective study, 12,860 screening mammograms were interpreted with the 
assistance of a CAD system15. Each mammogram was initially interpreted without 
CAD assistance and was immediately followed by a re-evaluation of areas marked by 
the CAD system. The study showed an increase in recall rate from 6.5%-7.7%, no 
change in the positive predictive value for biopsy ay 38%, a 19.5% increase in 
number of cancer detected and an increase in the proportion of early stage (0 and 1) 
malignancies detected from 73% to 78% when CAD was used. However, the
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experience and skill of the reporting radiologist had a significant influence in this 
study, and this was the main limitation. At present, the ability of CAD to improve 
diagnostic accuracy and performance is unclear from the limited number of published 
studies16,17.
Digital tomosynthesis is a technique through which 3-dimensional tomograms can be 
generated from a series of low dose digital mammograms at different levels within the 
b reast18. This is performed by moving the x-ray source to various positions above the 
breast19. This technique has the potential to reduce the visibility of normal breast 
tissue and the effects of superimposed tissue, thus improving the visibility of breast 
cancers and providing better demonstration of lesion morphology, especially in 
women with radiographically dense breasts 19,2°.
Contrast digital mammography involves the use of an intravenous iodine based 
contrast agent and the acquisition of a series of pre and post contrast digital images20. 
Images are subsequently processed by digital subtraction of the pre-contrast image 
from post-contrast image thereby enhancing visibility of contrast agent. A series of 
images over time is obtained with time-series subtraction. Contrast digital 
mammography enables tumour visualisation based on the increased vascularity of
1 ftmalignant tissue over normal breast tissue , and can potentially visualise smaller 
lesions than those currently seen with screening mammography20. Both digital 
tomosynthesis and contrast digital mammography are emerging technologies, 
currently being evaluated by clinical studies.
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1.4.3 Ultrasonography and recent advances
Ultrasonography or ultrasound (US) uses high-frequency sound waves, which are 
reflected from different tissue structures to generate images of internal structures. As 
it does not involve ionised radiation, it is considered safe for women of any age, as 
well as those who are pregnant. A typical examination takes 5 to 15 minutes and is 
totally painless.
The main diagnostic role of US is to differentiate solid lesions (e.g. breast cancer, 
fibroadenomas and prominent breast tissue) from fluid filled lesions (e.g. breast cysts) 
based on the differences in their echogenic pattern. Other indications for US include 
(1) the initial diagnostic imaging for palpable lumps in young women due to the 
intrinsic high density of breasts, (2) the evaluation of masses not completely evaluated 
with mammography, (3) in inflammatory breast conditions, (4) as guidance for 
intervention procedures, (5) the evaluation of mammographic asymmetry and (6) the 
evaluation following breast augmentation and breast conservation surgery21.
US has a sensitivity range between 49-100% and a specificity range between 29- 
100% for breast cancer diagnosis in a recent systematic review21. Although US is not 
part of TA, it is often used as a supplement to mammography. In a study of 2020 
patients, US detected 8 extra malignancies whilst correctly downgraded 332 cases 
from a positive to a negative diagnosis (i.e. from a suggested malignancy to no 
malignancy) following clinical examination and mammography22. The systematic 
application of breast US improved the overall diagnostic yield especially in patients 
with palpable breast lumps or with abnormal screening mammography22.
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Recent advances in breast US include 3-dimensional US and tissue harmonic imaging. 
3-dimensional US provides additional images and characteristics of the breast lesions. 
Whether this provides additional value in differentiating breast masses is 
controversial23,24.
Tissue harmonic imaging is a new US technology. It produces images from US 
frequencies that are generated as the incident US wave propagates through tissue. 
Harmonic frequencies are multiples of the fundamental beam frequency. Few 
prospective clinical studies have reported reductions in image artefacts, improvements 
in lesion contrast and margin evaluation25'27.
1.4.4 Magnetic resonance imaging and recent advances
MRI generates images of breast structures using signals emitted from tissues 
following excitation by radiofrequency waves in a strong magnetic field. Excellent 
imaging of breast lesions can be achieved with intravenous contrast such as 
dimeglumine gadopentate (Magnevist ) and by placing the breast within a special 
magnetic coil to ensure a high magnetic field. Various imaging techniques such as 
dynamic imaging, fat suppression and subtraction imaging are available, but are 
beyond the scope of this thesis.
Contrast-enhanced breast MRI has demonstrated a sensitivity o f 94%-100% in the 
detection of breast cancer. The main limitation of MRI in breast cancer diagnosis is its 
specificity which is lower and more variable, ranging between 37% and 97%28. This 
is partly because benign lesions such as fibroadenomas, proliferative benign disorders, 
areas of inflammation and active glandular tissue can all show enhancements. The
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other contributing factor is the lack of standard interpretation criteria for image 
evaluation. The two major approaches to image interpretation are (a) evaluation of 
enhancement kinetics following contrast agent administration and (b) evaluation of 
lesion morphology.
The advantages of MRI over mammography are that it involves no ionising radiation, 
it can identify lesions down to 2-3mm, it has a near 100% sensitivity in detecting 
breast cancer using contrast enhancement, its images are not affected by breast 
density and breast implants, it gives a good definition of the local extent of cancer, 
and it is sensitive to lobular carcinoma. However, the drawbacks of MRI include a 
low and variable specificity, the cost of equipment and maintenance, poor reliability 
in showing microcalcifications, failure of breast lesions to selectively take up contrast 
agent and time taken for acquisition and interpretation of multiple MRI images.
In the United Kingdom, MRI is not a standard imaging procedure for breast cancer 
diagnosis. However, MRI has diagnostic roles in (1) diagnosing multi-centric or 
bilateral diseases (MRI sensitivity of 89-100% versus Mammography sensitivity of 0- 
66%29), (2) evaluating difficult diagnostic problems and (3) identifying occult 
tumours in patients with axillary metastasis and negative clinical examination, 
mammography and US30. This is particularly the case in patients with invasive lobular 
carcinoma because of its variable presentation on clinical examination and 
mammography. Other roles include (1) cancer staging such as assessment of lesion 
size and disease extent to nipple, skin and chest wall, and axillary lymph node
• 29involvement , (2) imaging used to evaluate silicone implants and (3) monitoring 
changes following breast conservation surgery, chemotherapy and interstitial laser
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photocoagulation31. MRI has a limited role in breast screening due to its cost, its time 
consuming nature and more importantly, its inability to detect microcalcifications. 
However, MRI appears to have a role in screening high risk women younger than age 
40 due to the poorer sensitivity and specificity of mammography29.
Recent advances in MRI include developments in functional MRI, magnetic 
resonance spectroscopy (MRS), 3-dimensional imaging, and magnetic resonance 
elastography.
Functional MRI is a relatively new technology that uses T2 weighted imaging 
technique to measure metabolic changes in tissues during disease process. It differs 
from traditional MRI by combining anatomical changes with physiological changes 
resulted from disease process. There are several types of functional MRI such as 
perfusion MRI, diffusion-weighted MRI and Blood-Oxygen-Level-Dependent MRI. 
However, these are beyond the scope of this thesis.
MRS is a type of functional MRI, which is capable of measuring certain metabolites. 
In breast cancer cells, there is an accumulation of choline-containing compounds, 
which can be detected by MRS. Figure 2.1 demonstrates typical MRS spectra of 
different breast tissue types. Malignant breast tissues are characterised by a “choline” 
peak at 3.3ppm.
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Figure 1.1: Typical MRS spectra from different types o f  breast tissue
Choline
Freauencv loom)
— Invasive lobular carcinoma 
Invasive ductal carcinoma 
—  DCIS
Fibroadenoma 
Breast cyst
Normal breast parenchyma
(Modified from illustration from Using Magnetic Resonance to Diagnose Breast Cancer 
and Predict Therapeutic Response (http://www.cmrr.umn.edu/research/breast.shtml). 
Center for Magnetic Resonance Research, University o f Minnesota, Minnesota, 2005.)
Although individual MRS spectrum can be analysed by visual inspection, such 
strategy is not optimal when there is a large volume o f  data. A potential solution is to 
devise a classification strategy, which was developed by Mountford et a l32. Their 
technique involves a three-stage process. Firstly, a genetic algorithm-based 
programme was used to pre-process the MRS spectra to define the maximally 
discriminatory subregions in the spectra. The second stage involves the use o f  these 
discriminatory subregions to develop a linear discriminant analysis (LDA) classifier. 
Approximately half o f  the MRS spectra were randomly selected to train the LDA 
classifer. The LDA classifer was then used to validate on the remaining MRA spectra. 
If  classification is problematic, the third stage, computerised consensus diagnosis, was 
used. Using this technique, MRS has an overall sensitivity o f  92% and specificity o f
- 2 8 -
93% in determining malignant and benign fine needle aspirate. This compares to a 
sensitivity of 85% and specificity of 82% with visual inspection of MRS spectra.
A typical MRS examination takes 20 to 30 minutes to perform. Both in-vivo and ex- 
vivo tissues can be studied. Potential applications of MRS include (1) incorporation of 
MRS into MRI to improve its low specificity and (2) to monitor and predict response 
to chemotherapy.
1.4.5 Nuclear Medicine Imaging
The nuclear medicine imaging modalities for breast cancer diagnosis are 
scintimammography and positron emission tomography (PET). These depend on the 
physiological distribution of a radiolabelled tracer (radiopharmaceutical), which 
consists of a radioactive isotope such as " mTechnectium (99mTc) and 18Fluorine (18F) 
attached to a carrier molecule. The latter can be a metabolite or antibodies to 
oestrogen receptors. Radiopharmaceuticals are usually administered intravenously and 
then accumulate preferentially in breast cancer cells, which can be detected as an area 
of focal uptake by appropriate radiation imaging.
1.4.5.1 Scintimammography
Scintimammorgaphy is a physiological imaging technique used to visualise primary 
breast cancer using a radiopharmaceutical. Although various radiopharmaceuticals are 
available, " mTc sestamibi ( " mTc MIBI) is the agent of choice because of its higher 
sensitivity and specificity. In addition, " mTc sestamibi is the only agent with Food 
and Drug Administration (FDA) approval for this purpose. Although the precise 
mechanism of uptake in breast cancer cells is unknown, it appears that " mTc
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sestamibi is taken up by active transport mechanisms and is accumulated in 
mitochondria. Uptake appears to be influenced by the degree of tumour differentiation 
but not by tumour size or histological type33.
A review of 21 studies using " mTc sestamibi totalling 2682 patients with at least 1541 
palpable and 939 impalpable lesions showed sensitivity range of 50% to 95% and 
specificity range between 58 to 100%34. Of these studies, the largest was a 
prospective multi-centre trial of 673 women . The blinded readers’ diagnostic 
accuracy was 78% to 81% with an inter-reader agreement between 95% and 100%. 
Sensitivity was higher for tumours ^  cm than for tumours <1 cm (74.2% and 48.2% 
respectively).
When compared to other imaging modalities, sensitivity and specificity of " mTc 
sestamibi was shown to be 84% and 80% respectively compared to values of 68% and 
65% for US in 76 patients undergoing excision breast biopsy or FNAC 36. A separate 
study of 56 patients comparing scintimammography, mammography and MRI 
reported sensitivities of 60%, 60% and 100% respectively and specificities of 75%, 
25% and 50% respectively37.
The advantage of scintimammography is that the diagnostic accuracy is not affected 
by breast density and nodularity, the presence of breast implants, and scaring from 
previous surgery or radiotherapy 34,38. Therefore, scintimammography has a specific 
diagnostic role in these clinical situations.
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1.4.5.2 Positron emission tomography
PET is a computed tomographic imaging technique using positron emitting 
radioisotopes (fluorine-18 and carbon-11) which are labelled to biologically active 
molecules such as metabolites, hormones and antibodies. The majority of PET studies 
in oncology have concentrated on fluorine-18 fluorodeoxyglucose (FDG). As a 
glucose analogue, FDG is taken by cells particularly those in high metabolic state 
such as malignant cells, and is subsequently converted into FDG-6-phosphate by 
phosphorylation. FDG-6-phosphate does not undergo glycolysis and therefore 
accumulates within the cells. The rationale behind using FDG is based on the 
observations by Warburg that glucose metabolism is increased in malignant tissue. 
Therefore, interpretation and diagnostic criteria of FDG-PET is based on the intensity 
of tracer uptake, which is expected to be more pronounced in breast cancer.
Several studies of the use of FDG-PET in diagnostic imaging for primary breast
TOtumour have reported sensitivity and specificity ranging from 80% to 100% . 
However, these studies were based on a pre-selected patient population with a bias for 
breast cancer and a small number of benign lesions. Hence, specificity and negative 
predictive value have not been fully determined 40.
In the largest study to date of 144 patients with 132 histologically confirmed breast 
cancer and 53 benign lesions, Avril et al observed an overall sensitivity of 64.4% 
using conventional imaging reading (i.e. regarding only focal tracer accumulation as 
to represent malignancy) and 80.3% using sensitive image reading (i.e. including 
probable and definite malignant lesions). Detection rate is significantly lower in pTl 
(<2 cm) tumours (68.2%) than in pT2 (>2 cm -  5cm) tumours (91.9%) with a higher
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false negativity for invasive lobular carcinoma (65.2%) compared with invasive 
ductal carcinoma (23.7%). As for multi-focal tumours, only 50% of multi-focal 
tumours were identified 41. In a separate study by the same group, FDG uptake by 
breast cancer has a positive correlation with histological tumour type, microscopic 
tumour growth pattern and tumour cell proliferation. However, other factors such as 
tumour microenvironment may have significant effects on metabolism 42. In view of 
limited sensitivity, FDG-PET currently has no defined clinical role in the diagnosis of 
breast cancer 43.
1.4.6 Other Imaging Modalities
There are several other imaging technologies currently under development for the 
screening and diagnosis of breast cancer. These include thermography, optical 
imaging, electrical impedance imaging, thermoacoustic computed tomography and 
magnetic/ultrasonic elastography. Unlike MRI, Scintimammography, and PET, these 
technologies are not widely available. In addition, there is a lack of published clinical 
data to merit further discussion.
1.5 Pathological Evaluation
Pathological evaluation provides the definitive diagnosis of breast cancer with 
microscopic evidence of malignant cells from within the lesion concerned. Various 
techniques are available to obtain cellular or tissue specimens. These include EBB, 
fine needle aspiration cytology (FNAC) and core needle biopsy (CNB). More recently, 
vacuum assisted core biopsy (VACB) and percutaneous breast biopsy (PBB) have 
been developed.
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1.5.1 Excision breast biopsy
EBB is historically the “gold standard” for pathological diagnosis44. It is an operative 
procedure performed under local or general anaesthesia. Skin incisions are usually 
made immediately over the palpable lump, but circum-areolar incisions can be used in 
lesions close to nipple for better cosmesis. Lesions are removed with or without a rim 
of normal breast tissue. Excised specimens are routinely sent for histology, but fresh 
frozen section (FFS) has been used for intra-operative diagnosis.
For impalpable lesions detected by mammography, EBB can be performed with a pre­
operative localisation. This involves the insertion of a needle (under local anaesthetic) 
using imaging guidance (usually mammography) to locate the lesion. The lesion is 
excised with the needle in situ, and is subsequently x-rayed to confirm complete 
removal45. Needle localisation EBB is the gold-standard procedure for impalpable 
beast lesion because of its diagnostic accuracy (between 99% and 100%)46.
The main complications of EBB are wound infection and post-operative haematoma. 
The latter may require re-operation for evacuation of haematoma or to arrest on-going 
haemorrhage45. Clinical disadvantages of EBB as a primary pathological diagnostic 
procedure are (1) the requirement of an invasive operation, which may not be 
necessary in benign diseases, (2) inability to offer preoperative patient counselling in 
cases turning out to be malignant, (3) inability for clinicians and patients to plan a 
single definitive operation for malignant lesions, (4) potential post-operative cosmetic 
defects and (5) potential dissemination of cancer if excision line goes through part of 
the tumour2,44. Hence, EBB is not the pathological diagnostic procedure of choice, 
and is usually reserved for equivocal cases after TA.
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1.5.2 Fine needle aspiration cytology
FNAC is the simplest, cheapest and least invasive of the non-operative diagnostic 
techniques. It requires a venepuncture needle, a 5- or 10-ml syringe and microscope 
slides. The needle is guided through the breast lesion. With suction applied, a few 
forward and backward passes of the needle are made within the lesion. Suction is 
relieved before withdrawing. The content in the hub of the needle is smeared onto 
microscope slides. The slides are either air-dried or fixed prior to staining. For 
palpable lesions, FNAC can be performed “freehand” by clinicians whilst for 
impalpable lesions, FNAC can be performed under ultrasound imaging by allowing 
real time demonstration of needle traversing the lesion47.
The main staining methods for breast FNAC are Papanicolaou (PAP), and May- 
Griinwald-Giemsa (MGG or Diff-Quik™), and their essential differences are outlined 
in Table 1.4.
Table 1.4: Comparison o f Papanicolaou and Mav-Grunwald-Giemsa stains
Requires wet fixed specimens Requires air-dried specimens
Cells remained 3-dimensional Cells flatten out and enlarge
Cells within clusters seen on focusing Cells within clusters difficult to see
Cytoplasm -pale blue & transluscent Cytoplasm -blue/pale purple & dense
Nucleus -bluish purple & sharp margins Nucleus -purple & margins not as sharp
Chromatin pattern clearly visible Chromatin pattern not as well seen
Nucleoli -blue or red Nucleoli seen as pale areas
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PAP is the method of choice because of its superior quality. For example, cells remain 
3-dimensional enabling close examination of all cells and architectural patterns within 
the clusters. Subtle variations in chromatin patterns and clear nucleoli provide 
additional features for interpretation. However, PAP is time consuming and laborious. 
MGG is used if immediate reporting is required. Other rapid staining techniques 
include toludine blue and the Rapid Papanicolaou methods. Immunocytochemistry is 
also possible and requires wet fixation. In general, the choice of staining is dependent 
on the individual preference of the cytologist or pathologist and on whether 
immediate reporting is required44,47.
In the UK, FNAC results should be reported in the following categories used by the 
NHS Breast Screening Programme48 (Table 1.5), which is similar to the BIRADS 
system for mammography10.
Table 1.5: Diagnostic categories for breast FNAC reportin2
Cl Inadequate specimen for diagnosis
C2 Benign cytology
C3 Atypia probably benign
C4 Suspicious of malignancy
C5 Malignant cytology
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The success of FNAC depends on a sample that is adequate and representative of the 
lesion, a suitable processing and staining without artifact and an accurate 
interpretation of cytological material with a clear report conveyed to the rest of the 
clinical team2. FNAC is operator dependent with a superior success rate and lower 
rate of technically inadequate specimens found in experienced aspirators49.
Interpretation of FNAC requires careful examination of several cytological features, 
which are outlined in Table 1.6. However, it is important to appreciate that cancers, 
particularly low-grade carcinomas, do not always exhibit all features of malignancy. 
Hence, interpretation and reporting of FNAC requires special cytological training and 
experience.
The accuracy of FNAC is dependent on the operator skill and experience during the 
aspiration process, and the interpretation skill and experience of the reporting 
pathologist. Other significant factors affecting the success rate of FNAC include poor 
tumour palpability, small tumour size, low tumour grade, scattered cellular 
distribution of cancer cells and benign-like ultrasound findings50. Other sources of 
errors in diagnosis include (1) the dilution of aspirate by blood or fluid, (2) blood 
clotting of aspirate, (3) fibrosis masking tumour cells, (4) presence of nuclear 
pleomorphism of some benign tumours, and (5) lack of clinical information for 
reporting cytologist/pathologist51. Therefore, FNAC results should be interpreted in 
the light of clinical history and imaging findings. It is not possible to provide the 
absolute sensitivity and specificity of FNAC in the diagnosis of breast cancer. 
However, the maximum attainable performance of individual breast services can be 
described through auditing. The suggested thresholds for FNAC performance in 
breast screening in the UK are illustrated in Table 1.752.
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Table 1.6: General diagnostic criteria for the recognition o f benign and malignant conditions
(From Table 3: Non-operative diagnostic subgroup o f the National Coordinating Group for Breast Screening Pathology: Chapter 3 FNAC Reporting Guideline, 
Guidelines for non-operative diagnostic procedures and reporting in breast cancer screening. NHSBSP Publication, Sheffield, 2001 p.22.48)__________________
Cellularity* Usually poor or moderate Usually high
Cell to cell adhesion* Good with large defined clusters o f cells Poor with cell separation resulting in dissociated cells 
with cytoplasm and small groups o f intact cells
Cell arrangement Even, usually in flat sheets (monolayers) Irregular with overlapping and 3-dimensional 
arrangement
Cell types Mixture o f epithelial, myoepithelial and other cells 
with fragments o f stroma
Usually uniform cell population
Bipolar (elliptical) bare nuclei Present, often in high numbers Not conspicuous
Background General clean except in inflammatory conditions Occasionally with necrotic debris and sometimes 
inflammatory cells including macrophages
Nuclear characteristics
Size (in relation to red blood cell diameter)* Small Variable, often large, depending on tumour size
Pleomorphism* Rare Common
Nuclear membrane (PAP stain)* Smooth Irregular with indentations
Nucleoli (PAP stain)* Indistinct or small and single Variable but may be prominent, large and multiple
Chromatin (PAP stain)* Smooth or fine Clumped and may be irregular
Additional features Apocrine metaplasia, foamy macrophages Mucin, intracytoplasmic lumina
* indicates major cytological feature
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Table 1.7: Suggested threshold for FNAC performance in breast screening in the UK
Absolute sensitivity* >60 >70 57.1
Complete sensitivity* >80 >90 81.5
Specificity >55 >65 58.4
Positive predictive value >98 >99 99.6
False positive rate <1 <0.5 0.2
False negative rate <6 <4 6.3
Inadequate rate* <25 <15 23.4
Inadequate rate for 
cancer <10 <5 9.8
Suspicious rate <20 <15 15.8
* Absolute sensitivity = number of breast cancers with C5 on FNAC x 100%
total number of carcinomas undergoing FNAC
Complete sensitivity = number of breast cancers with C3, 4 and 5 on FNAC xl00%
total number of carcinomas undergoing FNAC
Inadequate rate = number of inadequate specimen_______  xl00%
total number of cases undergoing FNAC
(From Table 9: Non-operative diagnostic subgroup of the National Coordinating 
Group for Breast Screening Pathology: Chapter 6 Quality Assurance, Guidelines for 
non-operative diagnostic procedures and reporting in breast cancer screening. 
NHSBSP Publication, Sheffield, 2001 p.50.)
For impalpable lesions, the performance of imaging guided FNAC from a review of 
16 studies by Britton is illustrated in Table 1.853.
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Table 1.8: Performance o f imasins suided FNAC for impalpable breast lesions
No. of studies (No. of FNAC) 12 (5895) 4 (2673)
Absolute sensitivity 62.4 83.1
Complete sensitivity 83.1 95.1
Specificity 86.9 84
Positive predictive value of C5 99.3 98.3
False negative rate 0.5 1.4
Inadequate rate 6.4 12.8
Inadequate rate in cancers 5.0 2.1
The main advantages of FNAC are that it is simple and accurate in expert hands. 
Immediately reporting is possible. Other advantages of FNAC are that it is quick 
(usually takes 1-2 minutes for aspiration), well tolerated by patients and cost effective. 
In addition, FNAC has the least complications of all biopsy techniques. These include 
pain during aspiration, slight haematoma and pneumothorax. The latter is rare and 
occurs usually in women with small breasts or medial lesions. There have been 
reports of epithelial displacement and tumour seeding, which are more common with 
CNB.
1.5.3 Core needle biopsy
CNB is a percutaneous procedure that involves removing a core of breast tissue 
approximately l-2cm in length and l-3mm in width using a cutting needle. The 
needle consists of an inner trocar with a special notch for trapping a sliver of breast 
tissue and an outer hollow needle. The needle is larger than that used in FNAC, and 
local anaesthetics are required. A variety of automated devices such as Bard Biopsy
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gun and Manan gun (Manan Medical Products) are available in addition to the 
original manual needles (Trucut, Surecut).
Automated devices are preferred because of higher sampling success rate, greater 
diagnostic sensitivity, better specimen quality and ease of use54. Upon loading and 
releasing the trigger, the inner trocar is propelled first into the lesion and is 
immediately followed by the hollow needle coring the breast tissue. The CNB needle 
is subsequently removed from the patient and reloaded to retrieve the specimen.
For palpable lesions, CNB can be performed “freehand”, and a minimum of five cores 
is recommended to ensure adequate sampling55. For impalpable lesions, CNB is 
usually performed with stereotactic guidance. This can be carried out with the patient 
in prone, lateral recumbent or upright position on a specially designed stereotactic 
mammography system. The patient’s breast is slightly compressed and held in 
position throughout the procedure. A pair of x-ray images is acquired, and computer 
analysis provides precise settings, enabling correct placement of the CNB needle by 
radiologists. Alternately, US can be used to guide the biopsy needle precisely to the 
correct location under continuous imaging.
The core specimens are fixed in formaldehyde and sent for standard histopathology. 
The standard histopathology is a 3-step process involving fixation, embedding and 
staining. Fixation preserves the physical structure of tissue using a buffered isotonic 
solution of 4% formaldehyde. Fixation typically takes 12 hours, and the minimum 
time for CNB specimens is 6 hours56. Embedding involves dehydrating the tissue 
specimen by bathing it in a graded series of ethanol and water mixtures, and clearing,
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in which ethanol is cleared by xylene to allow impregnation with paraffin. Embedding 
takes between 8 to 30 hours. The paraffin-embedded tissue is sectioned longitudinally 
by a microtome to a thickness of 1-10/mi, and sections are transferred onto glass 
slides for staining57. The standard stain for histopathology is haematoxylin and eosin 
(H&E) and the staining process takes between 15 to 30 minutes. For mass lesions, 
H&E stained sections from one level are usually sufficient, but for microcalcifications, 
cores should have a minimum of 3 levels examined. Further levels and 
immunohistochemistry can be performed56. Alternately, core specimens can be 
examined using fresh frozen section (FFS) for immediate reporting. However, this is
c o
associated with higher false positive diagnosis .
CNB yields a larger sample for histological assessment, thus enabling a definitive 
diagnosis with histological type and interpretation by any pathologist without the need 
of cytological expertise. In addition, CNB provides further prognostic information 
such as histological grade and hormone receptor status59. Like FNAC, CNB results 
should be reported in the following categories (Table 1.9) used by the NHSBSP56.
Table 1.9: Diagnostic categories for breast CNB reporting
B1 Normal tissue
B2 Benign lesion
B3 Lesion of uncertain malignant potential
B4 Suspicious of malignancy
B5 Malignant
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The accuracy of CNB is dependent on the operator skill and experience, tumour 
palpability and tumour size. For palpable lesions, freehand CNB has the maximum 
attainable sensitivity of 95% and specificity of 100% from published data59. Like 
FNAC, sensitivity and specificity vary between individual centres. For breast 
screening, the current suggested thresholds for CNB in UK are outlined in Table 
1. 1052.
Table 1.10: Suggested thresholds for CNB performance in breast screening in the
UK
Absolute sensitivity >70 >80 >76.4
Complete sensitivity >80 >90 84.5
Specificity >75 >85 81.2
Positive predictive value >99 >99.5 100
False positive rate <0.5 <0.1 0
False negative rate <15 <10 15.1
Miss rate from cancer <15 <10 15.1
Suspicious rate <10 <5 4.8
(From Table 10: Non-operative diagnostic subgroup of the National Coordinating 
Group for Breast Screening Pathology: Chapter 6 Quality Assurance, Guidelines for 
non-operative diagnostic procedures and reporting in breast cancer screening. 
NHSBSP Publication, Sheffield, 2001 p.50.)
- 4 2 -
CNB allows a more accurate assessment with larger samples and also histological 
assessment. However, CNB is more invasive and can be uncomfortable. CNB is more 
time consuming, and has a higher risk of haematoma. CNB is limited by the 
histological processing, and therefore cannot provide an immediate diagnosis. Some 
published studies reported the superiority of CNB over FNAC in both freehand and 
imaging guided setting60,61, whilst others reports claimed higher accuracy with 
FNAC62. It is important to appreciate that both techniques are highly operator 
dependent.
1.5.4 Vacuum assisted core biopsy
VACB (Mammotome, Ethicon Endo-Surgery, Cincinnatti, USA, and Minimally 
Invasive Breast Biopsy, United States Surgical, Norwalk, USA) provides breast cores 
for histological evaluation similar to CNB, but differs fundamentally in its design and 
mechanism of action. VACB uses biopsy probes with a sampling chamber that has a 
vacuum channel incorporated. The latter applies a gentle negative pressure drawing 
breast tissue into the probe’s sampling chamber before a rotating cutting cylinder is 
passed down within the probe separating the core of tissue. Specimens are retrieved 
using the negative pressure without the need of removing the probe. Further 
specimens can be obtained from the same insertion. A simple rotational mechanism is 
incorporated to orientate the aperture of the sampling chamber for sampling outer 
areas. A small metal clip can be accurately deposited to localise the biopsy area 
should surgical excision be required .
Because no firing mechanism is involved, image-guided VACB of impalpable breast 
lesions has shown to be superior to CNB in (1) calcification retrieval, (2) ADH 
underestimates and (3) DCIS underestimates (Table 1.11)64.
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Table 1.11: Calcification retrieval. ADH and DCIS underestimates at stereotactic
breast biopsy usin2 CNB and VACB
Calcification
retrieval 7 1474/1591 (93%) 2241/2269 (99%)
ADH
Underestimates 9 90/194 (46%) 36/177 (20%)
DCIS
Underestimates 7 118/579 (20%) 107/985 (11%)
Other advantages of VACB include less internal scaring and bleeding because the 
probe remains in situ during the entire sampling procedure. The vacuum mechanism 
can be used to remove bleeding during and at the end of the procedure. Epithelial 
displacement mimicking stromal invasion is less in VACB65. The disadvantage of 
VACB over CNB is the cost of expensive equipment, whilst the learning curves of 
both techniques are similar66.
1.5.5 Percutaneous breast biopsy
PBB (Advanced Breast Biopsy Instrumentation, United States Surgical, Norwalk, 
USA) is designed to provide a precise total removal of mammographic lesions using a 
large bore cutting cylinder with digital stereotactic imaging as an alternative to needle 
localisation breast biopsy. PBB is also referred as large volume breast biopsy.
PPB is performed with the patient lying on a prone biopsy table. Under local 
anaesthesia, a wire is stereotactically guided into the breast lesion, and is used as a 
guide for the insertion of cutting cylinder. A variety of sizes up to 2cm are available.
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The specimen produced is in the form of a core, and is removed with the wire guide. 
Post-procedure mammography and specimen radiology can be performed to confirm 
complete excision.
PBB is more invasive than CNB and VACB, requiring a 15-20mm skin incision for 
the insertion of the biopsy probe. Clinical studies showed that ABBI is a reliable 
stereotactic breast biopsy technique and a safe alternative to needle localisation breast 
biopsy67-71, with considerable cost savings67. In a large series of 1785 lesions during a 
7-year period, imaging-histologic discordance occurred in 3.1% and is significantly 
higher in first 2 years 72. In this series, there was a high prevalence (24.4%) of breast 
cancer found.
As a primary procedure for breast cancer, PBB has a high percentage of positive 
excision margins requiring further open surgical re-excision (Tablel.l2). However, if 
restricted to less than 10mm, tumour-free excision margins can be achieved in 55% 
with no residual disease found at re-excision in 89% . Therefore, there is no clear 
advantage of PBB over stereotactic CNB at present. The average operating time using 
PBB is over 60 minutes67,71. This is significantly greater than EBB.
Table 1.12: Positive excision margins using PBB
Liberman55 54 7 6 (86%)
Rebner73 Unspecified 11 7 (64%)
Smathers74 101 27 23 (85%)
Lifrange68 Unspecified 53 11 (79%)
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1.6 Discussion
An accurate and reliable system for breast cancer diagnosis is of paramount 
importance. Misdiagnosis and delays at any stage of the diagnostic process may result 
in considerable anxiety and distress for the patient. TA is the current standard 
diagnostic system in the UK, because of its simplicity and accuracy. Despite this, 
false negative and equivocal cases continue to occur resulting in diagnostic delays and 
benign breast biopsies. This is partly due to the inherent limitations of the existing 
technologies such as the reduced sensitivity of mammography in dense breast and 
human errors, such as misinterpretation of mammograms. These in turn have been the 
driving force behind the efforts to develop and refine existing and new technologies. 
Table 1.13 summaries the sensitivity and specificity of the existing diagnostic 
techniques for breast cancer quoted in this chapter.
Table 1.13: Sensitivity and specificity o f the existing diagnostic techniques for breast 
cancer
Clinical examination75 48-69% 85-99%
Mammography11 72-94% 75-94%
US21 49-100% 29-100%
MRI76 94-100% 37-97%
Scintimammography34 50-95% 58-100%
PET77 80-100% -
FNAC52 57% 58%
CNB52 76% 81%
VACB Not available Not available
PBB Not available Not available
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It is important to appreciate that none of the above techniques are 100% sensitive and 
100% specific in diagnosing breast cancer. However, each one of them has specific 
roles.
Advances in the diagnostic technologies for breast cancer can be classified into 3 
groups: (1) improvements in existing technology such as digital mammography, 3- 
dimensional ultrasound, VACB and PBB, (2) reduction human error such as CADD 
and (3) developments using other modalities such as MRI, PET, scintimammography 
and EIS. The first group is essentially a technological up-grade to provide higher 
quality using existing techniques, whilst the third group explores the differences 
between normal and malignant breast tissue in other physical parameters such as 
tumour vascularity, biochemical, electrical and optical. Although such advances are 
welcomed, it is important that these technologies provide additional value without 
additional complexity. The latter can only result in unnecessary anxiety and delays in 
patients.
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Chapter 2 Surgical Management of Breast Cancer and Recent 
Advances
2.1 Introduction
Breast cancer is widely recognised by clinicians as a systemic disease originating in 
the breast with local and systemic manifestations. This reflects the evolution of breast 
cancer management over the past century from radical surgery alone to multimodal 
therapy guided by individual patient factors and disease stage. Although recent 
advances in breast cancer management have centered on systemic treatments such as 
chemotherapy, immunotherapy and hormonal therapy, the role of surgery remains 
important for local disease control and disease staging. The aim of this chapter is to 
review the surgical management of the breast cancer and in particular sentinel lymph 
node biopsy (SLNB).
2.2 Surgical Management of Breast Cancer
The aims of surgical management of breast cancer are:
• To cure patients where the disease is confined to the breast
• To control disease locally, preventing progression to 
ulceration, bleeding and lymphoedema
• To determinate tumour characteristics such as tumour grade, 
hormonal receptor status and other prognostic markers
• To determinate lymph node involvement
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Surgery consists of either mastectomy or breast conservation surgery together with 
axillary surgery. Reconstructive surgery to rebuild the contour of the breast is also an 
important option for patients undergoing mastectomy. However, this is beyond the 
context of this thesis and will not be discussed further.
At present, surgery remains an integral part of the breast cancer management. Most 
patients undergo surgery prior to systemic therapy. Occasionally, some patients 
undergo systemic therapy before surgery to reduce the size of the tumour or in the 
case of inflammatory breast cancer. Surgery may be contraindicated in patients with 
extensive local disease, in those who are unfit for anaesthesia or in those who are too 
old. In these situations, disease control can be provided by hormonal therapy such as 
tamoxifen and anastrozole.
2.3 Mastectomy
Mastectomy is the surgical removal of a breast. There are several types of mastectomy 
(Table 2.1). Simple mastectomy and modified radical (Patey) mastectomy are the 
most commonly used. Classical radical (Halsted) mastectomy is rarely performed 
because of its radical nature. Subcutaneous mastectomy spares the skin overlying the 
breast, which is used for breast reconstruction.
The advantages of mastectomy are (1) post-operative radiotherapy is not required, and 
(2) the risk of ipsilateral metachronous breast cancer is abolished. The main 
disadvantage of mastectomy is disfigurement following the removal of the breast. 
Common complications after mastectomy include wound complications such as 
haematoma, infection, delayed healing, and shoulder weakness or stiffness.
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Table 2.1: Types o f  m astectom y
Procedure Tissues removed
Simple or Total 
Mastectomy
Removal o f the entire breast with skin, nipple and areola, but 
no lymph nodes
Modified radical 
(Patey) mastectomy As simple mastectomy with pectoralis minor muscle
Classical radical 
(Halsted) mastectomy
Removal o f the entire breast, nipple, areolar, pectoralis major 
and minor muscles and lymph nodes
Subcutaneous mastectomy Removal o f entire breast only leaving skin
The indications for mastectomy are:
• Large tumour and/or extensive in-situ disease
• Multifocal disease
• Patient preference e.g. fear of recurrence and ease of follow-up
• High risk e.g. young patients with known genetic predisposition
• Cosmetic outcome e.g. small breasts
Although breast conservation surgery is the procedure of choice for the primary 
tumour, mastectomy continues to be an important and useful operation for many 
patients and constitutes around a third of all operations for primary breast cancer.
2.4 Breast Conservation Surgery
Breast conservation surgery involves the removal of the tumour whilst preserving the 
remainder of the breast. This is done either by quadrantectomy in which an entire of 
quadrant of the breast is removed or by wide local excision in which the cancer is
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excised with a margin of normal breast tissue. Breast conservation surgery for small 
tumours (T1 and T2) is favored because the breast is preserved without the need for 
prosthesis. More important is the similar patient survival in both breast conservation 
and mastectomy as demonstrated by numerous studies. The most important are the 
three randomized trials with more than 20 years follow-up.
The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-06 trial started 
in 1976 to determine whether breast conservation with or without radiotherapy was as 
effective as mastectomy1. 1851 women were randomized into three treatment groups: 
mastectomy, lumpectomy alone and lumpectomy with breast irradiation. The trial 
showed no significant differences among the three groups with respect to disease-free 
survival, distant-disease-ffee survival and overall survival.
The European Institute of Oncology trial recorded similar findings as NSABP B-062. 
Between 1973 and 1980, 701 women with breast cancers less than 2cm were 
randomized to radical mastectomy (349 women) and quadrantectomy (352 women) 
followed by radiotherapy to ipsilateral breast. After 1976, patients in both groups with 
positive lymph nodes also received adjuvant chemotherapy. The 20 year death rate 
from breast cancer was 24.3% in the mastectomy group and 26.1% in the breast 
conservation group. However, 30 women in the breast conservation group developed 
local recurrence and 8 women in the mastectomy group over the 20 year period giving 
a crude cumulative incidence of 8.8% and 2.3% respectively. Similar findings were 
recorded by the National Cancer Institute trial, which had 247 patients enrolled and 
had a median follow-up of 18 years3.
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The risk of ipsilateral recurrence of tumour is a major concern for women undergoing 
breast conservation surgery. The NSABP B-06 trial showed a significant ipsilateral 
recurrence rate of 39.2% when lumpectomy was performed without post-operative 
breast radiotherapy compared with a recurrence rate of 14.3% when lumpectomy was 
accompanied with breast radiotherapy1. This compares with a recurrence rate of 
14.3% when lumpectomy was accompanied with breast radiotherapy. Therefore, 
breast conservation surgery is commonly followed by at least six weeks of 
radiotherapy.
Another important factor for local recurrence is the resection margins. In a recent 
study by Leong et al.4, 452 women with pathologically node-negative breast cancer 
underwent breast conservation surgery and radiotherapy. 352 (77.9%) had a negative 
margin, 42 (9.3%) with positive (invasive and/or in situ) margin and 58 (12.8%) with 
indeterminate margin. With a median follow-up of 80 months, the 5-year ipsilateral 
recurrence rates were 3.1%, 11.9% and 6.9% respectively. Similar findings were 
observed by Smitt et al. in their study of 535 patients undergoing breast conservation 
surgery with radiotherapy5. With a median follow-up of 6 years, local recurrence 
occurred in 14% of margin-positive patients and 3% of margin-negative patients.
Although it is widely accepted that resection should aim at complete macroscopic 
removal of tumour with clear margins, there is no consensus in the definition of a 
negative margin and the subsequent management of a positive margin. By the NSABP 
definition, a negative margin is defined as the absence of tumour cells at the specimen 
surface on microscopy1, whilst the European Institute of Oncology trial had relatively 
wide margins because of quadrantectomy2. In the National Cancer Institute study,
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complete macroscopic removal of tumour was mandated with no requirement of 
microscopically clear margins. In a recent review of the significance of resection 
margins, Gennaro et al. concluded that negative margins do not guarantee complete 
removal of the disease and positive margins are not necessarily associated with 
residual disease6. In the case of negative margins, the risk of leaving residual tumour 
is low but not negligible. The risk of local recurrence is high if margin involvement is 
extensive or more than one margin is involved. The group proposed to divide 
marginal involvement into five distinct categories: absent, focal, minimal, moderate 
and extensive. If more than one margin is involved or there is extensive involvement 
of one margin, further excision or mastectomy should be considered. For others, re­
operation may not be necessary if adjuvant therapy is given.
Breast conservation surgery is suitable when there is no evidence of advanced local 
disease (i.e. tumour <4cm and no extensive nodal involvement), multifocal disease, 
or distant metastasis. Post-operative complications after breast conservation surgery 
are similar to those of mastectomy, which includes haematoma, wound infection, 
delayed healing, and seroma formation. Long-term complications include breast 
fibrosis, pneumonitis and pulmonary fibrosis, fat necrosis, rib fracture and arm 
oedema, which are secondary to radiotherapy.
The disadvantages of breast conservation surgery are (1) the need for post-operative 
radiotherapy, which currently consists of daily treatments for 6 weeks, and (2) the risk 
of local recurrence, which requires further surgery in approximately 1% of patients 
per year and also requires regular long term follow up with mammogram surveillance. 
Breast conservation surgery is not feasible where facilities for radiotherapy and 
follow-up are not available locally or are too expensive.
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2.5 Surgical Management of the Axilla
2.5.1 The role of axillary surgery
Lymphatic metastasis to axillary lymph nodes was the first route through which 
systemic dissemination of breast cancer was recognised. Its importance has been 
appreciated for more than 200 years. Axillary surgery in the form of axillary lymph 
node dissection (ALND), also known as axillary lymph node clearance, was 
developed in the 19th century to remove axillary lymph nodes with an intention to 
improve survival. Since then, axillary surgery has become an integral part of the 
surgical management of breast cancer.
ALND was initially thought to improve survival by removing all potentially involved 
lymph nodes. This belief no longer holds, as many studies have demonstrated no 
survival advantage with ALND. However, the axillary lymph node status remains a 
major prognostic indicator and a principal determinant in adjuvant chemotherapy. 
Hence, the role of ALND has evolved over the past 30 years to that of disease staging 
and local disease control.
At present, the axillary lymph node status is determined by histological examination 
of axillary lymph nodes. ALND is the standard procedure used to obtain these lymph 
nodes. Other methods such as physical examination7, lymphoscintigraphy, US8'11, 
computed tomography12, MRI13’14, " mTc-sestamibi scanning15'18, and PET19 have 
been evaluated, but have failed to achieve equivalent sensitivity and specificity to 
histology. The limitation of imaging techniques is their inability to detect small 
metastatic lesions within a macroscopically normal lymph node. It seems that 
histology will remain the standard method for axillary nodal staging, using axillary
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surgery to harvest the axillary lymph nodes. The controversy over axillary surgery is 
the extent of the dissection. ALND is an extensive procedure with significant 
morbidity. As a result, less radical procedures such as axillary lymph node sampling 
(ALNS) and sentinel lymph node biopsy (SLNB) were developed.
Axillary lymph node status plays an important role as an indicator for chemotherapy. 
However, indications for chemotherapy have widened over the years and have 
become less reliant on axillary lymph node status20. Other factors such as tumour 
features may provide adequate information for evaluating the risk of metastasis and 
the decision on chemotherapy.
The role of ALND in local disease control in the axilla is well recognised. Local 
failure after complete axillary dissection is rare and in the range of 0-2% ' . 
However, in terms of local disease control, axillary radiotherapy offers the same 
efficacy. A recently published 15 year update on a prospective randomized trial 
comparing ALND and axillary radiotherapy in 658 patients with a breast tumour less 
than 3 cm in diameter and clinically uninvolved lymph nodes, found no difference in 
long term survival in both groups (73.8% versus 75.5% at 15 years)20. Axillary 
recurrence was less in ALND group (1% versus 3%), but there were no difference in 
recurrence rates in the breast or supraclavicular and distant metastases.
In summary, axillary surgery in the management of breast cancer has evolved from 
playing a therapeutic role to playing a role in disease staging. In the absence of a 
reliable test for axillary lymph node staging, axillary surgery forms an important part 
of breast cancer management. The controversy in axillary surgery is over the extent of 
the axillary dissection.
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2.5.2 Axillary lymph node dissection
ALND is the surgical removal of the axillary lymph nodes. The extent of ALND can 
be defined by the level from which the lymph nodes are removed. The axillary lymph 
nodes are grouped into 3 levels in relation to the pectoralis minor muscle. Level 1 
consists of axillary lymph nodes inferolateral to pectoralis minor, level 2 posterior to 
pectoralis minor and level 3 superomedial to pectoralis minor.
ALND is usually limited to level 1 and 2, because the risks of complications are 
higher with the more extensive dissection. Complications of ALND are outlined in 
Table 2.2. With the exception of damage to the nerves to serratus anterior and 
latissimus dorsi, which is rare and avoidable, early complications are treatable and 
settle with time.
Late complications are more troublesome. Paraesthesia in the axilla and the medial 
aspect of the arm is one of the most common post-operative problems resulting from 
the surgical division of the intercostal brachial nerve. This can be avoided by 
identifying and preserving the nerve in the dissection as it emerges from the medial 
aspect of the axilla. Restriction of shoulder mobility may improve with physiotherapy. 
The most troublesome complication is lymphoedema secondary to the disruption or 
obstruction of lymphatics, because it is often resistant to treatment and causes 
significant morbidity. The incidence of lymphoedema following ALND ranges from 
5.5%% to 80%, and may be underestimated because milder cases might readily be 
overlooked24. The extent of breast surgery and subsequent axillary irradiation are the 
main risk factors for lymphoedema24.
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Table 2.2: Com plications following ALND
Early complications Late complications 
Haemorrhage & Haematoma
Damage to the nerves to serratus anterior 
and latissimus dorsi
Lymphoedema
Reduced upper limb mobility
Wound infection Axillary recurrence
Seroma formation Paraesthesia in upper arm and axilla
At present, ALND is the standard axillary procedure for breast cancer. However, its 
role is controversial because of its complications and the increasing diagnosis of 
breast cancer at early stages with decreased likelihoods of nodal metastasis. ALNS 
and SLNB provide alternative, less invasive procedures when there is no clinical 
evidence for nodal involvement.
2.5.3 Axillary lymph node sampling
Numerous methods of ALNS have been described, but the technique most widely 
used in the United Kingdom is the sampling of the firmest or largest four nodes within 
the axilla. A recently published randomized clinical trial using this technique reported 
no increase in axillary recurrence or mortality rate compared with ALND25. In this 
study, 466 patients aged under 70 years with unilateral invasive breast tumours less 
than 4cm and no evidence of metastatic disease were randomized to ALND (232 
patients) and ALNS (234 patients) with axillary irradiation given selectively. There 
were no differences in the rates of ipsilateral breast (ALND 14 versus ALNS 15), 
axillary (8 versus 7) or distant (29 versus 29) recurrences, and no statistically 
significant differences in 5-year survival rates (82.1% in ALND group versus 88.6 in
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ALNS group)25. Morbidity in general was least in ALNS group without radiotherapy. 
In terms of arm swelling, ALND had an early mean increase in arm volume of 4%, 
which remained constant over the next 2.5 years whilst ALNS had an increase of 2% 
which improved with time25. This result was supported by the similar findings from
9 Aan earlier randomized trial of 417 patients by the same unit in Edinburgh and 
another similar randomized trial of 100 patients by a Swedish group27.
The main argument against ALNS is the risk of axillary recurrence. In the NSABP B- 
04 trial, the local failure rate for patients who had mastectomy and six or less axillary 
nodes removed was 12% compared to a 0.3% local failure rate in patients with more 
than 10 nodes removed21. However, a re-analysis of this data by Harris and Osteen 
showed that these figures have no statistical power because of a small patient group . 
A more recent study from Denmark consisting of 3128 patients showed the 5-year 
probability for axillary recurrence was 19% in patients with no ALND, 10% with 1-2 
removed and negative nodes, 5% with 3-4 nodes removed, 3% with 5-10 nodes 
removed and 3% with more than 10 removed and negative nodes22. From the above 
studies, it appears that the optimal number of nodes that need to be harvested for 
ALNS is between 4 to 5 nodes. In practice, the removal of an extra lymph node does 
not result in a statistically significant difference in outcome.
2.6 Sentinel Lymph Node Biopsy
2.6.1 The sentinel lymph node concept
Sentinel lymph node (SLN) is a lymph node that receives direct lymphatic drainage 
from the primary tumour. Over the recent years, there have been significant interests
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in SLNB as an alternative and less invasive procedure for lymphatic staging of breast 
cancer. This is because a large number of clinical studies have demonstrated the high 
sensitivity and specificity of SLN in predicting the axillary lymph node status. 
Therefore patients with a negative SLN can be spared from unnecessary ALND.
The SLN concept is based fundamentally on two principles. First, the pattern of 
lymphatic drainage to a specific regional lymph node i.e. the SLN is orderly and 
predictable. Secondly, the SLN functions as an effective filter for tumour cells. 
Therefore, metastatic breast cancer cells would disseminate to the SLN first where 
they form metastatic deposits before progressing onto other lymph nodes. The SLN 
concept follows the lymphatic permeation theory as the mechanism of breast cancer 
metastasis, which was central to the ALND. The aim of SLNB is to identify and 
retrieve the first “temporary barrier” in patients with clinically node-negative early 
stage breast cancer. In these patients, the risk of metastasis is relatively low, and 
ALND could be avoided if the SLN is free of metastasis.
Opponents to the SLN concept view tumour dissemination as a random process via 
both the blood and lymphatic system. This is determined by the biological nature of 
the tumour and the immunocompetence of the host. In the case of lymphatic 
dissemination, the process is unpredictable and lymph nodes do not act as barriers as
29was once suggested . However, it is important to bear in mind that haematological 
dissemination is now widely regarded as an independent mechanism for tumour 
dissemination. As for lymphatic dissemination, there is still no consensus as to the 
precise mechanism. The validation of the SLN concept would provide further
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evidence to support the lymphatic permeation theory as the mechanism for tumour 
dissemination within the lymphatic system.
2.6.2 Validation and current status of the SLNB
Since the first publications on SLNB in breast cancer30'32, there has been immense 
research and clinical interest in SLNB because of its potential clinical benefits. This 
resulted in a large volume of published research evaluating SLNB. Much of these 
studies centred on (1) whether the SLN can be accurately identified, (2) whether SLN 
status predicts status of the axilla, (3) the optimal technique for SLN biopsy, and (4) 
identifying the appropriate population for SLN. Many of these studies shared similar 
protocols, which involve the SLNB using various techniques followed by ALND. The 
SLN status is then compared with the axillary lymph node status.
A meta-analysis of 69 studies between 1994 and 2000 involving 8059 patients found 
an overall SLN identification rate of 96% (7765 patients) and an overall false negative 
rate of 8.4% (range: 0-29%)33. In 28 (44.8%) studies, successful SLN mapping was 
>90%, and these studies were also associated with lower false negative rates (6.3% 
versus 11.1%) .11 trials reported zero false negative rate whilst 26 trials had rates
>10% . Other studies identified factors influencing successful SLN identification and 
false negativity. These include patient factors such as age and body mass index, and 
surgeons’ experience32,34,35. These studies have shown that SLN can be identified and 
that SLN can predict the axillary lymph node status with acceptable accuracy.
The potential role of SLNB is to identify patients with negative SLN, who do not 
require ALND thereby avoiding the risk of axillary morbidity. The current phase of
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research addresses the various clinical aspects of SLNB such the safety of 
implementation of SLNB in the management of breast cancer, the establishment of 
optimal SLN localisation technique, and the management of the axilla following a 
positive SLNB.
To date, there is only one published randomised clinical trial comparing SLNB with 
routine ALND. In this study (March 1998 to December 1999), 516 patients with 
primary breast tumours ( <2 cm in diameter) were randomly assigned either to SLNB 
and immediate ALND (the ALND group, 257 patients) or to SLNB followed by 
ALND only if the SLN contained metastases (the SLN group, 259 patients)36. 83 
patients in ALND group (32.3%) had metastasis, and the overall accuracy of SLNB in 
this group was 96.9% (sensitivity 91.2%, specificity 100%). 92 patients in the SLNB 
group (35.5%) had positive SLN and had ALND. The 167 patients with negative SLN 
in the SLNB group had less pain and better arm mobility and had no cases of overt
•J iT
axillary metastasis during follow-up . Other trials are currently underway and are 
summarised in Table 2.3.
SLNB is rapidly becoming standard practice for axillary lymph node staging in breast 
cancer. In the case of a negative SLN, ALND is not indicated. In the case of a positive 
SLN, ALND is currently recommended because of the risk of residual disease in the 
axilla. However, this is controversial as there are also alternatives such as axillary 
irradiation and observation. These are currently evaluated through randomised trials 
(Table 2.3). As the results of these randomised trials are unlikely to be available in the 
immediate future, a number of consensus statements have been issued to guide the 
clinical management of SLNB performed out with clinical trial settings. In the 
Consensus Statement on Guidelines for Performance of Sentinel Lymphadenectomy
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for Breast Cancer (third revision, October 2003) from the American Society of Breast 
Surgeons, a level I or II ALND is recommended in the event of a positive SLNB37.
Table 2.3: Summary o f onsoinz clinical trials evaluating the role o f SLNB in breast
38cancer (from Goval A. et al. )
Axillary Lymphatic Mapping 
Against Nodal Axillary 
Clearance (ALMANAC)
2000 1260 Randomise to: ALND or ALNS vs. SLNB
After Mapping o f the Axilla: 
Radiotherapy or Surgery 
(AMAROS)
2001 3485 If SLN positive randomise to: ALND vs. Radiotherapy
German Clinical 
Interdisciplinary Sentinel Study 
(KiSS)
2000 1912 If SLN negative randomise to: ALND vs. no ALND
French Randomised Sentinel 
Node Study (Fransenod) NA* 446
SLNB patients randomised to peritumoural 
injection vs. periareolar injection
International Breast Cancer 
Study Group Trial 
(IBCSG 23-01)
2001 1960 If SLN positive for micrometastases(IHC), randomise to: ALND vs. no ALND
American College o f Surgeons 
Oncology Group 
(ACOSOG-ZOOIO)
1999 5300
IHC positive SLN patients(H&E negative) 
observed to determine prognostic significance; 
bone marrow also assayed for micrometastasis 
to determine incidence and significance
American College o f Surgeons 
Oncology Group 
(ACOSOG-ZOOl 1)
1999 1900 If SLN positive(H&E) randomise to completion ALND vs. observation
National Surgical Adjuvant 
Breast and Bowel Project 
(NSABP-B-32)
1999 4500 If SLN negative randomise to: completion ALND vs. no additional axillary treatment
Royal Australasian College o f  
Surgeons Sentinel lymph Node 
biopsy versus Axillary 
Clearance (RACS SNAC)
2001 1000
SLN negative patients randomised to 
completion ALND vs. no additional axillary 
treatment
IHC, Immunohistochemical staining; H&E, Haematoxylin and eosin. *Not available
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2.6.3 The technique of SLNB
SLNB is a two-staged procedure involving first the localisation of SLN followed by 
the surgical biopsy. Current techniques for SLN localisation use a vital blue dye (such 
as Patent Bleu V and Isosulphan bleu) and/or " mTechnetium (99mTc) labelled 
radioactive colloid tracers. The commonly used colloids are " mTc sulfur colloid, 
" mTc human serum albumin nanocolloid and " mTc antimony trisulfide, which vary in 
particle size and range.
The tracers are injected into or in close proximity to the primary breast tumour. The 
rationale is that the tracer particles will enter the lymphatic system and be transported 
to the SLN by the lymphatic flow. The tracers are retained by the SLN, which is 
identifiable by the accumulation of blue dye and/or by the radioactivity using a 
handheld gamma probe.
Despite the consensus over the principles underlying SLNB, there are significant 
variations in the actual techniques used such as the choice of tracers, the site of 
injection and pre-operative imaging. In a meta-analysis of 40 studies, Liberman et al 
demonstrated 91% localisation rate using radioisotope only and combination
TOtechniques compared to 80% using blue-dye technique (Table 2.4) . With a narrower 
range of localisation rate, the combination technique appeared to be more consistent 
and reliable over radioisotope technique.
Operative issues such as the surgical definition of SLN, multiple SLNs, removal of 
additional non-SLN and credentialing have also contributed to the significant 
variations in SLN biopsy between institutions. However, these are beyond the scope 
of this thesis.
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Table2.4: Successful localisation rate, sensitivity and specificity o f  SLNB using blue 
dve. radioisotove and combination o f tracers
Blue Dye 
(12) 993
80%
(69-99%) 91% 100%
Radioisotope
(16) 1934
91%
(66-98%) 93% 100%
Combination
(12) 873
91%
(81-100%) 95% 100%
Total
(40) 3800 88% 93% 100%
(Adapted from Table 27.2 Validation studies of SLN biopsy in breast cancer: Hirman 
S Cody III: Sentinel Lymph Node Biopsy. Dunitz, London, 2002)
2.6.4 The SLNB Protocol at UCLH
At UCLH, patients, who were diagnosed with breast cancer by TA or following EBB, 
were recruited for SLNB following informed consent. Exclusion criteria were 
pregnancy, lactation, previous axillary surgery or irradiation, multifocal breast cancers 
and clinically positive axilla.
SLN localisation uses both " mTc-nanocolloid (Nycomed Amersham, UK) and Patent 
V blue dye. " mTc-nanocolloid is characterised by a very small size of albumin 
particles with typically more than 95% of the labelled colloid below 80nm. 15MBq of 
" mTc-nanocolloid in 0.2ml volume is injected intradermally overlying the palpable 
tumour or the site of previous excision breast biopsy (Figure 2.1). In the case of
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impalpable tumour, the site o f injection is at the areolar border o f  the corresponding 
quadrant. The injection takes place approximately 18 to 24 hours before surgery.
Fisure 2.1: Intradermal injection o f" n'Tc-nanocolloid
(Illustration from Figure 5b: M.R.S. Keshtgar, W.A. Waddington, S.R. Lakhani and 
P.J. Ell: Chapter 5 Injection techniques, The sentinel node in surgical oncology. 
Springer-Verlag, 1999 p.53)
Following injection, anterolateral dynamic imaging is acquired for a period o f  10 
minutes followed by static imaging with anterior and lateral views each for a period o f 
5 minutes using a low energy high-resolution collimator (400XC/T Single-headed 
large field-of-view, GE Medical Systems, USA). Dynamic imaging visualises the 
passage o f  the radio-colloid along the lymphatics (Figure 2.2a), whilst static imaging 
confirms the num ber o f  SLN localised using radio-colloid (Figure 2.2b).
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F isu re  2.2: D ynam ic and sta tic  images. (a ) D ynam ic im ages taken a t different tim e
frames illustrating the passage o f  radioisotope (dotted arrow) and uptake o f  colloid 
by SLN (arrow) and (b) anterior-posterior (left) and lateral (right) static images 
confirming successful localisation o f SLN.
(a)
5MIN5
15MINS
(b)
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At the time o f  surgery, 2ml o f Patent V blue dye is injected in the same fashion as the 
" mTc-nanocolloid (Figure 2.3). Using the gamma probe detector (Neoprobe 1500), 
the site o f  the maximal radioactivity is determined and marked as the site o f  incision. 
Following incision, the gamma probe is used to guide the dissection towards the SLN. 
SLN was defined as any lymph node which is radioactive and/or blue in colour. SLN 
is removed and ex-vivo radioactivity is measured to verify the excision o f  SLN. The 
residual radioactivity within the cavity is measured to confirm completion o f  SLNB. 
Biopsy o f  internal mammary SLN was not performed. All patients had ALND unless 
they refused.
Figure 2.3: A blue lymphatic tract after patent blue dve injection
,V”i;
(Illustration from Figure 5a: M.R.S. Keshtgar, W.A. Waddington, S.R. Lakhani and 
P.J. Ell: Chapter 7 Surgical techniques, The sentinel node in surgical oncology. 
Springer-Verlag, 1999 p.82)
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The SLNB protocol at UCLH was evaluated by Mr Mohammed Keshtgar in 2 phases 
that is in learning and recruitment40. In the learning phase, a total of 30 patients were 
recruited, in which SLN localisation was successful in 29 (97%). Three patients 
consented to SLNB only. Two patients had SLN in the internal mammary chain, but 
also had ALND. In the 24 patients, who had both SLNB and ALND, 7 patients had 
axillary nodal metastasis. SLN status was positive in 5 out of 7 patients (sensitivity of 
71%) and there were 2 false negatives (specificity 89%). In total, SLN correctly 
predicted the axillary status in 22 patients (91%).
In the recruitment phase, a total of 51 patients were recruited40. One patient 
underwent bilateral procedures. SLN localisation was successful in all 52 procedures 
(100%). 15 patients had axillary metastasis (28.8%), and all had positive SLN 
(sensitivity 100%). In 4 of 15 patients, the SLN was the only involved lymph node. 
There was no false positive (specificity 100%). Following the recruitment phase study, 
the combined intra-dermal injection technique was adopted for SLN localisation at 
UCLH.
2.6.5 Pathological aspects
The role of pathology is crucial to the success of SLNB as an alternative to ALND. 
An accurate pathological assessment of SLN is necessary in order for the SLN to 
predict axillary lymph node status.
In a standard level III ALND, 20 or more lymph nodes are usually removed for 
pathological analysis. Conventionally, each lymph node is longitudinally bisected 
through its hilum and is examined with H&E staining at the level of the bisection.
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However, this had been shown to underestimate lymph node metastases in several 
studies41. This is particularly so for smaller metastatic lesions such as micrometastases, 
which were first defined by Huvos et al. as tumour deposits smaller than 2mm42. In 
the Ludwig trial consisting of 921 patients, micrometastases were missed in 9% of 
node-negative patients, which were associated with significantly worse disease-free 
survival and overall survival at 5 and 10 years43,44.
With an average yield of 1 to 3 SLN, SLNB provides an opportunity for a detailed 
examination of nodal metastasis by making step sectioning and 
immunohistochemistry practical. Previous studies showed that the detection rate of 
metastasis increases by 9 to 47% using these techniques45. However, these techniques 
are too labour intensive and expensive for routine use in ALND specimens. In the 
Ludwig study43, it took 12 sections per tissue block and 12 tissue blocks per patient to 
identify micrometastasis in 9% of node-negative patients or 1600 slides to identify 
one additional node-positive patient. In a separate study, Wilkinson et al. found that 
an addition of 1449 slides was required to identify each additional node-positive 
patient46.
Many studies have confirmed the upstaging of breast cancers on the basis of a more 
detailed pathological work-up for SLNs45. However, there are considerable 
discrepancies in practice and varying opinions on the optimal histological protocol47. 
These include the number of step sections, the step size, the roles of 
immunohistochemistry and molecular techniques, and intra-operative assessment. The 
main factor for these controversies is the significance of micrometastasis.
- 7 4 -
Micrometastasis is an arbitrary term first defined in the 1970s to describe any 
metastatic lesions less than 2mm42. This ranges from a single cell or a small group of 
cells to tumour deposits. The advent of SLNB has led to more specific definitions. In 
the 6th edition of the American Joint Committee on Cancer Staging Manual48, 
micrometastasis is defined as a tumour deposit between 0.2 and 2 mm, which is 
usually seen on H&E staining. Such lymph nodes are designated as pNlmi, which is 
distinguishable from the traditional macrometastasis pN 1. As for single cells or small 
groups of cells, the term “isolated tumour cells” (ITC) applies with the pN0(i+) 
designation. ITC are usually detected by immunohistochemistry but can be confirmed 
by H&E staining. The nature of ITC is controversial and some authors regard ITC as 
merely dislodged cells during surgery that are biologically meaningless. Although the 
Ludwig and other studies have demonstrated a poorer prognosis associated with 
micrometastasis, whether the same applies to ITC is uncertain. Prospective trials 
(IBCSG23-01, ACOSOG-ZOOIO and NSABP-B32) are currently underway to 
determine the significance of micrometastasis and ITC. However, in a recently 
published case-control study, the axillary lymph nodes of 48 patients with stage 1 
breast cancer who subsequently developed metastasis after 15 years of follow-up were 
re-examined and compared with the axillary lymph nodes from an age- and stage- 
matched group of patients, who did not develop metastasis. It was concluded that 
micrometastasis >0.2mm leads to a worse prognosis whilst the significance of ITC 
remained unclear49. If ITC is found to be clinically significant, then a vigorous 
protocol for pathological examination may be required.
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2.6.6 Intra-operative assessment
SLNB is a significant advancement in the management of breast cancer. At present, 
patients undergoing SLNB would require ALND if SLN is found to be positive for 
metastasis. This occurs at a rate between 25% and 40% of SLN biopsies45. Because of 
the histological processing of the SLN, ALND has to be delayed as a second 
operation. This is inconvenient for patients, and may increase patients’ anxiety whilst 
waiting for the outcome of SLN histology. In addition, readmission for ALND incurs 
additional resources on the health service, which may limit the widespread clinical 
application of SLN biopsy. Intra-operative assessment of SLN is a potential solution 
as it enables clinical decisions to be made on ALND at the time of SLNB.
Touch imprint cytology (TIC) and fresh frozen section (FFS) are the two main 
techniques that have been widely evaluated for this purpose. Other techniques such as 
scrape cytology and intra-operative serial sectioning have also been described.
TIC is an established cytological technique. It has been used for intra-operative 
assessment of lymph node for metastasis in a variety of malignant diseases and intra­
operative assessment of excision margins of breast lesions. At UCLH50, the technique 
for assessing SLN involves bisecting the SLN along its longitudinal axis and through 
the hilum and gently touching the sectioned surface onto glass slides. These can be 
separately stained with rapid cytological stain such as RAL555 (Cell Path, UK), MGG 
and anticytokeratin immunocytochemistry. Slides can then be examined by an 
experienced cytologist under light microscope (Figure 2.4).
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Figure 2.4: SLN imprints, (a) Low-power view o f  SLN imprint. MGG. xlOO. (b)
High-power view o f malignant cells. MGG. x600. (c) Positive immunocytochemistry 
staining o f malignant cells. MNF116. x600.
(a) (b)
(c)
€
(Illustrations from Figures 3, 7a and b: G. Kocjan: Chapter 10 Cytology in the sentinel 
node. In M.R.S. Keshtgar, W.A. W addington, S.R. Lakhani and P J . Ell: The sentinel 
node in surgical oncology. Springer-Verlag, 1999 p. 114-115)
TIC is simple and quick to perform. TIC provides clear cytological details for 
evaluation and avoids the consumption o f tissue. However, potential pitfalls are the 
presence o f  large aggregates o f lymphoid cells, which may mimic metastatic lesions, 
the presence o f  single malignant cell, which can be missed, and 
immunocytochemistry staining o f  follicular dendritic cells^0.
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Fresh frozen section is also an established pathological technique. FFS involves the 
rapid freezing of specimen followed by sectioning and staining. As with TIC, the SLN 
is initially bisected so that the sectioned surface is examined. Unlike TIC, the tissue 
removed for FFS is consumed and cannot be re-used for definitive histopathology. 
The limitations of FFS include freezing artefact with loss of good tissue architecture 
and cytological detail, difficulty in obtaining a good complete section and difficulty in 
identifying small foci of tumour especially in lobular carcinoma51.
The drawbacks for intra-operative assessment of SLN include (1) variation in 
sensitivity of TIC and FFS, (2) delays whilst waiting for the results, (3) the need for 
an experienced pathologist, (4) pressure for the pathologist to provide a definitive 
report within a limited time frame and (5) patient anxiety resulting from false results
2.6.7 Pathological protocol at UCLH
The protocol for pathological assessment of SLN at UCLH is51:
1. Bisection of SLN along its longitudinal axis and through the hilum
2. TIC obtained from the sectioned surface: 3 slides with 3 imprints 
per slide. Staining using RAL555 (Cell Path, UK), MGG stain and 
anticytokeratin immunocytochemistry
3. SLN individually labelled and fixed in formalin
4. Standard H&E sections at 3 levels
5. IHC performed if the H&E sections show no evidence of 
metastasis.
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2.7 Summary
Surgical management of breast cancer has evolved significantly over the past few 
decades. For the primary tumour, radical surgery alone has given way to breast 
conservation with radiotherapy in clinically appropriate cases. For the axilla, the trend 
is towards less radical axillary dissection such as ALNS and SLNB. The overall aim 
is to minimize the extent of surgery thereby reducing the morbidity and disfigurement 
without compromising clinical outcome. With the exception of SLNB, landmark 
randomized clinical trials with long-term follow-up have supported such advances.
To facilitate widespread adoption, such advances must have a positive impact on 
resource utilization as well as clinical and patient benefits. For breast conservation 
surgery, post-operative radiotherapy is required, but further demands on resources are 
made by positive resection margins, which may require readmission for re-excision of 
margins. Likewise for SLNB, additional resources such as radioisotopes, gamma- 
probe detectors and nuclear medicine facilities are required. Readmission may be 
required for the completion of ALND or axillary radiotherapy in the event of a 
positive SLN. In these situations, readmissions increase the demands on resources and 
create inconveniences and anxiety for the patients. If re-operation is to be avoided, 
intra-operative margin and SLN assessments are necessary. This can be provided by 
TIC and FFS, but this requires additional specialist histopathology support.
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Chapter 3 Elastic Scattering Spectroscopy
3.1 Introduction
Elastic scattering spectroscopy (ESS) provides information on the elastic light 
scattering and light absorption properties of matter in the form of a spectrum.
Recently, there has been significant interest in its potential applications in
• 18biomedicine. These include the detection and diagnosis of tissue pathologies ' , non-
invasive drug concentration monitoring9’10, monitoring tissue-engineered constructs
1112and early repair in collagenous tissues ’ . This is because optical properties of tissue 
can change along with structural changes to tissues brought about by disease 
processes, trauma and healing. Such changes are often predictable and detectable by 
ESS.
ESS belongs to a group of technologies known as optical biopsy. Optical biopsy 
exploits the various interactions between light and tissue (1) to study the mechanical 
or biochemical structures of tissue, (2) to detect and to diagnose tissue pathology, 
and/or (3) to image tissue structures. There are numerous types of optical biopsy such 
as Raman spectroscopy13"15, fluorescence spectroscopy16 or imaging, and optical 
coherence tomography17"20, which have been evaluated clinically. However, these are 
beyond the scope of this thesis. The aim of this chapter is to discuss the physical basis 
of ESS, the design principles of ESS system, spectral analysis and results of clinical 
studies.
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3.2 Physical Basis of ESS
Several optical processes take place when light interacts with biological tissues. In 
combination, these interactions enable biological tissues to have different physical 
appearances to the human eye. At the basic level, reflection, propagation and 
transmission occur (Figure 3.1). When a beam o f  light is incident upon the tissue 
surface, some o f  the light is reflected. The remainder enters and propagates through 
the tissue medium. If enough light propagates through to the back surface, light can be 
transmitted through or be reflected by the back surface.
Figure 3.1: The reflection, propagation and transmission o f light
1 Reflection
2 Propagation
3 Transm ission
It is during the propagation phase that most o f the optical interactions take place. The 
principal interactions are elastic scattering and absorption. Other interactions such as 
Raman scattering and fluorescence also occur but these effects are considerably 
weaker in comparison. Optical biopsy technologies can be classified according to the 
type o f optical interaction (Table 3.1).
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Table 3.1: C ategories o f  optical b iovsv technologies
Fluorescence Steady-state fluorescence spectroscopy 
Time gated fluorescence spectroscopy 
Auto-fluorescence imaging
Enhanced-Fluorescence imaging/Photodynamic diagnosis
Raman scattering Raman spectroscopy
Elastic scattering Elastic scattering/Diffuse reflectance spectroscopy 
Polarised light scattering spectroscopy
Optical coherence Optical coherence tomography
3.2.1 The nature of light
Light is a form of electromagnetic radiation characterized by its dual nature as a wave 
and a particle. Electromagnetic radiation transfers energy in discrete ‘packs’, known 
as photons. Each photon has a specific frequency of oscillation (v) and a specific 
wavelength (X). The energy (E) of a photon is proportional to its frequency (v) by the 
equation E = hv, where h is Plank’s constant.
The electromagnetic spectrum classifies photons according to their frequency. 
Electromagnetic radiation between the wavelength ranges of 400 to 700 nm is visible 
to the human eye as light. This is often referred as the visible spectrum and ranges 
from infrared to ultraviolet (Figure 3.2).
- 8 6 -
Fieure 3.2: The visible spectrum
UltravioletInfrared
Wavelength (nm)
All photons have identical electromagnetic nature. Within a non-absorbing medium 
such as a vacuum, all photons travel at the same velocity, which is proportional to the 
product o f its wavelength and frequency. As a wave, light undergoes reflection, 
refraction and diffusion in the same manner as other waveforms.
3.2.2 Light absorption
Absorption is a major optical process, which determines the colour and transparency 
o f  biological tissues. It occurs at atomic and molecular levels, where light is captured 
and converted into internal energy by an absorber (chromophore). The process 
involves the transition o f  the chromophore from a lower energy state to a higher 
energy state, which is quantized. Absorption is governed by the Beer-Lambert Law, 
which states a linear relationship between absorbance and the concentration o f  the 
chromophore.
Each chromophore has a specific absorption profile (extinction coefficient), which 
describes the level o f  absorption at different wavelengths. The major chrom ophores in
- 8 7 -
biological tissue are haemoglobin, melanin, deoxyribonucleic acid (DNA), 
cytochrome c oxidase and p-carotene.
Water is an absorber of electromagnetic radiation below 200nm and above 900nm 
wavelengths. Therefore, it has very little effect on the visible spectrum thus allowing 
the propagation of light through biological tissue.
Haemoglobin is one of the most important chromophores in human tissue because of 
its omnipresence and its high absorptive properties. In the human body, haemoglobin 
exists in two main forms: deoxygenated (Hb) and oxygenated (HbC>2). Each has a 
characteristic extinction coefficient (Figure 3.3). The absorptive properties derive 
from the haem protein, which has two characteristic bands. The main band is in the 
blue region (390-450nm) of the visible spectrum (black arrow), and is known as the 
Soret band. The other lies in the 450 to 700 nm range and is called the ’’visible" or 
"alpha" and "beta" band(s) (white arrow). The Soret band is typically 5 to 10 times 
more intense than the visible bands. The Soret band of HbC>2 appears at 415 nm (black 
arrow, red spectra) and the alpha and beta bands appear at 577 nm and 542 nm 
respectively (white arrow, red spectra). For Hb, the Soret band is a red shifted to 
431nm (black arrow, blue spectra), and a single broad band at 555nm replaces the 
alpha and beta bands (white arrow, blue spectra). In addition, Hb has a much weaker 
but characteristic absorption peak at 760 nm (dotted arrow).
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I
Figure 3.3: Molar extinction coefficient for haemoglobin in water
Hb02 cm- 1/M 
Hb cm-1 /M
DNA absorbs in the ultraviolet range between 280 and 320nm, which can induce 
structural changes in DNA resulting in carcinogenesis e.g. malignant melanoma and 
other skin cancers. The design o f  ESS systems must take this into account. In addition, 
DNA has scattering properties in the visible spectrum.
Other chromophores such as melanin and (3-carotene are present in specific parts o f  
the body such as skin and fat (Figure 3.4) respectively. These must be taken into 
account in the analysis o f  ESS data.
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Fisure 3.4: Absorption coefficient o f  fat corrected  for sca ttering  contribution
600 700 800 900 1000 1100
Wavelength (nm)
3.2.3 Elastic scattering
Scattering is an optical process, w hich causes light to change its direction o f  
propagation. There are several d ifferent scattering processes such as refraction, 
R ayleigh scattering, R am an scattering  and Elastic scattering. These are different 
processes occurring  at d ifferent levels e.g. subatom ic, m olecular and cellu lar levels. 
N ot all scattering p rocesses take place in b iological tissue. The scattering processes in 
biological tissues are e lastic  scattering and Ram an scattering.
Elastic scattering is the predom inant scattering process in tissue. It is term ed elastic 
because the frequencies o f  the scattered photons are the sam e as the incident photons. 
E lastic scattering occurs w hen light interacts w ith spherical bod ies such as cells and
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organelles21. An important characteristic of elastic scattering is the angular 
distribution of the scattered light also known as the angular effect. Differences in the 
light scattering properties of normal and malignant cells are attributed to a change in 
the average size of the scattering centres22.
The angular distribution can be described by Mie theory, which consists of a series of 
complex formulae. The angular distribution is dependent on the wavelength of the 
photon and size of scattering particle23,24. In general, a tissue component whose size is 
small compared to the wavelength will scatter light more isotropically than larger 
components, and in biological tissue, elastic scattering is highly anisotropic. The 
physics of light scattering in biological tissue is complex and is beyond the context of 
this thesis.
When light propagates through biological tissue, it is subjected to multiple scattering 
events. Therefore, the data acquired do not provide information as to the individual 
scattering events but rather indicate the overall scattering properties of the tissue,
99which is the effective scattering coefficient . This coefficient is proportional to the 
density of the scattering particles.
Raman scattering is a complex phenomenon occurring at molecular level. It is an 
inelastic scattering process, because the scattered photons have different frequencies 
from the incident photons. Several Raman scattering systems are currently under 
evaluation for their abilities to diagnose tissue pathology including breast cancer13'15.
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3.3 The Elastic Scattering Spectroscopy System
3.3.1 Key features
The ESS system at NMLC consists o f a pulsed xenon lamp, an optical probe, a 
charged couple device (CCD)-spectrometer and a laptop personal computer for 
system control and spectral record. Figure 3.5 illustrates the schematic diagram o f  the 
ESS system. The design o f  the ESS system reflects on the four basic processes o f 
optical biopsy: (1) light delivery to tissue, (2) light-tissue interaction, (3) light 
collection from tissue and (4) display o f collected data.
Figure 3.5: Schematic diagram o f the ESS system
X e n o n
Spectrometer
Laptop PC
V
Optical probe
Tissue
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The operating manual of ESS system is enclosed in Appendix 1 of this thesis. Spectral 
acquisition is full automated upon activation. It initiates by acquiring a “dark 
spectrum” without triggering the xenon lamp. This is followed by repeated pulses of 
light from the xenon lamp until a threshold of light intensity is reached at the 
spectrometer. The “dark spectrum” is subtracted from the spectrum recorded to 
provide an ESS spectrograph. The entire process takes approximately one second. 
Table 3.2 illustrates the key features of the ESS system.
Table 3.2: Key features o f ESS
• ESS system is portable and is easy to set up
• Components are widely available and relatively inexpensive
• Spectral acquisition takes approximately one second
• ESS system is safe and does not involve ionised radiation or
laser (see Light Source)
• Optical probes can be supplied sterilised for intra-operative
use (see Optical Probe)
• ESS permits in-vivo and ex-vivo spectral acquisition
• Software is currently under development to analyse
spectrographs. No expert interpretation is needed (See Spectral
Analysis)
3.3.2 Light source
The light source is a pulsed xenon arc lamp (Perkin Elmer, Inc.). It produces short 
pulses (approximately 1/xs) of broad spectrum light. Because of potential health 
hazard, ultraviolet B (280-315nm) and C (100-280nm) light have been filtered and the
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light output o f system ranges between 320-920nm. The spectral output taken against a 
white reflectance standard (Spectralon™, Labspere, Inc., North Sutton, New 
Hampshire) is illustrated in Figure 3.6.
Figure 3.6: Spectral characteristics o f xenon arc lamp against a white reflectance
standard
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Prior to operation, the ESS system is referenced against Spectralon™, which is 
spectrally flat between 250-1000nm, thereby allowing spectral variations in the light 
source, spectrometer, fibre transmission and fibre coupling to be accounted for.
The main considerations regarding the light source o f the ESS system are: (1) the type 
o f light source and (2) the safety aspects. Many types o f  light sources such as light 
emitting diodes, fluorescent bulbs and filament lamps are commercially available and 
can be used for optical biopsy. The choice o f a pulsed xenon arc lamp for our ESS 
system is because o f  the requirement for the production o f multiple pulses o f  stable 
broadband light in millisecond duration at high repetition rates.
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As regards to safety, the health hazard associated with ultraviolet B (280-315nm) and 
C (100-280nm) light and the thermal effect o f light must be appreciated. In our ESS 
system, both ultraviolet B and C are filtered. In our experience, there has been no 
discomfort or pain felt by subjects during in-vivo use and no histological evidence o f 
tissue damage.
3.3.3 Optical probe
The optical probe (Figure 3.7a) consists o f two parallel flexible optical fibres, the 
illuminator fibre and collection fibre, which are housed in a metal casing for the ease 
o f handling. The illuminator fibre is connected to the pulsed xenon lamp and delivers 
light to the tissue specimen upon activation o f  the ESS system. Following optical 
interactions, a portion o f  scattered light enters the collection fibre, and is delivered to 
the CCD-spectrometer. For ESS acquisition, the optical probe has to be in direct 
physical contact with the tissue specimen. Figure 3.7b is a schematic illustration o f 
this process.
Figure 3.7(a & b): Optical probe
C ollection
fibre
Illuminator
fibre
Light absorption  
Light scattering
N ucleus  
Other organelles
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Connections of the proximal ends of the optical fibres to the pulsed xenon lamp and 
CCD-spectrometer are by SMA connectors. The illuminator fibre is 400/mi in 
diameter, and the collection fibre is 200/zm in diameter. The centre-to-centre 
separation distance between the two fibres is 350/xm. For this probe geometry, the 
volume of tissue investigated is approximately 500 /mi long, 300fim wide and 300/xm 
deep. This was determined using Monte-Carlo simulation with Mie theory 
incorporated for the details of the scattering events25.
The separation of the fibres has a profound bearing on the character of the received 
signal26. For narrow separation, the ESS spectrum depends mainly on the scattering
9 f\properties of tissue although some absorptive features also influence the signal . 
With a wider separation distance, the ESS spectrum is predominantly influenced by 
absorption. The 350/un separation distance is an engineering compromise for optimal 
performance26.
3.3.4 Tissue specimen
The advantage of ESS is that ESS acquisitions can be made from in-vivo and ex-vivo 
tissues by simply placing the optical probe directly onto the tissue and without the 
need of tissue preparation i.e. fixation, staining and freezing. The optical probe can be 
sterilized by ethylene oxide for on-table use during surgical operations. Hence, the 
potential applications of ESS are vast.
As an emerging technology, technical information concerning the effects of tissue 
handling on ESS is not available. However, this may have potential significance, for
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example, in situations where ex-vivo ESS data are used for in-vivo applications and 
visa versa. Other variables such as time between surgical excision and ESS 
acquisition, the effects of temperature, tissue hydration and tissue fixation may have 
significant impact on the optical properties of tissues. At present, there are only a few 
published studies into the effects of tissue handling on optical biopsy. These include 
studies on non-human tissues and other optical biopsy technologies apart from 
ESS13’27-30.
For example, fluorescence intensity in fresh mouse skeletal tissue increases over a 
period of days with tissue dehydration and with formaldehyde fixation30. Raman 
spectroscopy of human bronchial tissues is significantly affected by tissue 
dehydration and formaldehyde fixation27. In contrast, formaldehyde fixation does not 
seem to induce significant changes in Raman spectra of human breast tissue13.
3.3.5 CCD-Spectrometer
CCD-spectrometer (S2000 Ocean Optics) produces a spectrograph of the light 
entering the collection fibre from tissue following elastic scattering. A CCD- 
spectrometer is used because of its high sensitivity for measurement at low light 
intensities and its short data collection time. The alternative is a photomultiplier tube, 
which is more sensitive at low-intensity but has a longer data collection time. CCD is 
most commonly used in optical biopsy. The information is transferred to laptop 
computer, where it is displayed in the form of a spectrograph.
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3.4 Elastic Scattering Spectrograph
Figure 3.8 illustrates typical ESS spectra o f normal breast tissue, breast fibroadenom a 
and breast cancer acquired using the ESS system. The X-axis is wavelength o f  light 
from 320nm to 820nm. The Y-axis is the light intensity. Each spectrograph contains 
1801 data points. Individually, each data point and its absolute intensity value are o f 
no significance. It is the overall patterns generated by the data points that are o f  
significance.
An ESS spectrograph is characterised by troughs and linear gradients. The troughs are 
absorption bands o f  chromophores. The most prominent are those o f haemoglobin 
(Soret, alpha and beta bands), which are clearly demonstrated in the tumour spectrum 
(red) above. The other feature o f  spectrographs is the linear gradients such as those at 
345-375nm and 620-820nm, which are attributed to elastic light scattering.
Figure 3.8: Typical optical spectra taken from normal breast. breast fibroadenoma
and breast cancer
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3.5 Spectral Analysis
The ESS spectrographs illustrated in Figure 3.8 are typical examples. However, there 
are wide variations in the spectrographic patterns within different breast tissue types. 
Visual inspection of ESS spectra is sub-optimal for spectral interpretation and also 
time consuming especially when a large number of ESS spectra is involved. A system 
for spectral analysis would be advantageous for the following reasons:
• Improving speed of spectral analysis,
• No requirements for training to interpret ESS spectra
• No human factor/error involved in misinterpretation
The technique used for ESS spectral analysis at NMLC is Model Based Analysis 
(MBA), which was developed in-house as there are no specifically designed and 
commercially available software. In addition to MBA, hierarchical cluster analysis 
and artificial neural networks were also studied31. MBA is a two-staged process 
consisting of Pre-processing and Linear Discriminant Analysis (LDA).
An ESS spectrum consists of 1801 data points, which together with its absolute 
intensity value are of no significance. It is the overall patterns generated by the data 
points that are significant. The role of pre-process is to reduce the dimensionality into 
various coefficients (or eigenvalues) suitable LDA.
First, ESS spectra underwent “smoothing”, in which each data point was replaced by 
the average of the 20 neighbouring data points thereby reducing 1801 data points to 
180 intensity values. Each “smoothed” spectrum was subsequently standardised by
- 9 9 -
subtracting to the mean intensity of the spectrum (i.e. the average intensity over the 
full spectral range) from each data point and then divided by the standard deviation of 
the smoothed spectrum. This gave all the spectra a mean intensity of zero and a 
standard deviation equal to 1. The standardisation process enabled each spectrum to 
have relative intensities rather than absolute values allowing spectral comparison and 
further processing. Once standardised, principal component analysis (PCA) was 
applied to the spectra to reduce the data to only those regions with large variability, 
which are referred as principal components. This was carried out using the statistical 
package, Systat 9.0 (Systat Software Inc., Richmond, California, USA).
The second stage, LDA, used all the principal components to develop an algorithm for 
discrimination between tissue pathologies (also using Systat 9.0). This was done by 
calculating a set of weights that specify a hyperplane that splits the data into groups 
such as cancerous and normal breast tissues and selecting a set of 6-10 principal 
components to form a LDA algorithm.
As spectral analysis is under development, clinical studies in this thesis were 
validated using 2 analysis techniques: bootstrapping and jackknife. In the bootstrap 
analysis, 50% of ESS spectra with corresponding pathology were randomly selected 
as the “training set” to train and develop a LDA algorithm. The LDA algorithm was 
then used to test the remaining spectra (the testing set) and the results were compared 
with the corresponding reported pathology. This process was repeated 1000 times 
with re-sampling of training and testing sets each time. The average sensitivity and 
specificity of spectral analysis is reported with standard variance. Bootstrapping 
provides a reliable test of our spectral analysis technique: it reduces the potential
- 100-
effects of a stochastic selection of training and testing sets, which would favour either 
exceptionally good or poor sensitivity and specificity.
A jackknife analysis is essentially a “leave one out” analysis, in which one spectrum 
was used for testing whilst the remainder were used for training. Analysis is repeated 
until each spectrum has been tested. Therefore, the sensitivity and specificity of the 
spectral analysis are absolute.
Other techniques for spectral analysis are available and have been evaluated by other 
institutions on different tissue types. These include mathematic models to calculate 
specific parameters such as haemoglobin concentration and saturation, scattering
99  1 f \  8 99parameters , fluorescence indices and nuclear sizes ’ . Spectral analysis in general 
is in the early stages of development. Many of the systems have been developed in- 
house and therefore not available for multi-institutional scrutiny. In addition, there is 
no consensus on the optimal techniques or comparative studies on different 
techniques.
3.6 Review of Clinical Data
Currently, only a limited number of clinical studies on optical biopsy have been 
published. These are illustrated in Table 3.3 together with their respective sensitivity 
and specificity. It is important to appreciate that most of these studies are only “proof 
of concept” as they are not prospective studies comparing against established 
standards such as histology, cytology and frozen section4. The sensitivities and 
specificities provide a general guide and reference demonstrating the potential of 
these emerging technologies. Direct comparisons between these studies should be
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avoided because of the differences in hardware, spectral analysis, different organ and 
diseases being studied, specimen handling and protocol in histological correlation. 
However, these sensitivities and specificities are acceptable and promising. Further 
developments and evaluations of optical biopsy technologies are merited.
Table 3.3: Published clinical results o f optical biopsy
Breast cancer* 69% 85% 31(72 tissue sites)
Bigio31 ESS
Sentinel nodes 
(Breast)* 58% 93%
31
(54 tissue sites)
Breast cancer** 67% 79% 31(72 tissue sites)
Sentinel Node 
(Breast)** 91% 77%
31
(54 tissue sites)
Jeijes2 ESS
Oral cancer 
(Excision margins) 87% 80% 21
Jerjes1 ESS (Lymph nodes) 98% 68% 13(130 lymph nodes)
Johnson3 ESS Sentinel Node (Breast) 84% 91%
68
(169 lymph nodes)
Lovat4 ESS Barrett’soesophagus 75% 80%
41 patients 
(71 tissue sites)
Mourant5 ESS Bladder cancer 100% 97% 10
Muller34 F, RS and ESS Oral cancer 96% 96%
15
(91 tissue sites)
Panjehpour16 F Barrett’s
oesophagus 90% 96% 36
Scarisbrick6 ESS Malignantmelanoma 100% 77%
77
(100 lesions)
Stone14 Raman Epithelial cancer >90% >90% Not stated
Utzinger7 RS
Ovarian tissue 
(Malignant) 86% 79% 16
Ovarian tissue 
(Benign) 86% 80%
(72 tissue sites)
Wallace8 ESS Barrett’soesophagus 90% 90%
13
(76 tissue sites)
Yamasaki15 Raman Lung cancer 91% 97% Not stated 
(210 tissue sites)
ESS: Elastic Scattering Spectroscopy; F: Florescence; RS: Reflectance Spectroscopy 
* using Artificial Neural Network, ** using Hierarchical Cluster Analysis
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3.7 Potential Applications of ESS in the Management of Breast Cancer
ESS is an emerging technology with potential widespread clinical applications 
because of its ability to detect and diagnose tissue pathology and its key features 
(Table 3.2). Its eventual success will depend on the adoption of this technology by 
clinicians and acceptance by patients. Therefore, it is important for ESS to 
complement and improve existing practices without complexity. Chapters 1 and 2 
reviewed the current diagnostic techniques and surgical management of breast cancer, 
and provided certain clinical situations where ESS can be applied. These include 
percutaneous diagnosis of breast cancer, ESS guided breast core biopsy, intra­
operative assessment of SLN and tumour excision margin.
3.8 Summary
ESS and other optical biopsy technologies are exciting developments in biomedicine 
with potential clinical and scientific applications. They exploit the interactions 
between light and tissue, and the change in optical properties of tissue with disease 
processes. Various systems are specifically designed to suit the particular optical 
interaction studied. As an emerging technology, technical information such as the 
effect of tissue handling is not available. These issues have to be considered.
The ESS system at NMLC is designed as a portable system for in-vivo and ex-vivo 
detection and diagnosis of tissue pathologies in particular malignant and pre- 
malignant conditions. The system involves broad spectrum light with harmful 
ultraviolet B and C light filtered, and is considered safe. Other advantages include the 
relatively low cost compared with existing technologies such as US, MRI and PET.
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The ultimate goal at NMLC is to produce an expert system, which is capable of 
analysing ESS spectra in real-time without the need of human interpretation. The 
technique used for spectral analysis is MBA, which involves the pre-processing of 
data and subsequent LDA, and is currently under development.
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Chapter 4 Aims of Thesis
Elastic scattering spectroscopy (ESS) is an emerging technology with potential 
widespread clinical applications. In the management of breast cancer, potential 
applications include percutaneous diagnosis of breast cancer, ESS-guided breast 
biopsy, intra-operative assessment of sentinel lymph nodes (SLN) for metastasis and 
tumour resection margins. The ultimate goal at the National Medical Laser Centre is 
to produce an expert system, which is capable of analysing ESS spectra in real-time 
without the need of human interpretation. This is considered as one of the critical 
success factors for its eventual success. The current stage of development is centered 
on the development of the spectral analysis system, which has direct influence on the 
sensitivity and specificity of ESS. The thesis of Dr Gavin Briggs identified Model 
Based Analysis as a suitable technique for spectral analysis. However, further 
validation and improvements are necessary. Other aspects, such as different 
proportions of normal and malignant breast tissue within the field of study, may have 
significant influence on the sensitivity and specificity of ESS, but have yet to be 
determined. In addition, other technical issues, such as the effects of ambient lighting, 
tissue handling and formaldehyde fixation, may have important but unknown effects.
The aims of thesis are:
1. To investigate the effects of ambient lighting, tissue handling 
and formaldehyde fixation on ESS
2. To improve the sensitivity and specificity of ESS in determining 
the axillary lymph node status in breast cancer
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3. To undertake a comparative study of ESS and touch imprint 
cytology in assessing SLN status in breast cancer
4. To determine the effect of different proportions of normal and 
malignant breast tissue within the field of study on the 
sensitivity and specificity of ESS, and to evaluate the impact of 
this, if any.
Chapter5: The Effects of Ambient Lighting, Tissue Handling and 
Formaldehyde Fixation on Elastic Scattering Spectroscopy
5.1 Introduction
ESS is capable of detecting pre-malignant and malignant changes in human tissues. 
The ultimate goal is to develop an expert system, which would analyse the spectra in 
real time. Therefore, it is necessary to acquire a large volume of spectra both for the 
development and the testing of MBA. Although all ESS spectra used in this thesis 
were acquired from freshly excised specimens, this may not always be possible, and 
spectral acquisition may take place after a significant period of time. Therefore tissue 
specimens need to be handled appropriately to prevent autolysis. Current standard 
practice for handling tissue specimens includes immediate fixation in 4% 
formaldehyde solution, storage in chilled conditions with ice and submersion in 
normal saline. The effects of these handling techniques on ESS are unknown. 
However, a few publications have demonstrated that tissue handling can have effects 
on Raman, fluorescence and diffuse reflectance spectroscopy1'4. The aim of this 
chapter is to investigate these effects on ESS in axillary lymph nodes. In addition, this 
chapter will evaluate the effect of ambient lighting on ESS. Axillary lymph nodes 
were specifically chosen because a major theme of this thesis is the clinical 
application of ESS in detecting lymph node metastases in breast cancer (Chapter 6).
5.2 The Effects of Ambient Lighting on ESS
5.2.1 Introduction
The ESS system at NMLC is a portable system, which can be used in various settings. 
These include surgical operating theatres, laboratories, clinics and even the outdoors.
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The ambient light intensities o f these environments vary significantly from 
approximately 700lux in a normal room to 20,0001ux under a standard operating lamp. 
As spectral acquisition involves the collection o f  scattered light from the tissue, 
ambient light could theoretically enter the tissue, undergo scattering and absorption, 
and be collected by the ESS system (Figure 5.1). This may contaminate ESS spectra 
and ultimately affect spectral analysis. The aim o f  this study is to investigate the 
effect o f ambient lighting on ESS spectra.
Fieure 5.1: Illustration to demonstrate potential contamination o f ESS by ambient 
light
Collection fibre
Illuminator fibre
Light from xenon lamp 
Ambient light
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5.2.2 Methods
Axillary lymph nodes were harvested from surgical specimens of patients with proven 
breast cancer undergoing axillary surgery following informed consent. The lymph 
nodes were bisected along their longitudinal axes. The optical probe was applied to 
the sectioned surface and was fixed in position using a clamp during the study. Two 
ESS spectra were acquired at different ambient light intensities from llux (total 
darkness) to 20,0001ux. All lymph nodes were fixed in 4% formaldehyde solution and 
sent for pathology at the end of the study.
ESS spectra were visually inspected. For comparison, ESS spectra at various ambient 
light intensities were normalised to the spectra taken in total darkness by division. The 
number of xenon lamp pulses per spectrum (Xe-PPS) was also recorded.
5.2.3 Results
In total, 3 sets of measurements were made from 3 normal axillary lymph nodes. A 
selection of ESS spectra from all 3 lymph nodes is illustrated in 3 ambient light 
intensity ranges: l-1001ux, lOO-lOOOlux and 1000-200001ux in Figure 5.2.
Fieure 5.2: ESS spectra acquired at various ambient light intensities (a) between 1-
lOOlux. (b) between lOO-lOOOlux and (c) between 1000-20000lux
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(b)
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(C)
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On visual inspection, there are minor changes in the spectra o f  all 3 lymph node 
between 1 and lOOOlux. These are mainly differences in spectral intensities whilst the
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overall spectral profiles (shape) remain unchanged. As the ambient light intensity 
increases from lOOOlux, there is a decreasing trend in the overall spectral intensities 
(i.e. downward shift o f  spectra) in all 3 lymph nodes. The spectral profiles also appear 
to flatten particularly in the Soret, alpha and beta bands, which are the strong 
absorption bands o f  oxygenated haemoglobin at 415nm, 577nm and 542nm 
wavelengths respectively (See Section 3.2.2). However if  the scale o f  spectral 
intensity is adjusted (Figure 5.3), the spectral profiles at 200001ux remained sim ilar to 
those at 1 lux between 320 and 620nm.
Figure 5.3: ESS spectra acquired at llux and 20000lnx ambient light intensities in
separate intensity scales
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From the practical point o f  view, difficulties in acquiring satisfactory spectra were 
encountered at 20,0001ux. Several spectra had to be discarded (Figure 5.4).
Figure 5.4: Examples o f discarded spectra acquired at 20. OOOlwc
150 i
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c
420 520320 620 720 820 920
Wavelength (nm)
 Lymph node 1
 Lymph node 2
Lymph node 3
Further comparisons between two given spectra can be made by normalising one 
against the other. This is carried out by dividing the spectral intensities o f  one 
spectrum by the corresponding spectral intensities o f  the other. An increase in spectral 
intensity at a particular wavelength in the former would result in a normalised
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intensity value greater than 1, and visa versa. A normalised intensity value of 1 
indicates no change. Figure 5.5 illustrates normalised spectra of Lymph Nodes 1, 2 
and 3 at various ambient light intensities, which were normalised to their respective 
spectrum at llux.
In all 3 lymph nodes, a sequence of changes can be seen in the Soret, alpha and beta 
bands even at low ambient light intensities. The sequence begins with an increase in 
normalised intensity in the Soret band followed by increases in normalised intensities 
in the alpha and beta bands. The sequence proceeds with a gradual resolution of the 
raised normalised intensities. The sequence occurs at different ambient light 
intensities in the 3 lymph nodes.
Otherwise, there are no significant changes in spectral profile between 620 and 
920nm. It is remarkable that the normalised spectra of all 3 lymph nodes at 10,000 
and 20,0001ux have a relatively horizontal trend between 620 and 920nm.
Fieure 5.5: Normalised spectra o f  Lvmnh Nodes 1. 2 and 3 at various ambient light
intensities (a) between 10-100lux. (b) between lOO-lOOOlux and (c) between 1000- 
20000lux normalised to their respective spectrum at llux
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The number of Xe-PPS at different ambient light intensities is illustrated in Table 5.1. 
This is determined by the threshold of light intensity being reached at the CCD- 
spectrometer during spectral acquisition, which in turn deactivates the xenon lamp 
(see Section 3.3.1). A reduction in the number of Xe-PPS suggests either more 
photons from the Xenon lamp or photons from an external source, i.e. ambient light, 
are being collected by the collecting fibre of the optical probe and delivered to the 
CCD-spectrometer. In general, the number of Xe-PPS remained the same at lower 
ambient light intensity ( ^OOOlux), and reduced in all 3 lymph nodes with increases in 
ambient light intensity.
Table 5.1: Number o f Xe-PPS o f Lymph Nodes 1-3 at various ambient light intensities
1 17 41 20
100 17 41 20
500 17 41 20
1000 17 41 20
2000 17 31 20
3000 17 31 15
4000 17 31 15
5000 17 23 15
8000 13 23 11
10000 9 15 11
20000 7 7 7
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5.2.4 Discussion
The findings of this study are as follow: (1) the overall spectral profile remained 
stable with minor changes at lower ambient light intensities (<10001ux), (2) there was 
a gradual reduction of overall spectral intensity and flattening of spectral profile as the 
ambient light intensity increased above lOOOlux, (3) spectral profiles at higher 
ambient light intensities were similar to those acquired in darkness after re-scaling, (4) 
normalised spectra demonstrated a sequence of changes that occurred in the Soret, 
alpha and beta bands, and (5) Xe-PPS reduced as the ambient light intensity increased.
In order to analyse these findings, it is important to appreciate the process of spectral 
acquisition. Spectral acquisition initiates with a background measurement from the 
tissue without triggering the xenon lamp. This is followed immediately by ESS 
measurement with the pulses of light from the xenon lamp until a threshold of light 
intensity is reached at the spectrometer. ESS spectrum is generated by subtracting the 
background measurement from the ESS measurement.
As the xenon lamp is controlled by the spectrometer, reductions in Xe-PPS at high 
ambient light intensities indicate that ambient photons entered the detector fibre of the 
optical probe via the lymph node, and were recorded by the spectrometer. 
Subsequently, less photons from the xenon lamp were needed to reach the light 
intensity threshold of the spectrometer; hence the reduction in Xe-PPS (Observation 
5). However, the level of ambient light intensity, at which Xe-PPS decreases, differed 
in all 3 lymph nodes, likewise the degree of Xe-PPS reduction. These may reflect the 
individual differences in optical properties of the lymph nodes in particular the 
surface of the lymph node.
At lower ambient light intensities (<10001ux), Xe-PPS was unchanged in all 3 lymph 
nodes. In addition, spectral profiles only showed minor changes. These suggest that 
the ambient lighting has little effect on ESS spectra at intensities below lOOOlux, 
which is typical of normal indoor conditions such as laboratories and clinics.
ESS spectra are generated by subtracting the background measurement from the ESS 
measurement. The difference between the background and ESS measurements is 
greatest when ESS spectra are acquired in total darkness. As the ambient light 
intensity increases, the difference decreases due to the contribution of ambient 
photons to the background measurement and the reduction of Xe-PPS. This explains 
the gradual reduction of overall spectral intensity and the flattening of spectral profile 
as ambient light intensities increase (Observation 2).
By subtracting the background measurement from the ESS measurement, the ambient 
light is accounted for in the ESS spectra. The essential difference between ESS 
spectra acquired at low and high ambient light intensities is that more photons from 
the xenon lamp were used in the former. This provides an explanation for the 
similarities in spectral profiles of the spectra taken at 1 and 20,0001ux after re-scaling 
(Observation 3).
Normalised spectra provide comparisons between ESS spectra at various ambient 
light intensities to that at llux. The most obvious changes in the normalised spectra 
occurred in the Soret, alpha and beta bands, which are the absorption bands of 
haemoglobin (Observation 4). As absorption is governed by the Beer-Lambert law,
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which states that there is a linear relationship between absorbance and the 
concentration of the chromophore, the changes in the normalised spectra cannot be 
explained by the changes in the ambient light intensity since the concentration of 
haemoglobin remained constant. Possible explanation would be the change in 
oxgenation status of haemoglobin during this study (see Section 5.3).
Apart from the above changes, the normalised spectra were relatively horizontal 
indicating that the only difference between ESS spectra at various ambient light 
intensities is in spectral intensity. This is resolved by standardisation during the pre­
processing stage of spectral analysis (See Section3.5). The spectral profile, from 
which the principal components are derived for analysis, remained relatively 
unaffected. Theoretically, ambient light intensity should not influence Principle 
Component Analysis (PCA) and subsequent spectral analysis despite the observed 
changes in ESS spectra. Further investigations with larger specimen numbers is 
needed to establish the effect of ambient light intensity on spectral analysis.
5.2.5 Conclusion
In conclusion, ambient light can enter the ESS system via tissue. Increases in ambient 
light intensity can result in decrease in spectral intensity, flattening of ESS spectra and 
reduction in Xe-PPS. These changes are explicable by the process of spectral 
acquisition, and can be resolved potentially by standardisation during the pre­
processing stage of spectral analysis. Underlying changes in spectral profile can be 
seen in the Soret, alpha and beta bands, which are not related to the changes in 
ambient light intensity. No other changes were seen in the spectral profile. Therefore, 
increases in ambient light intensity are not expected to affect spectral analysis.
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5.3 The Effect of Exposure in Room Condition on ESS
5.3.1 Introduction
ESS is an emerging technology with potential in-vivo and ex-vivo clinical 
applications. For ex-vivo applications such as intra-operative assessment of resection 
margins of excised tumours and SLN for metastasis, the time between excision and 
spectral acquisition may vary. During this time, significant changes in the ESS spectra 
may occur. The aim of this study is to investigate the effect of time on ESS spectra of 
axillary lymph nodes in room conditions following excision.
5.3.2 Methods
Axillary lymph nodes were harvested from surgical specimens of patients with proven 
breast cancer undergoing axillary surgery following informed consent. The lymph 
nodes were bisected along their longitudinal axes. The optical probe was applied to 
the sectioned surface and was fixed in position using a clamp during the study. The 
initial ESS spectrum was taken at time zero. Subsequent ESS spectra were taken 
every 30 seconds for the first 15 minutes, then every 60 seconds for the next 15 
minutes and finally every 5 minutes for the next 30 minutes. At the end of the study, 
the lymph nodes were fixed in 4% formaldehyde solution and sent for pathology. ESS 
spectra were visually inspected. For comparison, ESS spectra at various time intervals 
were normalised to the spectra taken at zero minute by division.
5.3.3 Results
In total, 6 sets of measurements were made from 5 normal lymph nodes and 1 
metastatic lymph node (Lymph node 2). A selection of ESS spectra from all 6 lymph 
nodes is illustrated over 2 time intervals: 0-10 min and 10-60 min in Figure 5.6.
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Figure 5.6: ESS spectra o f Lymph Nodes 1 to 6 acquired between 0-10 minutes and 
between 10-60 minutes following excision
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On visual inspection, a sequence of changes can be seen in Lymph Nodes 2, 3 and 4. 
This is characterised by (1) a right shift of the Soret band trough from approximately 
415nm to 431nm, (2) a gradual replacement of the alpha and beta bands by a single 
broad band at 555nm and (3) flattening of peak at 390nm. These changes occurred 
after 2 minutes for Lymph Node 2, after 50 minutes for Lymph Node 3, and after 4 
minutes for Lymph Node 4. No other spectral changes were observed in these lymph 
nodes. For lymph nodes 1, 5 and 6, no significant spectral changes were observed 
throughout the 60 minute period.
Figure 5.7 illustrates the corresponding normalised spectra of the 6 lymph nodes. This 
is done by dividing individual ESS spectra by the ESS spectrum at zero minutes. As 
in Section 5.2, an increase in spectral intensity at a particular wavelength results in a 
normalised intensity value greater than 1. Conversely, a decrease in spectral intensity 
results in a normalised intensity value less than 1. The peaks and troughs in the 
normalised spectra signify changes in spectral profiles with increasing and decreasing 
spectral intensities respectively over that bandwidth. A horizontal line represents no 
spectral change.
In all 6 lymph nodes, normalised spectra demonstrated changes in the Soret, alpha and 
beta bands. These are more prominent in Lymph Nodes 2, 3 and 4, and correspond to 
the spectral changes observed by visible inspection. The same pattern of changes can 
also be seen in the normalised spectra of Lymph Nodes 1, 5 and 6 but were less in 
magnitude. The remaining band areas have a horizontal profile in all 6 lymph nodes 
indicating the stability of ESS spectra over the duration of this study.
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Figure 5.7: Normalised ESS spectra o f  Lymph Nodes 1 to 6 acquired between 0-10
minutes and between 10-60 minutes following excision
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5.3.4 Discussion
The spectral changes in Lymph Nodes 2, 3 and 4 are illustrated in Figure 5.8a. In this 
illustration, the blue spectrum is the start spectrum at 0 minutes, whilst the red 
spectrum is acquired at 10 minutes. The right shift o f  the Soret band trough (black 
arrow), the gradual replacement o f  the alpha and beta bands by a single broad band at 
555nm (white arrow) and the flattening o f  peak at 390nm (brown arrow) correspond 
to the differences in the inverse molar extinction coefficient o f  oxygenated and de­
oxygenated haemoglobin in Figure 5.8b.
Fisure 5.8: (a) ESS spectra demonstrating the observed chanses seen in Lymph
Nodes 2, 3 and 4 and (b) Inverse molar extinction coefficient for oxygenated and de- 
oxvgenated haemoglobin
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The similarities between the two indicate that de-oxygenation o f  haemoglobin is the 
process responsible for the observed spectral changes in Lymph Nodes 2, 3 and 4. 
These can be confirmed by comparing their corresponding normalised spectra 
(Figures 5.9a and b), which are very similar with peaks and troughs at almost identical 
wavelengths.
Figure 5.9: (a) Normalised spectra o f Lymph Node 2 and fb) Normalised absorption 
spectra o f de-oxygenatecl haemoglobin normalised to oxygenated haemoglobin
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The reason for the de-oxygenation o f  haemoglobin is likely to be the continual 
oxygen demand o f  viable cells within the lymph nodes. This process was evident in 
the normalised spectra o f  all 6 lymph nodes even though only Lymph Nodes 2, 3 and 
4 had corresponding changes in the ESS spectra. The tim ing and pace o f  de­
oxygenation cannot be determined by this study. However, further studies with larger 
numbers may reveal a trend especially if  m alignant cells are considered to have a 
higher metabolic rate.
Apart from the changes associated with de-oxygenation o f  haemoglobin, ESS spectra 
remained stable over 60 minutes. Individual spectra within each series can be 
superimposed upon each other, and the corresponding norm alised spectra have a 
horizontal profile. In addition to the stability o f  ESS spectra over time, this study also 
demonstrated the reproducibility o f  ESS spectra from a fixed anatom ical point.
The limitation o f  this study is that spectral acquisition did not progress beyond 60 
minutes. Certainly, it would be o f  interest to investigate beyond the 60 minutes with 
serial spectral acquisitions once the process o f  tissue degradation is established.
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5.3.5 Conclusion
De-oxygenation of haemoglobin occurs following surgical excision, which is 
detectable by ESS. The timing and pace of this process vary between different 
specimens. Apart from this, ESS spectra remain stable for at least 60 minutes 
following surgical excision in a normal in-door environment. This study also 
demonstrated the reproducibility of ESS spectra from a constant anatomical point. 
The implication of this study is that ex-vivo spectral acquisitions can take place 
within 60 minutes following surgical excision with no significant effects other than 
de-oxygenation of haemoglobin.
5.4 The Effect of Submersion in Saline at Room Temperature on ESS
5.4.1 Introduction
Tissue hydration is important when freshly excised tissue specimens such as lymph 
node and renal biopsies are required for pathological processing. Drying must be 
avoided. Usually, specimens are wrapped in paper or pads moistened with normal 
saline and transported to laboratories immediately. If there will be any delay in 
transportation, the specimen should be placed in normal saline solution. Specimens 
may be transported at room temperature for up to two hours. For delays of 2-24 hours, 
specimens should be stored at 4°c or cooled on wet ice but not allowed to freeze. The 
effect of submersing specimens in normal saline on ESS is unknown. The aim of this 
section is to investigate this effect on ESS of axillary lymph nodes at room 
temperature.
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5.4.2 Methods
Axillary lymph nodes were harvested from surgical specimens o f  patients with proven 
breast cancer undergoing axillary surgery following informed consent. The lymph 
nodes were bisected along their longitudinal axes and were submerged in 0.9% saline 
solution. The optical probe was applied to the sectioned surface and was fixed in 
position using a clamp during the study (Figure 5.10). The initial ESS spectrum was 
taken at zero minutes. Subsequent ESS spectra were taken every 30 seconds for the 
first 15 minutes, then every 60 seconds for the next 15 minutes and finally every 5 
minutes for the next 30 minutes. At the end o f  the study, all lymph nodes were fixed 
in 4%  formaldehyde solution and sent for pathology.
ESS spectra were visually inspected. For comparison, ESS spectra at various time 
intervals were normalised to the spectra taken at zero minute by division.
Figure 5.10: Illustrations to show (a) the fixed position o f the optical probe onto 
tissue and (b) submersion o f tissue in normal saline
(a) (b)
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5.4.3 Results
In total, 2 sets o f  measurements were made from 1 m etastatic lymph node (Lymph 
Node 1) and 1 normal lymph node (Lymph node 2). A selection o f  ESS spectra from 
both lymph nodes is illustrated over 2 time intervals: 0-10 minutes and 10-60 m inutes 
in Figure 5.11. The corresponding normalised spectra are illustrated in Figure 5.12. 
As in Sections 5.2 and 5.3, normalisation was carried out by dividing individual ESS 
spectra by the ESS spectrum at zero minutes.
Figure 5.11: ESS spectra o f Lymph Nodes 1 and 2 acquired between 0-10 minutes 
and 10-60 minutes following submersion in normal saline
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On visual inspection, de-oxygenation o f  haemoglobin can be observed in Lymph 
Node 1 with no other spectral changes. The corresponding normalised spectra closely 
resemble to those o f  Lymph Nodes 2, 3 and 4 in Section 5.3.
As for Lymph Node 2, spectral profiles show that haemoglobin was already in the de­
oxygenated form. No significant changes in spectral profile were observed throughout 
the 60 minute period. In the normalised spectra, there are changes at the Soret, alpha 
and beta band areas as well as in the ultra-violet region
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Figure 5.12: Normalised ESS spectra o f  Lymph Nodes 1 and 2 acquired between 1-
10 minutes and between 10-60 minutes follow ins submersion in normal saline
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5.4.4 Discussion
The findings in Lymph Node 1 are consistent with the findings in the previous study 
demonstrating the haemoglobin de-oxygenation. The late changes seen in normalised 
spectra o f  Lymph Node 2 are not characteristic o f  the de-oxygenation o f  haemoglobin. 
However, the corresponding ESS spectral profile o f  Lymph Node 2 showed only 
slight changes in the band regions concerned. Therefore, its significance is doubtful. 
However, this cannot be verified because only 2 lymph nodes were studied in this 
series. Further studies may reveal more information.
Tissue hydration is an important consideration in the handling o f  tissue specimens for 
optical biopsy. It is known to affect Raman spectroscopy in biological tissue13. 
However, its effect on ESS is unknown. An inadvertent variable in Section 5.3 is the 
potential desiccation o f  the lymph nodes by evaporation. The sim ilar findings in both 
studies suggest that this is not the case. However, these two studies were not designed 
to investigate the effect o f  tissue hydration on ESS specifically.
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5.4.5 Conclusion
This study demonstrated that submersion of tissue specimens in normal saline has no 
effect on ESS for up to 60 minutes although de-oxygenation of haemoglobin can 
occur during this period.
5.5 The Effect of Tissue Chilling on Ice on ESS
5.5.1 Introduction
Storage in ice is standard practise for handling freshly excised tissue specimen during 
transportation to the laboratory. The effect of this practice on ESS is unknown. 
However, the process of freezing and thawing was found to affect fluorescence 
spectroscopy2. The aim of this study is to investigate the effect of tissue chilling on 
ESS.
5.5.2 Methods
Axillary lymph nodes were harvested from surgical specimens of patients with proven 
breast cancer undergoing axillary surgery following informed consent. The lymph 
nodes were bisected along their longitudinal axes. The optical probe was applied to 
the sectioned surface and was fixed in position using a clamp for the duration of the 
study. The lymph node was chilled using a bag of ice. Initial ESS spectra were taken 
at zero minutes. Subsequent ESS spectra were taken every 30 seconds for the first 15 
minutes, then every 60 seconds for the next 15 minutes and finally every 5 minutes 
for the next 30 minutes. At the end of the study, all lymph nodes were fixed in 4% 
formaldehyde solution and sent for pathology. ESS spectra were visually inspected. 
For comparison, ESS spectra at various time intervals were normalised to the spectra 
taken at zero minutes by division.
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5.5.3 Results
In total, 3 sets o f measurements were made from 1 metastatic lymph node (Lymph 
Node 1) and 2 normal lymph nodes (Lymph Node 2 and 3). A selection o f  ESS 
spectra from both lymph nodes is illustrated over 2 time intervals: 0-10 m inutes and 
10-60 minutes in Figure 5.13. The corresponding normalised spectra are illustrated in 
Figure 5.14. As in previous studies, normalisation was carried out by dividing 
individual ESS spectra by the ESS spectrum at zero minute.
Figure 5.13: ESS spectra o f lymph nodes 1. 2 and 3 acquired between 0-10 minutes 
and 10-60 minutes following chilling in ice
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On visual inspection, spectral profiles at zero minutes demonstrated that haemoglobin 
was in a de-oxygenated state in Lymph Nodes 1 and 2, and in an oxygenated state in 
Lymph Node 3. For Lymph Node 1, this and the overall spectral profile remained 
unchanged throughout the 60 minute period. In the normalised spectra, only m inor 
changes occurred in the Soret bandwidth.
For Lymph Node 2, the ESS spectral profile remained unchanged for the initial 10 
minutes. However, the normalised spectra over this period are identical in profile as 
those o f  Lymph Node 2, 3 and 4 in Section 5.3. Between 20 and 30 minutes, alpha 
and beta bands became evident together with a left shift o f  the Soret band. These 
changes are indicative o f the oxygenation o f  haemoglobin and were associated with 
changes in the profiles o f  corresponding normalised spectra. No other significant 
changes were observed in ESS spectra and normalised spectra.
For Lymph Node 3, de-oxygenation o f  haemoglobin occurred in the same m anner as 
the Lymph Nodes 2, 3 and 4 in Section 5.3 during the first 10 minutes o f  this study. 
No other changes were observed in ESS spectra and normalised spectra.
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Figure 5.14: Normalised ESS spectra for Lymph Nodes 7. 2 and 3 between 0-10
minutes and 10-60 minutes following chilling in ice
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5.5.4 Discussion
The most interesting observation in this study is o f  the oxygenation o f  haemoglobin in 
Lymph Node 2. The initial ESS spectral profile indicated that haemoglobin was in a 
de-oxygenated state, which is characterised by a single broad band at 555nm. The 
spectral profile remained unchanged for 10 minutes. However, the corresponding 
normalised spectra showed that further de-oxygenation o f  haemoglobin was in 
progress. Between 10 and 30 minutes, a single broad band at 555nm was replaced by 
the alpha and beta bands o f  oxygenated haemoglobin with accompanied changes in 
normalised spectra. Figure 5.15a demonstrates the changes in the normalised spectra 
o f  Lymph Node 2 during this period. This is different from that o f  Lymph Node 3 
(Figure 5.15b) where de-oxygenation was in slow progress.
Figure 5.15: Normalised spectra o f Lymph Nodes (a) 2 and (b) 3 between 10 and 30 
minutes
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The process observed in Lymph Node 2 is the oxygenation o f  haemoglobin. This can 
be confirmed by comparing the normalised spectra at 60 minutes (Figure 5.16a) and 
the inversed normalised molar extinction coefficient o f  the oxygenation o f  
haemoglobin (Figure 5.16b). The profiles o f  Figures 5.14a and b appear similar with 
corresponding peaks.
Figure 5.16: (a) Normalised spectra o f Lymph Node 2 after 60 min and (b) Inverse 
molar extinction coefficient o f oxygenated Hb normalised to deoxvsenated Hb
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The likely explanation for the oxygenation o f  haemoglobin after initial de­
oxygenation is the change in haem oglobin’s affinity to oxygen with tem perature. At 
lower temperatures, the stability o f  the bond between oxygen and haemoglobin 
increases resulting in greater affinity o f  haemoglobin to oxygen and a “ left shift” o f  
the oxygen dissociation curve. This is dem onstrated by the oxygen dissociation curve 
o f  haemoglobin in Figure 5.17. Otherwise, no other changes were observed in the ESS 
spectra and normalised spectra o f  Lymph Node 2.
For Lymph Node 1, only minor changes were noted in the normalised spectra between 
320 and 420nm, whilst Lymph Node 3 exhibited de-oxygenation o f  haemoglobin in 
the same fashion as described in Sections 5.3 and 5.4.
- 1 5 2 -
Fieure 5.17: Oxygen dissociation curve o f  haemoglobin illustrating a “le f t” shift
with decreased temperature
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5.5.5 Conclusion
Oxygenation and de-oxygenation o f  haemoglobin can occur in tissue during storage in 
chilled conditions following excision and can be detected by ESS. Otherwise, ESS 
spectra o f  tissue specimens remain stable and reproducible when stored in ice for at 
least 60 minutes following surgical excision. Therefore, storage o f  tissue specim ens in 
ice up to 60 minutes is acceptable for subsequent ESS studies.
- 1 5 3 -
5.6 The Effect of Formaldehyde Fixation at Room Temperature on ESS
5.6.1 Introduction
Formaldehyde fixation is an established technique for the storage of tissue specimens 
prior to pathological processing. Formaldehyde prevents tissue degradation by 
forming covalent bonds between two components of a protein or between two 
different proteins. Formaldehyde fixation has been shown to significantly affect near- 
infrared Raman spectroscopy of normal and cancerous human bronchial 
tissues1,whilst it has only a weak effect on the fluorescence spectroscopy4. However, 
the effect of formaldehyde fixation on ESS is unknown. The aim of this section is to 
investigate the effects of formaldehyde fixation over two time frames: up to 60 
minutes in fixation (Study A) and overnight in fixation (Study B).
5.6.2 Methods
Axillary lymph nodes were harvested from surgical specimens of patients with proven 
breast cancer undergoing axillary surgery following informed consent. The lymph 
nodes were bisected along their longitudinal axes and were submerged in 4% 
formaldehyde solution. The optical probe was applied to the sectioned surface and 
was fixed in position using a clamp during the study. Initial ESS spectra were taken at 
zero minutes. For Study A, subsequent ESS spectra were taken every 30 seconds for 
the first 15 minutes, then every 60 seconds for the next 15 minutes and finally every 5 
minutes for the next 30 minutes. For Study B, ESS spectra were taken at various time 
points up to 24 hours. At the end of the study, all lymph nodes were sent for 
pathology.
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ESS spectra were visually inspected. For comparison, ESS spectra at various time 
intervals were normalised to the spectra taken at zero minutes by division.
5.6.3 Results 
Study A
In total, 4 sets o f  measurements were made from 4 normal lymph nodes (Lymph 
Nodes 1-4). A selection o f  ESS spectra from both lymph nodes is illustrated over 2 
time intervals: 0-10 minutes and 10-60 minutes in Figure 5.18. The corresponding 
normalised spectra are illustrated in Figure 5.19. As in Sections 5.2, 5.3 and 5.4, 
normalisation was carried out by dividing individual ESS spectra by the ESS 
spectrum at zero minute.
Figure 5.18: ESS spectra o f Lymph Nodes 1-4 plotted at 0-10 minutes and 10-60
minutes following submersion in formaldehyde solution
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On visual inspection, initial spectral profiles demonstrated that haemoglobin was in 
the oxygenated state in Lymph Nodes 1, 3 and 4, and in the de-oxygenated state in 
Lymph Node 2.
For Lymph Node 1, there was a right shift in the Soret band in the initial 10 minutes, 
which was accompanied by minor changes in the alpha and beta bands. The 
corresponding normalised spectra were consistent with progressive de-oxygenation o f  
haemoglobin as seen in previous studies. Beyond 10 minutes, there was a reversal o f  
the changes so that by 60 minutes the Soret band returned to its initial position within 
the ESS spectrum with increased prominence o f  the alpha and beta bands. The 
normalised spectrum at 60 minutes resembled that o f  Lymph Node 2 in Section 5.5 
and was suggestive o f  oxygenation o f  haemoglobin. No changes were noted in other 
bandwidths during the 60 minutes period.
For Lymph Node 2, there were no changes in the ESS spectra in the first 10 minutes, 
but the corresponding normalised spectra suggested a small degree o f  de-oxygenation
- 158-
o f haemoglobin. In the 10-60 minute period, alpha and beta bands became evident 
together with a left shift o f  the Soret band. Normalised spectrum at 60 m inutes was 
similar to that o f  Lymph Node 2 in Section 5.5 indicating that oxygenation o f  
haemoglobin had occurred. Otherwise, no other changes were observed.
For Lymph Node 3, minor changes occurred in both ESS and normalised spectra over 
the 60 minute period. As for Lymph Node 4, there were no changes in ESS spectra in 
the initial 10 minutes, but normalised spectra during this period showed evidence o f  
de-oxygenation. In the subsequent 10-60 minutes, a slight left shift and increased 
prominence o f  alpha and beta bands occurred with associated changes in the 
normalised spectra identical to those observed in Lymph Node 1.
Figure 5.19: Normalised spectra o f Lymph Nodes 1-4 plotted at 0-10 minutes and
10-60 minutes follow ins submersion in formaldehyde solution
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In total, 2 sets o f  measurements were made from 1 m etastatic lymph node (Lymph 
Node 5) and 1 normal lymph node (Lymph Node 6). A selection o f  ESS spectra from 
both lymph nodes is illustrated over 3 tim e intervals: 0-1 hour, 1-4 hours and beyond 
4 hours in Figure 5.20. The corresponding norm alised spectra are illustrated in Figure 
5.21. As in previous studies, norm alisation was carried out by dividing individual ESS 
spectra by the ESS spectrum at zero m inutes. Because o f  the exceptionally high value 
o f  the normalised intensity o f  Lymph Node 6 between 400 and 450nm  band width, the 
normalised intensity axis o f  Lymph N ode 6 was restricted to 0-5 range in order to 
reveal the details in other areas.
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Figure 5.20: ESS spectra o f  Lymph Nodes 5 and 6 plotted at 0-1 hour. 1-4 hours
and beyond 4 hours following submersion in formaldehyde solution
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On visual inspection, minor changes were observed in the spectral profiles of both 
lymph nodes in the first hour. During this period, the normalised spectral profiles of 
both lymph nodes were identical to those of Lymph Nodes 1, 2 and 4 in Study A and 
therefore indicative of haemoglobin oxygenation.
Between 1 and 4 hours, the most notable change is in the gradient of spectra between 
720 and 920nm in Lymph Node 6. Minor changes were also noted in the ESS spectra, 
but the overall profile of both lymph nodes remained similar. Over this period, the 
normalised spectra of both lymph nodes resembled those in the earlier period and 
those of Lymph Nodes 1, 2 and 4 in Study A. However, as time progressed, there was 
a gradual change in the normalised spectra in Lymph Node 6 between 500-620nm 
where the triple peaks were gradually replaced by a single broad peak at 560nm. This 
change also occurred in Lymph Node 5 in the 4-17 hour period.
Beyond 4 hours, ESS spectra of both lymph nodes changed beyond recognition from 
their initial spectra at zero minute. Both the alpha and beta bands were obliterated, 
and changes in the spectral gradient between 720-920nm also occurred. The spectral 
changes were accompanied by the change in the profile of the normalised spectra.
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Fisure 5.21: Normalised ESS spectra for Lymph Nodes 5 and 6 at 0-1 hours. 1-4
hours and beyond 4 hours
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5.6.4 Discussion
Formaldehyde fixation is a standard technique for tissue handling. Due to its chemical 
interaction with biological tissue, it is important to determine its effect on ESS. If the 
effect is significant, ESS spectral acquisition should take place prior to formaldehyde 
fixation. Also, ESS spectra taken from formaldehyde fixed specimens cannot be used 
for spectral analysis of in-vivo or unfixed ex-vivo tissues, and visa versa.
The findings of Studies A and B are as follows: (1) changes in ESS spectra within 60 
minutes of formaldehyde fixation occurred within the bandwidths of haemoglobin 
absorption, (2) beyond the initial 60 minutes, there were changes in the gradient of 
spectra between 620 and 920nm, (3) beyond 4 hours, ESS spectra did not bear any 
resemblance to the initial spectra at zero minutes, and (4) oxygenation of 
haemoglobin was evident in 5 out of 6 lymph nodes (Lymph Nodes 1, 2, 4, 5 and 6) 
within 60 minutes of formaldehyde fixation.
The changes in ESS spectra within the first 60 minutes occurred within the 
bandwidths of haemoglobin absorption with no other changes in the remaining 
bandwidths. Therefore, it appears that ESS spectra acquired from formaldehyde fixed 
tissue specimens is acceptable for subsequent in-vivo or fresh ex-vivo studies if 
spectral acquisition takes place within one hour of fixation and haemoglobin effects 
are accounted for during spectral analysis. However, beyond this period, changes in 
ESS spectra also involved bandwidths independent of haemoglobin absorption. The 
resultant spectra bore less resemblance to the initial spectra, and therefore, cannot be 
used in in-vivo and fresh ex-vivo applications. Further studies with larger numbers 
would be useful (1) to confirm the findings of these studies, (2) to establish whether
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there is a predictable trend of changes induced by formaldehyde and (3) to investigate 
whether ESS spectra acquired within the first 60 minutes of formaldehyde fixation 
affects subsequent spectral analysis.
Although Lymph Node 2 was the only lymph node to demonstrate the re-oxygenation 
of de-oxygenated haemoglobin in the ESS spectra, normalised spectra of Lymph 
Nodes 1, 4, 5 and 6 in the first 60 minutes had similar profiles to that of Lymph Node 
2 thus suggesting that further oxygenation of haemoglobin took place, which is an 
interesting finding. One possible explanation is that formaldehyde increased the 
oxygen affinity of human haemoglobin. This interaction may be due to combination 
with sulfhydryl groups of the protein, but nitrogenous groups are probably also 
involved5.
However, it has been suggested that formaldehyde causes the formation of 
methaemoglobin6. Figure 5.22 is the light absorption spectra of methaemoglobin 
which is characterised by peak absorptions at 500nm and 632nm (arrows)7. If 
formation of methaemoglobin was to be the case, two troughs would be expected to 
develop at 500nm and 632nm in the ESS spectra and normalised intensity at 500nm 
and 632nm bandwidths would less than 1. This was not observed in Study B, and 
hence, the formation of methaemoglobin was unlikely to be responsible for the 
observed changes.
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Fieure 5.22: Absorption spectra o f methaemoglobin (Curve 1. solid) in the visible
range
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Illustration taken from Figure 1 (right panel) Zijlstra et al, Clinical Chemistry 37/9,
1633-1638(1991)
The extended duration of Study B provides a glimpse of the changes in ESS induced 
by formaldehyde. Unfortunately, ESS spectra of Lymph Nodes 5 and 6 were acquired 
at different times and therefore are not comparable. However, Study B achieved its 
aim by demonstrating significant changes in ESS following formaldehyde fixation.
Two published studies from NMLC investigating the ability of ESS to detect cervical 
intranodal metastasis and to assess bony resection margins in oral cancer used
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formaldehyde fixed tissues6,8. In the lymph node study, specimens were fixed between 
24 and 72 hours, and spectral analysis involved analysis of spectral intensities at 360, 
450, 630 and 690 nm providing a sensitivity of 98% and a specificity of 68% for 
detecting cancer6. As for the bony resection study, specimens were fixed for up to 10 
years, and spectral analysis involved analysis of spectral intensity at 400nm and 
spectral gradient between 570 and 680nm8. Sensitivity and specificity of ESS in this 
study was 87% and 80% respectively for detecting cancer. Formaldehyde fixation 
appears to provide a much simpler discrimination between normal and malignant 
tissue when compared to detecting metastasis in freshly excised unfixed axillary 
lymph nodes in breast cancer. A possible hypothesis is that the elastic scattering and 
absorption properties of normal and malignant tissues change differentially during 
formaldehyde fixation.
5.6.5 Conclusion
In conclusion, the changes in ESS spectra within the first hour of formaldehyde 
fixation are attributable to oxygenation of haemoglobin, which is probably secondary 
to the increased oxygen affinity of haemoglobin by formaldehyde. If this is accounted 
for in subsequent spectral analysis, formaldehyde fixation appears to be suitable for 
tissue storage for up to 60 minutes prior to ESS spectral acquisitions. Beyond 60 
minutes, significant changes occurred. Therefore, ESS spectral acquired after 60 
minutes of formaldehyde fixation should not be used for clinical applications unless 
future studies can allow for formaldehyde induced changes in the analysis.
5.7 Summary and Conclusion of Chapter
The studies in this chapter have provided much needed technical information on the 
effects of ambient light and tissue handling on ESS. It is important to establish these 
effects prior to large scale data acquisition and clinical studies so that these effects can 
be accounted for in subsequent spectral analysis if necessary. Failure to do so may 
result in the corruption of the database ultimately affecting sensitivity and specificity.
Section 5.2 demonstrated that ambient light could enter the ESS system via tissue. At 
higher ambient light intensities (>10001ux), effects on ESS spectra become more 
prominent. Theoretically, these effects may be abolished by the processes of spectral 
acquisition and analysis. However, further studies involving spectral analysis of a 
large number of spectra would establish whether this is the case.
The studies into the effects of tissue handling have established that the changes that 
occurred in ESS spectra within the initial 60 minutes following excision when tissue 
specimens were left in various conditions were attributed to the change in 
oxygenation status of haemoglobin. In general, de-oxygenation of haemoglobin 
occurred over time, but oxygenation of haemoglobin was also observed during 
chilling in ice and formaldehyde fixation. Otherwise, ESS spectra remain stable and 
reproducible within this time period thus confirming that the various methods of 
tissue handling are suitable for subsequent spectral acquisition within 60 minutes. 
More important is the reproducibility of ESS spectra from a given anatomical point, 
which is fundamental to ESS.
Study B in Section 5.6 demonstrated significant changes to ESS spectra following 
prolonged formaldehyde fixation. Therefore, formaldehyde fixation should not be 
used for tissue handling prior to spectral acquisition if the subsequent ESS spectra 
database is to have a clinical application unless some way can be found to correlate 
the ESS spectra before and after formaldehyde fixation.
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Chapter 6 Elastic Scattering Spectroscopy: An emerging technology for 
the detection of axillary lymph node metastasis in breast cancer
6.1 Introduction
ESS is an emerging technology, which is capable of detecting changes in tissue 
structures by studying the elastic scattering and absorption of light in tissues. The key 
features of ESS system at NMLC are listed in Table 6.1.
Table 6.1: Key features o f ESS
• ESS system is portable and is easy to use
• Components are widely available and relatively inexpensive
• Spectral acquisition takes approximately one second
• ESS system is safe and does not involve ionised radiation or laser
• Optical probes can be supplied sterilised for intra-operative use
• ESS permits in-vivo and ex-vivo spectral acquisition
• Software for spectral analysis is currently under development
A potential application of ESS is the intra-operative detection of SLN metastasis in 
breast cancer. The purpose of intra-operative assessment is to identify the patients 
with SLN metastases so that ALND can be carried out at the time of SLNB. Since 24- 
31% of patients with T1 (<2cm) tumour and 44-49% of patients with T2 (2-5cm) 
tumour have axillary metastases1, a reliable intra-operative technique to assess the
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SLN would reduce readmissions for ALND thereby conserving resources and 
popularizing SLNB in breast cancer. An ideal technique for intra-operative 
assessment of SLN should be reliable, rapid, simple, cheap and non-operator 
dependent -  “an expert system”. The ability for “in-theatre” or “on-table” assessment 
would be desirable.
At present, TIC and FFS are established techniques for intra-operative assessment for 
tissues, and have been evaluated for this purpose. Many studies have demonstrated 
that a high degree of sensitivity and specificity can be achieved by both (Tables 6.9 
and 6.10). Although rapid in the actual processing of specimen, both TIC and FFS can 
be time consuming considering the time taken for the delivery of SLN to laboratories 
and for detailed examination. In addition, both techniques are operator dependent 
requiring highly trained and experienced pathologists for interpretations. Therefore, 
intra-operative SLN assessment by TIC and FFS is not widely practiced.
Studies by Gavin Briggs at NMLC have demonstrated the ability of ESS to detect 
metastases in excised axillary lymph nodes in patients with breast cancer2. In his 
thesis, Briggs recruited 34 patients. 11 patients underwent SLNB, 2 patients had both 
SLNB and ALND, and the remaining 21 patients had ALND. 62 axillary lymph nodes 
were harvested, and 14 were found to have metastases. A total of 117 ESS spectra 
were acquired. Spectral analysis was performed using Artificial Neural Network 
(ANN), Hierarchical Cluster Analysis (HCA) and Model Based Analysis (MBA). The 
sensitivities and specificities are illustrated in Table 6.2.
Table 6.2: Sensitivities and specificities o f ESS in determinin2 normal and metastatic
2
axillary lymph nodes using ANN. HCA and MBA (from Gavin Briggs )
Sensitivity 58% 91% 57%
Specificity 93% 76% 85%
Since this study, MBA has become the analysis technique of choice at NMLC for ESS. 
However, the sensitivity and specificity achieved using MBA were significantly lower 
than the 94% sensitivity and 92% specificity in differentiating normal and malignant 
breast tissue using identical spectral analysis technique2.
The aims of this chapter are (1) to improve the sensitivity and specificity of ESS in 
determining the axillary lymph nodes status in breast cancer and (2) to undertake a 
comparative study of ESS and TIC in assessing SLN status in breast cancer.
6.2 Study to improve the sensitivity and specificity of ESS using MBA in 
determining the axillary lymph nodes status in breast cancer
6.2.1 Introduction
In Dr Brigg’s thesis, the sensitivity and specificity of ESS in detecting axillary lymph 
node metastases using MBA were 57% and 85%, which were significantly lower than 
the 94% sensitivity and 92% specificity he achieved in differentiating normal and
- 176-
malignant breast tissues using an identical spectral analysis technique2. One possible 
factor was the small number of ESS spectra and lymph nodes in this study. Our initial 
approach was to increase the size of the data. Following further recruitment, a total of 
2804 ESS spectra from 327 lymph nodes were obtained. ESS spectra were correlated 
to the overall histology of the lymph node. Using identical spectral analysis technique, 
a similar sensitivity of 69% and specificity of 85% were achieved.
Subsequent scrutiny of our methodology found 4 areas of weakness. Firstly, ESS 
spectra were acquired randomly from the sectioned surface of the lymph nodes. With 
an average of 8.6 spectra acquired per lymph node, spectral acquisition did not cover 
the entire sectioned surface of the lymph nodes. Secondly, ESS spectra were 
correlated with the overall histology of the lymph nodes. These 2 factors resulted in a 
lack of precise correlation between ESS spectra and the histology of the area within 
the lymph nodes, where ESS spectra were acquired. This becomes problematic in 
lymph nodes with minimal or partial metastases because spectra taken from a normal 
area would be classified as metastatic. Thirdly, the use of spectra from the same 
lymph node in both training and testing datasets could potentially influence spectral 
analysis, and finally, there was a lack of discrimination between different types of 
breast cancer in spectral analysis. The aim of this study is to explore these issues by 
running different spectral analyses using MBA with different criteria for selecting 
datasets for training and testing.
6.2.2 Methods
All the lymph nodes used in this study were selected from the 327 lymph nodes in the 
preliminary study. These lymph nodes were harvested from female patients
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undergoing ALND and SLNB for breast cancer following informed and written 
consent (Appendix B). Immediately following surgical excision, each lymph node 
was bisected along its longitudinal axis. Multiple ESS spectra were acquired from the 
sectioned surfaces at random. Each lymph node was labeled individually and was 
fixed with 4% formaldehyde in separate containers.
Histological sections of the sectioned surface were made individually and were 
stained with H&E. For SLN, 2 further H&E sections were made at different levels, 
and LHC was performed if the SLN was negative on H&E. Histopathological 
reporting was perfomed by Dr Mary Falzon, Consultant breast pathologist. The lymph 
nodes were classified as negative or positive for metastasis. For the latter, the amount 
of metastatic replacement was assessed as a percentage. The histopathological report 
was correlated with the ESS spectra.
Spectral analyses using MBA was performed with different criteria for datasets 
selected for training. Only negative lymph nodes and those with more than 80% 
metastatic replacement were selected for analysis in order to minimise the effect of 
minimal and partial metastases.
6.2.3 Results and Discussion
In total, there were 28 lymph nodes with more than 80% metastatic replacement. 19 of 
28 lymph nodes (non-SLN) were from invasive ductal carcinoma. 4 lymph nodes 
were completely replaced by invasive ducto-lobular carcinoma whilst 3 were replaced 
by invasive lobular carcinoma. The remainder consisted of lymph nodes from
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invasive ductal carcinoma with extensive necrosis (1 node) and extensive 
microcalcification (1 node).
In presenting the statistical results, sensitivity, specificity and accuracy are presented 
in the standard way:
Sensitivity = True Positive / (True Positive + False Negative)
Specificity = True Negative / (True Negative+ False Positive)
Accuracy = (True Positive + True Negative) / Total number
Analysis 1: Sensitivity and specificity o f  ESS in determining axillary lymph node
status in invasive ductal carcinoma
This analysis used the spectra of the 19 lymph nodes which had invasive ductal 
carcinoma metastasis and an equal number of spectra taken from normal lymph nodes. 
In total, there were 291 spectra, of which 194 were used in the training set and the 
remaining 97 were used in the testing set.
The results are illustrated in Table 6.3. Of the 97 spectra used in the testing set, 50 
were taken from metastatic lymph nodes, and 47 from normal lymph nodes. ESS 
correctly identified 44 of the 50 positive spectra as positive with 6 false negatives 
giving a sensitivity of 88%. ESS correctly identified 45 out of 47 negative spectra as 
negative with 2 false positives giving a specificity of 96%. ESS correctly classified 89 
spectra giving an accuracy of 92%. The Kappa value for this analysis is 0.835.
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Table 6.3: Results o f  Analysis 1
ESS
Metastatic Normal
Histology
Metastatic 44 6
Normal 2 45
In this analysis, MBA achieved a sensitivity of 88% and specificity of 96% in 
determining the metastatic status of ESS spectra taken from lymph nodes in patients 
with invasive ductal carcinoma. Such sensitivity and specificity are comparable with 
the reported sensitivities and specificities of TIC and FFS in determining lymph node 
status in breast cancer thus demonstrating the potential of ESS in this application.
The improved sensitivity and specificity demonstrates the importance of the correct 
correlation of the ESS spectra and histology. In both of our preliminary studies, all 
ESS spectra taken from metastatic lymph nodes were classed as positive even if  they 
were acquired from a normal area. If these spectra were subsequently used for training, 
this would result in the spectral analysis recognising spectra from normal lymph 
nodes as metastatic thereby resulting in false positives. On the other hand if  these 
spectra were used for testing, spectral analysis would have recognised these spectra as 
negative, but these would be classed as false negatives because the histological 
correlation was metastatic. By selecting lymph nodes with >80% metastasis, this 
analysis reduced the error in spectra-histology correlation. Whether the sensitivity and 
specificity could be improved further by selecting lymph nodes with complete
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metastatic replacement cannot be determined in this study because only 6 lymph 
nodes were completely replaced.
Additionally, this analysis has demonstrated the suitability of our spectral analysis 
technique. MBA has been evaluated for similar tasks in other areas. One interesting 
study is computer gender classification from facial images3. In this study, the 
dimensionality of the face images was reduced into 8 coefficients by preprocessing. 
This was followed by analysis using other algorithms as well as LDA. The study 
found LDA is to be the preferred algorithm because of its performance (92% accuracy) 
and also it was considerably less expensive to compute.
Analysis 2: A jackknife analysis o f ESS spectra o f axillary lymph nodes with
metastatic invasive ductal carcinoma
In this analysis, the testing set consisted of spectra from 1 of the 19 lymph nodes with 
>80% metastatic replacement by invasive ductal carcinoma. The spectra of the 
remaining 18 metastatic lymph nodes were used as the training set along with an 
equal number of spectra from normal axillary lymph nodes. The tested lymph node 
was classified positive if  1 or more of spectra tested positive. The process was 
repeated for each of the 19 lymph nodes.
The result is illustrated in Table 6.4. Spectral analysis correctly classified 17 out of 19 
positive lymph nodes giving a “per node” sensitivity of 89.5%. In total, 129 spectra 
were tested, and MBA was correct in classifying 105 ESS spectra as positive giving a 
“per spectrum” sensitivity of 81.4%.
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Table 6.4: Results o f  Analysis 2: Spectra from lymph nodes with >80% replacement 
with cancer
1 2 0 2 0%
2 2 0 2 0%
3 4 3 1 75%
4 4 4 0 100%
5 8 8 0 100%
6 2 2 0 100%
7 8 8 0 100%
8 8 8 0 100%
9 8 8 0 100%
10 8 8 0 100%
11 8 8 0 100%
12 8 4 4 50%
13 8 6 2 75%
14 8 8 0 100%
15 8 2 6 25%
16 8 8 0 100%
17 12 12 0 100%
18 8 1 7 13%
19 7 7 0 100%
Total 129 105 24 81%
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The “leave one node out” approach of jackknife analysis provides a robust assessment 
of MBA. This is because all the spectra were used for training except for the one used 
for testing, and all metastatic lymph nodes were individually tested. Therefore the 
reported sensitivity is absolute. Two additional advantages of jackknife analysis are: 
(1) the potential influence of using spectra of the same lymph node for training and 
testing is abolished, and (2) jackknife analysis simulates a prospective analysis. 
Unfortunately, normal lymph nodes were not included in the testing, and therefore 
specificity could not be determined.
Of the 17 correctly classified lymph nodes, spectral analysis was correct in classifying 
all the spectra in 12 lymph nodes. In the other 5 lymph nodes, the percentage of 
spectra correctly classified ranged from 13% to 75%. As lymph nodes with >80% 
metastatic involvement were selected, one possible reason for the false negatives is 
that these ESS spectra were taken from a normal area of the lymph node. This would 
account for the false negatives in Lymph Node 3, 12 and 13. However, there may be 
other factors involved in Lymph Nodes 15 and 18. Without direct correlation of ESS 
spectra to actual histology, this cannot be investigated further. As for Lymph Nodes 1 
and 2, only 2 ESS spectra were taken from each, and this may not have been 
representative of the lymph nodes.
Analysis 3: Jackknife analysis using spectra o f metastatic lymph nodes o f different 
breast tumour types as testing set
In this analysis, the training set consisted of spectra acquired from lymph nodes with 
more than 80% metastatic replacement by invasive ductal carcinoma and equal
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number of spectra from negative nodes. The testing set consisted of spectra taken 
from lymph nodes with more than 80% metastatic replacement by other breast tumour 
types or by invasive ductal carcinoma with unusual histology.
The results of this analysis are illustrated in Table 6.5. ESS correctly classified 35 out 
of 49 ESS spectra giving a “per spectra” sensitivity of 71%. However, 8 out of 9 
lymph nodes were correctly classified giving a “per node” sensitivity of 89%.
Table 6.5: Results o f Analysis 3
1 Lobular carcinoma 6 0 6 0%
2 Lobular carcinoma 4 4 0 100%
3 Ducto-lobular carcinoma 4 4 0 100%
4 Ducto-lobular carcinoma 4 3 1 75%
5 Ducto-lobular carcinoma 4 3 1 75%
6 Ducto-lobular carcinoma 4 2 2 50%
7 Lobular carcinoma 7 5 2 71%
8 Ductal cancer with 80% necrosis 8 6 2 75%
9
Ductal carcinoma with 
extensive 
microcalcification
8 8 0 100%
Total 49 35 14 71%
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The purpose of this analysis is to determine whether spectra from negative and 
metastatic invasive ductal carcinoma lymph nodes alone are sufficient as training sets 
for testing of spectra from metastatic lymph nodes of other breast tumour types or 
with unusual pathology. It appears that spectral analysis using the training set 
consisting only of spectra from normal and metastatic invasive ductal carcinoma 
lymph nodes can determine lymph node metastasis from other tumour types. Despite 
correctly classifying 8 out of 9 as metastatic lymph nodes, the “per spectrum” 
sensitivity is less at 71%. This may be due to (1) the small numbers in this analysis, (2) 
the incorrect histological correlation of the testing spectra as discussed in Analysis 1 
and (3) the different tissue types. The implication of the latter is that the addition of 
spectra from metastatic lymph nodes of other tumour types is needed to the existing 
training set. The obvious limitation of this analysis is the small number of lymph 
nodes and spectra, and further studies with larger numbers would provide clarification.
Analysis 4: The effect o f adding spectra o f other tumour types to the training set 
consisting o f normal and metastatic invasive ductal carcinoma lymph nodes
The aim of this analysis is to determine whether the addition of spectra of other 
tumour types to the training set influences the sensitivity and specificity of spectral 
analysis. All the spectra taken from lymph nodes with more than 80% metastatic 
replacement by all tumour types and equal number of spectra from normal lymph 
nodes are used. Two-thirds were randomly selected for the training set. Once a LDA 
algorithm was established, the remaining one-third was used for testing.
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In total, there were 555 spectra, of which 370 were randomly chosen as the training 
set and the remaining 185 were used in the testing set. Of the 185 ESS spectra used 
for testing, 91 spectra were histologically positive. ESS correctly classified 82 spectra 
with 9 false negatives giving a sensitivity of 90% (Table 6.6). 94 spectra were 
histologically negative, and 86 were correctly classified with 8 false positives giving a 
specificity of 91%. Spectral analysis was correct in classifying 168 spectra giving an 
overall accuracy of 91%. The Kappa value in this study is 0.816136.
Table 6.6: Results o f Analysis 4
Histology
Positive Negative Total
ESS
Positive 82 8 90
Negative 9 86 95
Total 91 94 185
The sensitivity of 90%, specificity of 91% and accuracy of 91% achieved in this 
analysis is comparable to those of Analysis 1 (88%, 96% and 91% respectively) 
suggesting that the addition of spectra from metastatic lymph nodes of other breast 
cancer types has little impact on the performance of spectral analysis.
6.2.4 Discussion
Spectral analysis is an essential component of our ESS system. This study 
demonstrated (1) that current spectral analysis using MBA is suitable for analyzing
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ESS spectra and (2) the importance of correct spectral classification of the training 
datasets. By refining the training and testing sets, significant improvements in 
sensitivity and specificity (88% and 96% from Analysis 1) were achieved. For the 
purpose of this thesis, spectra from lymph nodes with partial metastasis and 
micrometastasis have to be discounted because it was not possible to correlate the 
ESS spectra to the precise histology.
The sensitivities and specificities achieved in Analyses 1 and 4 are comparable with 
the reported sensitivities and specificities of TIC and FFS in determining SLN 
metastasis indicating the potential of ESS technology in this application. In the 
clinical situation, a lymph node would be deemed metastatic if one or more ESS 
spectra are classified as positive as in the case of Analyses 2 and 3. Combining 
Analyses 2 and 3, spectral analysis correctly classified 25 of the 28 metastatic lymph 
nodes even though 10 of these lymph nodes had some of spectra classified as negative. 
Whether these negative spectra were taken from a normal area of the lymph node or 
were misclassified by spectral analysis is uncertain. However, the effect of 
misclassifying spectrum/spectra can be compensated by a correct classification of a 
positive spectrum as demonstrated. Clinically, there is a clear requirement for a 
thorough spectral acquisition from the entire sectioned surface of the lymph node.
The reporting of sensitivity and specificity of ESS in this chapter can be confusing. 
On one hand, Analyses 1 and 4 reported sensitivity and specificity per spectrum 
whilst Analyses 2 and 3 were presented per lymph node. Therefore, it is important for 
clarification when presenting the results to avoid confusion and to allow direct 
comparisons between different optical biopsy technologies. In addition, sensitivity
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and specificity per spectrum are more relevant for those with interests in the 
development of spectral analysis whilst for the surgeon, the sensitivity and specificity 
per node are more relevant as these would determine whether or not to proceed with 
ALND during SLNB.
The limitation of this study is that only normal and metastatic lymph nodes with more 
than 80% replacement were studied. Although spectral acquisitions were also made 
from lymph nodes with partial and micro-metastases, it was not possible to correlate 
the spectra to the precise histology. This raises the question of whether ESS can detect 
small or micro-metastases where the area of spectral acquisition may be partially 
involved with tumour infiltration. This is to be determined in Chapter 7.
6.2.5 Conclusion
Spectral analysis using MBA has “per spectrum” sensitivity of up to 90% and 
specificity of up to 96% in differentiating ESS spectra of normal and metastatic 
lymph nodes in breast cancer. This study confirms the suitability of MBA for spectral 
analysis in ESS, and also demonstrated the importance of correct histological 
correlation of ESS spectra.
6.3 A comparative study of ESS and TIC in assessing SLN status in breast 
cancer
6.3.1 Introduction
Touch imprint cytology (TIC) is an established cytological technique first described 
by Dudgeon and Patrick in 19274. TIC has proven useful as an intra-operative
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diagnostic tool for the detection of lymph node metastasis in a variety of malignant 
diseases5*7. In the management of breast cancer, TIC has been used to determine
8 9excision margins of breast lesions intra-operatively ’ .
TIC is simple and quick to perform. It provides clear cytological details for evaluation 
without artifacts. In addition to standard staining, it is also possible to perform 
immunocytochemisty. Furthermore, TIC avoids the consumption of tissue. For these 
reasons, TIC is more favored than FFS for intra-operative SLN assessment. The aim 
of this study is to compare TIC and ESS in assessing SLN status of patients with 
breast cancer.
6.3.2 Methods
Women with invasive breast cancer (< 5 cm in size) proven by triple assessment and 
clinically axillary node negative (T1/T2, NO) were recruited following informed 
consent. Exclusion criteria included (1) pregnant and lactating women and (2) 
previous axillary surgery. SLNB was performed using the combined blue dye and 
radioisotope technique.
On the day prior to surgery, each patient received 0.2ml of 15MBq " mTc-nanocolloid 
(Nycomed Amersham, UK) via a single intra-dermal injection to the skin overlying 
the tumour if  palpable or at the areolar border of the corresponding quadrant if tumour 
was impalpable. The injection site was then massaged for 1 minute to encourage 
lymphatic drainage. The uptake of radiotracer was confirmed by pre-operative gamma 
camera imaging.
At the time of surgery, intra-dermal injection of 2ml of patent blue dye was 
administered in the same manner as the radioisotope injection 5 minutes prior to the 
surgical incision. SLNB was performed using gamma probe detection. Biopsy for 
internal mammary SLN was not performed. A SLN was defined as a lymph node, 
which was radioactive or blue-stained or both.
Once harvested, the SLN was bisected along its longitudinal axis and through the 
hilum. The sectioned surface was gently touched onto glass slides, and if possible, 3 
imprints were made per slide. In total, 3 slides per SLN were made. This was 
followed by ESS spectral acquisition. The SLN were labeled and fixed separately in 
formaldehyde. TIC slides and SLN were sent to the Department of Histopathoogy.
For TIC, one slide was stained with rapid cytological stain (RAL555, Cell Path, UK), 
one with standard Giemsa stain and one with ICC staining (anticytokeratin). Slides 
were examined by Dr Gabrijela Kocjan, consultant cyto-pathologist, under light 
microscope but not in real time. The TIC results were compared with histology.
Histological sections of the cut surface of the SLN were made and were stained with 
H&E. In addition, 2 further H&E sections were made at different levels. 
Immunohistochemistry was performed if there were no metastases seen on H&E 
sections. Histo-pathological reporting was performed by Dr Mary Falzon. The lymph 
nodes were classified as negative or positive for metastases.
ESS spectra were correlated to histology. MBA was carried out, and two-thirds of the 
ESS spectra were randomly selected to establish the LDA algorithm. Once this has 
was done, the remaining one-third of the ESS spectra were used for testing.
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6.3.3 Results
A total of 89 SLN were harvested from 53 patients. Of these 89 SLN, 8 were found to 
contain metastases. TIC correctly identified 6 of the 8 SLN with metastases and all 81 
negative SLN giving sensitivity of 75% and specificity of 100% (Table 6.7). Of the 2 
false negatives for TIC, one SLN had metastatic deposits on the sectioned surface 
which were seen on histological section but not on TIC despite a detailed review. The 
second false negative had a small focus of metastasis in deeper sections detected by 
immunohistochemistry.
Table 6.7: Comparison o f TIC results with histopatholosv
Histology
Positive Negative Total
TIC
Positive 6 0 6
Negative 2 81 83
Total 8 81 89
ESS correctly identified 6 of the 8 SLN with metastases and 75 of the 81 negative 
SLN. This gives ESS sensitivity of 75% and specificity of 93% (Table 6.8). Of the 2 
false negatives for ESS, one SLN was the same false negative as TIC which had a 
small metastasis deposit in deeper sections detected by immunohistochemistry. The 
other is a different SLN which had metastatic deposits on the sectioned surface seen 
on histological section. A Student’s t-test on overall accuracy and Kappa value for 
TIC and ESS indicated equivalence at the 95% confidence level.
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Table 6,8: Com parison o f  ESS results with histopatholosy
Histology
Positive Negative Total
ESS
Positive 6 6 12
Negative 2 75 77
Total 8 81 89
6.3.4 Discussion
This study showed that TIC and ESS have similar sensitivity and specificity in 
determining SLN status when compared to standard histopathology with IHC. For 
ESS, the spectra were not tested prospectively in that two-thirds of the spectra were 
used for training whilst the remaining one-third was used for testing. Although this is 
not a direct comparison between ESS and TIC, the sensitivity of 75% and specificity 
of 93% achieved by ESS are comparable with most published reports on TIC and FFS 
in determining SLN status in breast cancer (Tables 6.9 and 6.10), and provide further 
evidence to support the potential role of ESS in assessing SLN status in breast cancer.
Unlike TIC, ESS assesses the SLN at individual points. To obtain the best 
performance, spectral acquisition has to be thorough, covering the entire sectioned 
surface. This may be responsible for one of the false negative where a metastasis was 
present in the sectioned surface. The other false negative had a small metastasis 
deposit in deeper sections detected by immunohistochemistry and was also missed by 
TIC. One possible solution to this problem is to have multiple sectioning. Further
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development should aim to produce an ESS system capable of prospective spectral 
analysis so that a true comparison can be made between TIC and ESS.
There are numerous advantages of ESS in assessing SLN status. For example, 
individual spectral acquisition requires just over 1 second, and for an average size 
SLN, probably 15 to 20 spectral acquisitions are required. With the eventual 
development of real time spectral analysis, ESS would not require specialist 
interpretation. The ESS system is portable and optical probes can be sterilised. So 
SLN assessment can be performed by the operating surgeon in sterile conditions 
following excision. Furthermore, ESS systems are relatively cheap to produce.
The sensitivity and specificity of TIC in this series were 75% and 100% respectively, 
which is comparable with most published reports on TIC and FFS in determining 
SLN status in breast cancer (Tables 6.9 and 6.10). However, in an earlier series at our 
institute, Keshtgar et al. reported a higher sensitivity and specificity26. The main 
advantages of TIC include: (1) TIC is a simple and quick technique, (2) TIC does not 
consume tissues unlike FFS. However the chief drawback is the requirement of an 
experienced cyto-pathologist, who is happy to interpret and to report the TIC in real 
time.
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Table 6.9: Published studies o f  TIC in determ ining SLN status in breast cancer
Barranger10 185 IHC 33.3 78.4
Bochner11 79 IHC 37 100
Deo12 76 Not stated 96.9 100
Ravichandran13 132 H&E 70 97
Aihara14 118 H&E 84 97.4
Bochner15 53 IHC 53 100
Leidenius16 139 IHC 68 98.5
Nagashima17 124 Not stated 70.3 99.6
Creager18 678 IHC 53 98
Baitchev19 87 IHC 83.3 100
Yu20 78 H&E 97.4 100
Csemi21 60 IHC 59 100
Motomura22 101 IHC 90.9 98.5
Usman23 55 H&E 100 99.2
Van Diest24 54 IHC 63 100
Total 2019 Average 70.6 Average 97.8
(Modified from Table 3: Implementation of Touch Imprint Cytology for Intra­
operative Detection of sentinel lymph node metastases in breast cancer -  Practice and 
implications. DW Chicken et al.25)
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Table 6.10: P ublished studies o f  FFS in determ ining SLN status in breast cancer
Leidenius16 375 IHC 83 98.3
1 7Nagashima 124 Not stated 83.8 100
Motomura27 101 H&E 52 100
Van Diest24 54 IHC 91 100
Cao28 234 IHC 85.7 100
Wada29 569 H&E 84 100
Khalifa30 96 Not stated 86 100
Aihara14 42 Not stated 92 100
Van der Loo31 275 IHC 83 100
Gulec32 157 IHC 44 100
Veronesi33 295 H&E 95.4 100
Tanis34 262 IHC 74 99
Total 2584 Average 79.5 Average 99.8
(Modified from Table 4: Implementation of Touch Imprint Cytology for Intra­
operative Detection of sentinel lymph node metastases in breast cancer -  Practice and 
implications. DW Chicken et al.25)
It is important to note that there are significant variations in the TIC technique. These 
include the number of sections made per SLN, longitudinal versus transverse 
sectioning, touching versus scraping of sections, the choice of stain and the inclusion 
of ICC, which may all have significant implications35. Apart from a comparative 
study on 635 axillary lymph nodes by Anastasiadis et al to show greater accuracy for 
MGG stain over H&E stain for TIC36, there are no large studies available to compare
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the various variations specifically and to establish the optimal protocol. With multiple 
sectioning, this could prevent one of the false negatives (the one with a small 
metastasis deposit in deeper sections detected by immunohistochemistry) in this study. 
However, extra intra-operative time would be needed for additional processing and 
interpretation, which may not be desirable in a busy operating schedule. Also multiple 
sectioning can be difficult in small SLN.
As for the other false negative of TIC, tumour cells failed to be imprinted onto the 
glass slides therefore highlighting a technical limitation of TIC. However, it is 
important to stress that care and attention are required throughout the preparation 
process even though TIC is a “quick and simple” technique. Although there were no 
false positives for TIC in this study, potential pitfalls can occur. For example, large 
aggregates of lymphoid cells (Figure 6.1a) may have a deceptive epithelial 
appearance37. Non-lymphoid cells such as follicular dendritic cell (Figure 6.b) can be 
confused with metastasis on immunocytochemistry37.
A general limitation of this study is that both TIC and spectral analysis were not 
carried out in real time. However, a study is currently undertaken to compare the 
effect of real time reporting of TIC at our institution25.
Figure 6.1: Potential pitfalls in TIC (a) Large aggregates o f  lymphoid cells and (b)
Follicullar dendritic cell
(Illustrations from Figures 8 and 10: G. Kocjan: Chapter 10 Cytology in the sentinel 
node. In M .R.S. Keshtgar, W.A. W addington, S.R. Lakhani and P.J. Ell: The sentinel 
node in surgical oncology. Springer-Verlag, 1999 p. 114-115)
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6.3.5 Conclusion
ESS has sensitivity and specificity comparable to TIC and FFS in assessing SLN 
status in breast cancer, but further developments and evaluations are necessary. TIC in 
our experience is a good technique for assessing SLN status
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Chapter 7 Elastic Scattering Spectroscopy for the detection of 
Primary Breast Cancer
7.1 Introduction
A number of studies investigating the various optical biopsy technologies have so far 
indicated acceptable sensitivities and specificities in distinguishing normal, pre- 
malignant and malignant tissues in a variety of organs (Table 3.3). The reported 
sensitivities and specificities can be considered as the “headline” values giving an 
overall performance. There are numerous factors that can affect sensitivity and 
specificity. The underlying change in the optical properties of the tissue and the point 
where this becomes detectable are especially important.
From our experience in Chapter 6, a metastatic axillary lymph node can be replaced 
by cancerous tissue completely, partially or as micrometastasis. In the same manner, 
the focus where an ESS spectrum was acquired may contain a variable proportion of 
normal and malignant tissues. As both normal and abnormal tissues contribute to the 
overall optical properties of the tissue, the proportion of normal and abnormal tissues 
is likely to have significant influence on the sensitivity and specificity.
The aims of this chapter are (1) to determine whether the proportion of normal and 
cancerous breast tissues within the field of optical biopsy influences the sensitivity 
and specificity of ESS, (2) to determine the sensitivities and specificities of ESS in 
detecting breast cancer at specific percentage field change and (3) to evaluate the 
impact, if  any, on the potential clinical application of ESS in the management of 
breast cancer.
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7.2 Methods
7.2.1 Patient selection and specimen handling
Female patients with proven invasive breast carcinoma by triple assessment 
undergoing mastectomy were recruited following informed and written consent 
(Appendix B). Following mastectomy, the surgical specimen was placed in a sterile 
plastic bag, which was subsequently sealed. The bag containing the specimen was 
then placed in a plastic container of ice. The specimen was taken immediately to the 
Department of Pathology where the specimen was processed.
The breast specimen was first coated with a blue-black colored dye and was then 
sliced using a knife. Each individual slice measured 1cm in thickness. An appropriate 
slice of breast tissue containing the breast tumour was selected for this study.
7.2.2 Spectral acquisition
The ESS system was set up as described in Appendix A. An area on the breast slice, 
which contained both the breast tumour and normal breast tissue, was selected for the 
study. A plastic grid with an 8 by 8 array of 2mm diameter holes (Figure 7.1) was 
placed over the selected area and was secured to the breast tissue with the application 
of pins into the tissue through the additional holes at the comer of the grid (yellow 
holes). ESS spectra were acquired systematically starting from the top left comer hole 
then across the top row then moving down to the next lower row. A maximum of 64 
spectra per grid were acquired. Following this, the specimen area was cut out into a 
separate tissue block using a scalpel and the slots in the plastic grid. The sides of the
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tissue block were colored using a different colored dye to allow histological 
correlation later. The different colours used for the side o f  the tissue block were 
recorded.
Figure 7.1: Diagram o f grid
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7.2.3 Histological correlation
The breast tissue block underwent standard histological processing. The surface 
where ESS spectra were obtained was sectioned, stained with H&E and mounted onto 
a glass slide. A transparent sheet with an 8 by 8-printed grid to scale was placed over 
the slide. The slide was orientated according to the colour coding o f  the original 
breast tissue block. Individual grid cells were reviewed by Dr Mary Falzon, consultant 
pathologist. Estim ated percentages o f  tumour, fat and normal breast tissue per grid 
cell w ere recorded and correlated to the corresponding ESS spectra.
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7.2.4 Spectral analysis
Spectral analysis using MBA as described in Section 3.5 was performed with different 
criteria for the selection of training and testing datasets (Analysis 2 and 3) in order to 
determine the sensitivities and specificities of ESS in detecting breast cancer at 
different percentages of field change. Because of the use of a grid system, there is a 
potential that spectra from a specific grid may have grid-specific characteristics. This 
could result in spectra being classified as normal or malignant breast tissue spectra 
based on the grid-specific characteristics rather than tumour-specific characteristics. 
The aim of Analysis 1 is to evaluate this possibility.
7.3 Analyses and Results
Data were obtained from 8 tissue blocks, which will be referred to as “Grids” for the 
purposes of simplicity. Each grid cell within each grid will be referred to as a “cell”. 
The paired ESS spectrum and corresponding histology of a cell will be referred to as a 
“dataset”.
Table 7.1 shows the breakdown of data. Some of the Grids have less than 64 datasets 
because some of the cells particularly at the edges of the grids were destroyed during 
histological processing. Therefore, ESS spectra with no corresponding histology were 
discarded. Grid 3 was taken from a smaller piece of tissue, and therefore only has 28 
datasets. Grids 5 and 6 were taken from the same patient, and Grids 7 and 8 were also 
taken from the same but a different patient. The number of categories describes the 
number of groups of datasets with different percentages of cancer replacement. Grid 8 
was taken from macroscopically normal breast tissue with no malignant tissue seen on 
histology and hence has only 1 category in Table 7.1.
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Table 7.1: Breakdown o f  g rid  data
1 60 2
2 64 15
3 28 10
4 64 12
5 58 14
6 57 13
7 64 4
8 64 1
The overall distribution of cells with different percentages of cancer is illustrated in 
Figure 7.2. The overall distribution is skewed as the majority of cells were normal 
without cancer (i.e. 0%). The distribution of other categories is not even. Within each 
grid, the distribution was also uneven (Figure 7.2 lower panel). For example, Grids 2, 
5 and 6 have significantly more cells with no cancer whilst Grid 4 has majority of 
cells with high percentages of cancer.
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Figure 7.2: Distribution o f  percentage cancer overall and within tumour grids 2. 3.
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(Tumours 1, 7 and 8 are omitted because they only have 2, 4 and 1 categories respectively.)
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Analysis 1: Analysis to determine the influence o f  grid-specific characteristics on 
spectral classification
Because of the variations among the grids in the distribution of cells with different 
percentages of cancer, there is a potential that this may influence subsequent analyses. 
The purpose for this analysis is to investigate the influence of patient grid-specific 
characteristics on spectral classification by determining whether spectral analysis can 
identify the correct patients grids from which spectra were acquired.
Standard principle components were calculated. Spectra were paired to the grid they 
were acquired (i.e. Grid 1) irrespective of the underlying histology. 60% of all the 
datasets were randomly selected as training set and the remaining 40% were used for 
testing. The analysis was repeated several times in a bootstrap manner to provide an 
average result, which is illustrated in Table 7.2. Sensitivity and specificity of a 
particular grid are defined as the sensitivity and specificity of spectra analysis in 
distinguishing spectra of that particular grid from all the rest in the testing set. For 
example, the sensitivity of 0.84 in Grid 8 means that the spectral analysis correctly 
classified 84% of Grid 8 spectra in the testing set as coming from Grid 8. Specificity 
of 0.97 means that spectra analysis correctly classified 97% of non-Grid 8 spectra in 
the testing set as non-Grid 8. The analysis showed that it is possible to classify spectra 
from Grids 1, 2, 3 and 4 according to their grid with good accuracy. However, the 
analysis found difficulty in discriminating the spectra between Grids 5 and 6, and 
between 7 and 8. In view that Grid 5 and 6 were specimens from one patient, and 
Grids 7 and 8 were another, this suggests that certain factors within the spectra that 
are specific to the particular surgical specimen or patient.
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Table 7.2: Results o f  A nalysis 1
1 60 1.00 0.00 0.99 0.00
2 64 0.99 0.00 0.99 0.00
3 28 0.96 0.01 1.00 0.00
4 64 1.00 0.00 1.00 0.00
5 58 0.86 0.01 0.99 0.00
6 57 0.83 0.01 0.98 0.00
7 64 0.81 0.01 0.97 0.00
8 64 0.84 0.01 0.97 0.00
In view of these findings, an investigation was carried out to identify the parts of the 
ESS spectra that are characteristic of the actual tissue specimen of the grids (i.e. 
individual patient) rather than to the underlying histology (i.e. cancer or normal). A 
mathematical model was created which calculated the variance within the spectra that 
were due to the actual tissue specimen (i.e. the patient grid) and the residual variance 
at individual wavelengths. The ratio of the residual variance and variance of the tissue 
specimen were plotted in Figure 7.3 (solid line). If the ratio is below 1 at a particular 
wavelength, this suggests that this part of the spectrum is influenced by the actual 
tissue specimen. This found that the part of ESS spectra between 510 and 660nm (the 
grey shaded area in Figure 7.3) is influenced mainly by the actual tissue specimen 
irrespective of the actual underlying histology.
Fieure 7.3: Study o f  variance to determine the area within ESS spectrum influenced 
by the actual tissue specimen
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Analysis 2: To determine the sensitivity o f  ESS in discriminating spectra taken from
cells containing between 1-80% cancer tissue
For this analysis, datasets from Grids 2, 3, 4, 5 and 6 were used because these grids 
contain a variety o f cells with different percentages of cancer. Datasets were grouped 
into the following: 0% (i.e. no cancer), 1-20%, 21-40%, 41-60%, 61-80 and 81-100% 
according to the percentage o f cancer detected by histology. MBA was performed 
using all 0% (51 datasets) and 80-100% (42 datasets) datasets for training. Once a 
LDA algorithm was established, the remaining datasets (1-20%, 21-40%, 41-60%, 61- 
80%) were used for testing. The results are illustrated in Table 7.3.
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Table 7.3: Results o f  A nalysis 2
1-20% 39 69% 39%
21-40% 28 91% 9%
41-60% 36 67% 33%
61-80% 39 96% 4%
This showed that sensitivity in detecting cancer is higher when the cell has a higher 
percentage of cancer. It is worth noting that there is no specificity in this analysis as 
all 0% (normal spectra) were used for training. A second analysis was also carried out 
using the same criteria except that the ESS spectra between 510 and 660nm (as 
identified in Figure 7.3) were excluded. The result is illustrated in Table 7.4 showing 
a slight improvement.
Table 7.4: Results o f  Analysis 2 with 510-610nm range o f  spectra excluded
1-20% 12% 28%
21-40% 91% 9%
41-60% 78% 22%
61-80% 96% 4%
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Analysis 3: MBA using 60% o f datasets randomly selected fo r  training to determine 
the sensitivity and specificity o f ESS in discriminating between the remaining 40% of  
datasets
For this analysis, datasets from Grids 2, 3, 4, 5 and 6 were used. Datasets were 
grouped into the following: 0% (i.e. no cancer), 1-20%, 21-40%, 41-60%, 61-80 and 
81-100% according to the percentage of cancer detected by histology. 60% of datasets 
from all groups were randomly selected for MBA. Once a LDA algorithm was 
established, the remaining 40% of datasets were used for testing. This analysis was 
repeated 100 times (“bootstrapping”) to give an average sensitivity and specificity for 
each group. The results are illustrated in Table 7.5a. As the figures are averages, the 
positive and negatives do not necessarily add up to 1. This shows that the average 
specificity is 74% (i.e. 0% datasets classified as negative). Between 1-20%, average 
sensitivity is 56% indicating that spectral analysis is poor at discrimination. However 
the average sensitivity increases as the amount of cancer increases. Table 7.5b showed 
a slight improvement when the ESS spectra between 510 and 660nm were excluded 
from analysis.
Table 7.5: Results o f  A nalysis 3 (a) w ithout and (b) with 510-610nm  ran2e o f
spectra excluded
(a)
0% 0.28 (0.02) 0.74 (0.02)
1-20% 0.56 (0.02) 0.44 (0.02)
21-40% 0.72 (0.02) 0.28 (0.02)
41-60% 0.60 (0.01) 0.40 (0.01)
61-80% 0.90 (0.01) 0.10(0.01)
81-100% 0.87 (0.04) 0.17(0.01)
(b)
0% 0.26 (0.02) 0.76 (0.02)
1-20% 0.60 (0.02) 0.40 (0.02)
21-40% 0.78 (0.02) 0.22 (0.02)
41-60% 0.69 (0.01) 0.31 (0.01)
61-80% 0.95 (0.00) 0.05 (0.00)
81-100% 0.90 (0.04) 0.14(0.01)
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7.4 Discussion
The original intentions for the grid system were to increase our collection of ESS 
spectra on breast tissues and to improve the correlation between ESS spectra and 
histology. Subsequently, this evolved to become a study to determine the minimal 
percentage of breast cancer present within the tissue that could be detected by ESS. 
This study has therefore provided further information and understanding into ESS in 
addition to the original objectives.
With the exception of Grid 8, the variety in the distribution of cells with different 
percentages of cancer among the grids was not intended. However, with Grids 2, 5, 
and 6 having more normal datasets and Grid 4 having more datasets with higher 
percentages of cancer replacement, this creates an interesting situation. Could this 
influence spectral classification i.e. can an ESS spectrum be classified as normal or 
cancerous based on which grid it came from? Do ESS spectra from a particular grid 
have some aspects in common and specific to that particular grid? Analysis 1 showed 
that this appears to be the case, and was particularly good at distinguishing the spectra 
o f Grids 1, 2, 3 and 4 from each other. It was less accurate in distinguishing spectra 
between Grids 5 and 6, and between Grids 7 and 8. Indeed, Grids 5 and 6 were taken 
from the same breast specimen of one patient, and Grids 7 and 8 were also taken from 
the same breast specimen but from a different patient. This suggests that certain 
aspects o f an ESS spectrum are specific to the tissue specimen rather than to the 
actual histology. These may be due to (1) patient factors (i.e. ESS spectra with 
characters specific to the individual patient or tumour), (2) technical factors (i.e. the 
set-up and functioning of the ESS system on the day), (3) specimen factors (i.e. 
specimen handling and timing of spectral acquisition) and (4) environmental factors
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(i.e. physical and laboratory conditions on the day). Subsequent analysis found that 
ESS spectra between 510 and 660nm showed patient grid-specific characteristics. As 
this spectra region is dominated by the absorption effects of haemoglobin, the 
oxygenation status of haemoglobin in the tissue may be responsible for the findings. 
However, this does not exclude patient, technical and environmental factors, and 
further investigations may reveal more information.
The limitation of the axillary lymph node study in Chapter 6 was that spectral 
analyses were performed using normal lymph nodes and lymph nodes with more than 
80% metastatic tumour replacement. Therefore, the 88% sensitivity and 96% 
specificity achieved was only for discriminating ESS spectra taken from an area of the 
lymph node with no or extensive metastatic cancer. Because it was not possible to 
correlate ESS spectra taken from areas with lesser metastatic tumour replacement 
with the underlying histology, it was not possible to assess sensitivity and specificity 
of ESS with partial metastatic replacement. An attempt to use the grid system on 
lymph nodes failed because histological processing of lymph nodes altered the shape 
of the lymph node significantly and it was not possible to correlate ESS spectra to the 
precise histology. However it was possible for primary breast tissue as in this chapter.
Analysis 2 is an extension of the lymph node study in Chapter 6. As in the lymph 
node study, only the datasets from normal breast tissue and tissue with extensive 
invasive ductal carcinoma were used for training. The testing set consisted of ESS 
spectra taken from tissues with variable amount of breast cancer. The result showed 
that ESS is able to detect cancer in spectra taken from areas with 1-20% tumour. The 
sensitivity and specificity improve where there is a higher proportion of cancer.
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The datasets used for training are as important as the actual process of spectral 
analysis. In Analysis 2, only datasets from normal breast tissue and tissue with 
extensive invasive ductal carcinoma were used showing good sensitivities. The 
purpose for Analysis 3 was to determine whether sensitivity and specificity can be 
improved with additional datasets from tissues with less extensive invasive ductal 
carcinoma. Unlike Analysis 2, datasets were randomly selected for training and 
testing with a 60/40 split, and analysis was bootstrapped (i.e. carried out 100 times 
with different random selections of training and testing datasets) (1) to provide an 
average sensitivity and specificity and (2) to negate the effect of a randomly selected 
training and testing sets with particular bias. The results showed reduced sensitivity 
for the detection of cancer by ESS in tissue which has between 1-20% cancer. 
However as with Analysis 2, sensitivity increases with more cancer within the field of 
ESS spectra.
The second parts of Analyses 2 and 3 attempted to determine the impact of the “grid- 
specific” part of ESS spectra. This was done by removing the part of the spectra 
between 510- 660nm from the analyses. In both cases, there were slight improvements 
in the sensitivities thus suggesting a minor effect.
The low ESS sensitivity in the 1-20% cancer group can be explained by the small 
amount of tumour resulting in no or insignificant changes in the elastic scattering and 
light absorption properties of tissue. However, another possibility is the position of 
the tumour tissue in relation to the optical fibres of the optical probe. Given that light 
has to propagate through the tissue from the delivery fibre to the receiving fibre of the 
optical probe, if the tumour is situated in this pathway, it is more likely to cause
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alterations in ESS spectra (Figure 7.4a) then otherwise (Figure 7.4b). If this is a 
contributory factor for the low sensitivity, then multiple receiving fibres surrounding 
the delivery fibre m ay improve sensitivity.
Figure 7.4: Illustration to demonstrate the influence o f the site o f tumour in relation 
to the path o f light (blue arrows)
(a) (b)
Delivery fibre
Receiving fibre
Breast cancer
Normal
The results o f  A nalyses 2 and 3 indicate that ESS has acceptable sensitivity to detect 
prim ary breast cancer when the field o f ESS interrogation contains 21% or more o f 
breast cancer. This would influence the potential applications o f ESS in the 
m anagem ent o f  breast cancer. W hether ESS has equivalent sensitivity in detecting
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metastatic breast cancer in lymph nodes needs further investigation. Assuming that 
this is possible, ESS has a potential role to play in the diagnosis and surgical 
management of breast cancer. These could involve (1) the optical diagnosis of breast 
cancer, (2) optical guided breast core biopsy, (3) intra-operative assessment of 
resection margins of breast cancer and (4) intra-operative assessment of SLN in breast 
cancer.
Table 7.7 illustrates the range of sensitivity and specificity of the various modalities in 
the diagnosis of breast cancer. Although this is a crude comparison of sensitivities and 
specificities, ESS appears to be comparable with other modalities. It is important that 
optical diagnosis should complement existing modalities without additional 
complexity, which can only result in unnecessary anxiety, excision biopsy and delay 
in breast cancer diagnosis. Therefore situations where optical diagnosis may be of 
benefit include remote areas where there are no radiological and pathological services. 
In this situation, the optical probe can be inserted into a breast through a hollow 
needle. ESS spectra can be taken and immediately analysed to provide the diagnosis 
or alternatively give an indication whether the lump contains suspected malignancy so 
that appropriate management can be arranged. Otherwise, optical diagnosis can be 
incorporated into other technologies such as mammary duct endoscopy. Optical 
probes can be miniaturized to fit into channels of the endoscope for this application. 
Obviously, the role of optical diagnosis in this situation requires further evaluation.
Table 7.6 Com parison o f  sensitivity  and specificity o f  various m odalities for breast
cancer diagnosis
Mammography1 72-94% 75-94%
Ultrasound2 86% 90%
MRI3 Near 100% Low
Scintimammography4 50-95% 58-100%
PET5 80-100% 80-100%
FNAC6 Absolute 57.1%* Complete 81% 58.4%
Core biopsy6 Absolute >76.4%* Complete 84.5% 81.2%
ESS 65-95% 76%
* Absolute sensitivity = number o f breast cancers with C/B 5 on FNAC/CNB x 100%
total number o f carcinomas undergoing FNAC/CNB
Complete sensitivity = number o f breast cancers with C/B 3. 4 and 5 on FNAC/CNB xl00%
total number o f carcinomas undergoing FNAC/CNB
ESS technology can also be incorporated into existing diagnostic modalities such as 
breast core biopsy. The biopsy needles can be manufactured with incorporated optical 
fibres. In this context, ESS could confirm the correct position of the biopsy needle.
The principle advantage is to minimize false negative core biopsies. In our institution,
ESS has been applied in gastro-intestinal endoscopy, although it is not yet firmly 
established.
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Resection margins in breast conservation surgery continue to be an important issue in 
the surgical management of breast cancer7,8. Although TIC has been shown to be 
useful for intra-operative assessment of resection margins9,10, it has not been widely 
practiced because of practicalities. At present, resection margins are assessed with 
histology. The limitations are (1) only a small area is actually assessed and (2) if the 
resection margin is positive, further resection would have to be carried out as a 
separate operation. ESS has a potential role in assessing resection margins in real time 
without the need of tissue preparation and pathological interpretation. Further margin 
resection can be undertaken to achieve complete resection at the same time if 
necessary. Although ESS sensitivity is poor when there is small amount (<20%) of 
cancer present, this should not be a significant issue as further resection is indicated 
when there is a moderate to extensive presence of cancer11. For focal or minimally 
involved margins, post-operative radiotherapy is adequate in the management. This 
was discussed in Chapter 2.
The value of intra-operative assessment of SLN was already discussed in Chapter 2 
and 6. If the sensitivity of ESS in detecting metastatic breast cancer in lymph nodes is 
equivalent to that in detecting primary breast cancer as demonstrated in this study, 
ESS has a definitive role in the intra-operative detection of SLN metastasis. Again the 
low ESS sensitivity when only 1-20% of cancer is present means that ESS is unlikely 
to detect micrometastasis. However, the optimal management of the axilla with 
micrometastic disease has not yet been established12,13 and randomised clinical trials 
are currently in progress to evaluate surveillance and axillary radiotherapy in place of 
ALND. As for larger SLN metastases where ALND is indicated, ESS is expected to 
be able to detect these lesions.
At present, spectral analysis is empirical as it is not completely known which 
histological and cytological features correspond to specific features of the ESS spectra. 
With better understanding of how ESS spectra are generated, more accurate spectral 
analysis can be produced.
7.5 Conclusion
This study has demonstrated:
• ESS spectra reflect both the characteristics of the 
underlying histology and of the individual tumour
• The individual tumour characteristics are in the spectral 
region between 520-660nm, which is dominated by the 
absorption properties of haemoglobin
• Sensitivity of ESS is greater when there is a higher 
percentage of cancer within the field of spectral acquisition
• ESS is able to detect breast cancer from areas with >20% 
tumour replacement with acceptable sensitivity
• ESS has potential clinical roles in the diagnosis and 
surgical management of breast cancer
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Chapter 8 Summary and Future Developments
8.1 Summary
The concept of ESS is relatively simple. Light entering tissue undergoes elastic 
scattering or absorption, which is dependent on the optical properties of the tissue. 
ESS is sensitive to those changes brought on by the malignancy. However, the 
eventual success and widespread clinical applications of ESS depend on various 
factors. These include scientific and technical development, validation of technology, 
intellectual rights, funding of start-ups, regulatory approval, physician adoption and 
social acceptance. This thesis has addressed a few of these aspects within the clinical 
setting of breast cancer.
Chapters 1 and 2 reviewed the current status in the diagnosis and surgical 
management of breast cancer. The sensitivities and specificities of various modalities 
for the diagnosis and detection of breast cancer were stated providing the basis for 
comparison with ESS. Chapter 3 provided a review of ESS which was pitched for 
clinicians. It also identified potential clinical applications of ESS in the management 
o f breast cancer. These include ESS guided percutaneous breast core biopsy, intra­
operative assessment of tumour excision margin and SLN for metastasis. Subsequent 
chapters were designed with these potential applications in mind.
Chapter 5 addressed the various technical issues involving the effects of ambient light 
intensities, tissue handling and formaldehyde fixation on ESS, which have not been 
investigated before. It found that ambient light can enter the ESS system. At ambient 
light intensities <10001ux (i.e. indoor or laboratory light intensity), the effect on the
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ESS spectra is unremarkable. At higher light intensities (i.e. beneath an operating 
lamp), the effects on ESS spectra becomes significant. However, the processes of 
spectral acquisition and standardisation can potentially resolve this effect as discussed 
in Section 5.2.4. Until this is fully investigated, spectra acquisition under strong 
ambient lighting (i.e. under an operating lamp or direct sunlight) should be avoided.
As for the effects of tissue handling, the changes observed in ESS spectra within the 
first hour following excision were related to the changes in oxygenation status of 
haemoglobin. Otherwise, there were no other changes to the ESS spectra irrespective 
of leaving the tissue specimen exposed in open laboratory conditions, chilled in ice or 
submersed in saline and formaldehyde during this time frame. However, significant 
changes in ESS spectra were observed gradually with formaldehyde fixation. Further 
studies are needed to clarify the effects of formaldehyde fixation in the first hour. 
Therefore, spectra acquisition from tissue specimens which have been submerged in 
formaldehyde is not recommended if spectra are intended for clinical use. In addition 
to technical issues, these studies demonstrated the reproducibility of ESS spectra, 
which is fundamental to the ESS concept.
Chapters 6 and 7 provided technical validation of the ESS concept and spectral 
analysis using MBA. In Chapter 6, ESS was applied to the detection of breast cancer 
metastasis in axillary lymph nodes. The “per spectrum” sensitivity and specificity 
achieved were between 88-90% and 91-96% respectively. The overall “per node” 
sensitivity was 89%. The “per spectrum” results are significant improvements from 
those achieved by Dr Briggs. This is primarily because of the improved correlation 
between spectra and histology, and the restriction in using only normal and metastatic
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lymph nodes with >80% metastasis. This chapter highlighted the importance of 
accurate histological correlation of the training and testing datasets. It also identified 
the importance of partial replacement by cancer within the area of spectral acquisition, 
which subsequently aided the development of the grid system in Chapter 7.
The comparative study of ESS and TIC in the second part of Chapter 6 was the first 
clinical study comparing ESS to other established clinical techniques. Although it was 
not prospective and has a relatively small numbers, it demonstrated that both 
techniques have similar sensitivity and specificity, and provides support for further 
studies.
In addition to a more accurate histological correlation, the grid system used in Chapter 
7 enabled the reporting of sensitivities at different percentage replacement by cancer 
within the area of spectral acquisition, which in turn allowed the evaluation of this 
issue. This found that the sensitivity of ESS increases (up to 96%) as the percentage 
of cancer replacement increases (Tables 7.3 and 7.5). The use of bootstrap and 
jackknife analyses provided more robust spectral analyses and in turn further 
technical validation to the spectral analysis. This provides a platform for further 
developments of spectral analysis. Furthermore, the reporting of sensitivities at 
different percentages of cancer replacement should be adopted as the standard format 
for reporting o f performance of optical biopsy technologies.
8.2 Future Developments
ESS is an exciting technology. As an emerging technology, further developments are 
essential in order to further the understanding of ESS and to improve its performance.
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Further scientific and technical developments such as statistical/mathematical aspects 
of spectral analysis and optical probe technology are necessary. However, these 
should be balanced with clinically orientated studies in order to address the clinical 
issues since the barrier for new technologies is often the end-users i.e. the clinicians. 
Several areas have already been identified and discussed such as the effect of strong 
ambient light intensities on spectral analysis and further formaldehyde studies. The 
development of spectral analysis systems for real time prospective studies is the most 
important of all for the ultimate clinical validation of ESS, to allow prospective 
comparisons with other modalities and to gain regulatory approval. Therefore, the 
expansion of datasets with accurate histological correlation for use as training data 
remains a top priority.
Societal acceptance of ESS technology is essential and the need for this should not be 
underestimated. Despite the advantages and safety of ESS, careful consideration is 
required when considering the potential clinical applications of ESS. It is important to 
appreciate that ESS should compliment or enhance the existing technologies and 
clinical practices without adding complexity or patient anxiety. In addition to 
assessing tumour excision margins and metastases, potential roles for ESS include 
guiding biopsies during endoscopy and surveillance of pigmented skin lesions.
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APPENDIX A
Optical Biopsy System 
Operating Manual
m edpptica
P rep ared  b y  A ndrew  C Lee
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Before sett ing off
Before setting off from the NMLC, it is advised to check that all equipment are 
complete in order to avoid unnecessary trips to collect forgotten items. The following 
is the check list:
In the computer bag: Computer, Power cable for computer, Foot switch, 
(Figure 1) Calibration pot, Optical probe
In the travel case: OBS, power cable for OBS
Figure 1: Equipment as packed in computer bag
Optical probe 
Calibration pot 
Power cable 
PC
Foot pedal
It is also important to check that the optical probe is functional. This is done by 
pointing the tip of the probe to a light source and checking that light is present at the 
connection point with good lamination (Figure 2). The optical probe is designed to 
have 2 optical fibres of different diameter.
Figure 2: Checking the optical probe
Tip of probe pointing to light 
source
Light from lamp fibre (larger 
diameter)
Light from detector fibre 
(smaller diameter)
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The OBS should be hand carried to avoid lose connection between the components 
within the OBS as the result o f bumpy pavements.
Setting up the OBS
The OBS should be set up within reach of power point. To avoid unintentional 
damage to the optical fibre by treading on or bending it, the OBS system and the fibre 
should not cause any obstruction. The OBS should be set up in the following steps:
1. Place the computer on top of the OBS
2. Connect the connection cable of the OBS to the interface card of the 
computer situated on the right hand side of the computer (Figure 3). 
Ensure that the white dot of the connection cable corresponds to the 
white dot on the interface card (Figure 4).
Figure 3: Interface card at side o f computer (Note the white dot (dotted circle))
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Figure 4: A tta c h in g  th e  c o n n e c tio n  cab le
3. Connect the OBS and computer to the power mains. If only one power 
socket is available, use it for the OBS. The computer can operate with 
its own power supply
4. Connect the optical probe to the OBS. Ensure that the lamp fibre is 
connected to the “Lamp” socket on the front of the OBS and the 
detector fibre to the “Dectector” socket (Figure 5). The lamp fibre has 
a larger diameter which is obvious when looking at the connection end 
of the optical probe whilst pointing the tip o f the probe to a light source
Figure 5: Connection sockets for optical probe
medOptica
5. Switch the computer on
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Setting up the software
Once the Microsoft Windows 98 is loaded, please follow the following steps:
1. Select the “Optical biopsy” icon
2. Select Bms2000
3. Select Bmsspec2.exe and a separate window opens
4. Under “LANL”, select “Use Standard Run Configuration”
5. Place the probe tip in the calibration pot with the lid on and keep the 
tip approximately 1mm away from the Spectralon
Figure 6: Calibration in progress
HHHI
6. Press “F5” on the keyboard to trigger the lamp to fire and a spectrum 
would appear.
7. Examine the overall pattern of the spectrum (Figure 7), which can be 
altered by dirt/blood at the tip of the probe.
Figure 7: Typical optical spectrum from spectralon
300
250 -
200  -
150 --
100  -
32 40 47 55 62 69 76 83 89
Wavg(p_ngth
8. Use alcohol wipes to remove any blood/dirt.
9. Once a satisfactory spectrum is obtained, press the button with the 
yellow light bulb in the tool bar and followed by the button with the 
blue R.
10. Note the “np” number at the bottom right of the screen. This is 
required for spectral analysis latter on.
11. To save optical spectra, select “LANL” and “File save option”
12. A separate window appears with two boxes. Enter the unique study 
number for your patient e.g. “L299”. In the second box, enter 11. Press 
return to exit. The first spectrum will be saved as L29911.
13. To use the foot pedal, connect the pedal (Figure 8)
Figure 8: Connecting the foot pedal
14. To enable auto save, select “Setup” option and then click on “Auto 
save on foot pedal”.
15. The OBS is now ready for use.
Acquiring spectral data
To acquire spectral data, the tip o f the probe must be in direct physical contact with 
the tissue concerned. Care should be taken not to apply too high a pressure onto tissue. 
Spectral measurement without saving is executed by pressing “F5” key or the foot 
pedal if  the latter is not set up to auto save. Spectral measurement with auto save is 
executed by pressing “F6” key or the foot pedal if  it is activated for auto save. The 
spectral number illustrated in the bottom of the screen indicates the spectral number 
of the next spectrum to be saved. It is generally advised to document the spectral 
number and the tissue specimen to ensure accurate correlation between spectrum and 
tissue histology. After the acquisition of spectra from
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After spectral acquisition, go back to BMS200 folder. Click on Data folder. Inside this 
folder are the saved spectra. In this folder create a folder and name it with your 
patient’s study number. Transfer all the spectra of this study into this folder so that it 
can be exported for analysis.
Packing up
To exit the Bmsspec2, simply close the window. Turn computer off. Disconnect the 
OBS. Do not eject the computer interface card especially if  the computer is still on. 
Ensure that all components are clean. Remove any blood/tissue fragments using 
alcohol wipes. To avoid any damage to optical probes, coil all fibres and place them 
in container bags. Pack all components into their appropriate carriers. Make sure 
nothing is left behind.
Probe care
Optical probes are very delicate and expensive. After use, please clean the entire 
length of the probe and the probe tip and connection ends with alcohol wipes. Do not 
use any abrasive materials to clean the ends.
Probes can be cleaned using the endoscopy wash cycle. The connection end must by 
outside the cleaning fluid. Staff at the endoscopy unit are happy to run the wash cycle 
for you.
For sterile probe, ethylene oxide is used. This is done by a commercial company in 
Scotland. The probe must be cleaned from physical dirt/blood/tissue, and placed in the 
instrument bags, which need to be sealed and sent via courier. The process takes 1 
week minimum. Please consult Dr Sandy Mosse.
If using the probe under sterile condition, the calibration pot must also be sterilized. 
This can be done by autoclave.
Further queries
If you have further queries, you can contact me (Andrew Lee) on 0788 755 0608 or 
via email: aclee@doctors.org.uk
APPENDIX B
CONFIDENTIAL 
PA T IE N T  I N  F O R M A  T IO N  S H E E T
OPTICAL BIOPSY FOR DIAGNOSIS OF LESIONS IN THE BREAST
Mr A Lee, MrMKeshtgar, Dr M Hall-Craggs, Prof S G Bown, Mr R Sainsbury,
Dr S Lakhani
We are sorry you have developed an area in your breast that needs investigation. The normal 
way to do this is to insert a thin needle into the suspicious area under local anaesthetic and remove a 
tiny piece o f tissue to examine under the microscope. Sometimes this is just done in the outpatient 
clinic and on other occasions some form o f imaging (usually an ultrasound scanner or a magnetic 
resonance (MR) scanner) is used to be sure the needle is in the right place. The tissue specimen is then 
processed and examined under a microscope. We are assessing a new technique known as “optical 
biopsy” which in due course, may be able to give an immediate answer, but at present we need to study 
how best to use it. We should like to ask you if  we could take optical biopsy measurements on your 
breast at the same time as a conventional biopsy so the results from the two can be compared.
The optical biopsy system is very simple in concept. A thin optical fibre (about the thickness 
o f a piece o f thread) is put down the needle used for the conventional biopsy and a short burst o f white 
light passed down the fibre. The diagnostic information is obtained by analysing the light that is 
reflected back up the fibre. The measurement only takes a few seconds and the power o f the light used 
is so low that it will not affect you in any way. Thus the optical biopsy will only increase the time o f  
your routine biopsy procedure by a few minutes and will not cause any additional discomfort.
If it is decided that you need an operation on your breast or your axilla (the area under your 
arm next to the breast), we should also like to take optical biopsy measurements during surgery on the 
tissues seen during the operation that are going to be removed, and then compare the results with 
microscopic examination o f  the tissues in the laboratory. One o f our research team will explain to you 
which areas we would like to measure in your case.
You do not have to take part in this study if  you do not want to. Please discuss it with anyone 
you wish before making a decision. If you decide to take part, you may still withdraw at any time 
without giving a reason. Your decision whether to take part will not affect the rest o f your care and 
management in any way. If you agree to take part, we will ask you to sign a consent form. All 
proposals for research using human subjects are reviewed by an ethics committee before they can 
proceed. This proposal was reviewed by the joint UCL/UCLH committees on the ethics o f Human 
Research.  
Supplementary information sheet
Principal investigator: Prof SG Sown.
Other investigators: Mr A Lee, Mr M Keshtgar, Dr M Hall-Craggs, Mr R Sainsbury,
Dr S Lakhani
As this research programme is being funded by the United States Army Medical Research and 
Materiel Command (USAMRMC) as part o f a major research programme on the diagnosis and 
treatment o f breast cancer, we are asked to provide further specific information to you before you agree 
to participate in the study.
Naturally, you will not be asked to pay any costs in relation to this study. We are not able to 
pay you for your participation, but we will reimburse you for any out o f pocket travel expenses 
incurred if  you make additional visits to this hospital solely related to your participation in this study. 
Should you be injured as a direct result o f participating in this research project, you will be provided 
medical care, at no cost to you, for that injury. You will not receive any injury compensation, only 
medical care. You should also understand that this is not a waiver o f  your legal rights. You should 
discuss this issue thoroughly with the principal investigator before you enroll in this study. If there is 
any possibility that you might be pregnant, you should not volunteer for this study. A urine pregnancy 
test will be done prior to treatment, and you will be excluded if  the results are positive.
Representatives from the US Army Medical Research and Materiel Command or the Food and 
Drug Administration may inspect the records o f the research in their duty to protect human subjects in 
research. By enrolling in this study, you should understand that the United States Army Medical 
Research and Materiel Command (USAMRMC) will collect certain information about you, including 
your name, address, study name and dates. The purpose is, first, to readily answer an individual's 
questions about their participation in research sponsored the USAMRMC; and second, to ensure that 
the USAMRMC can exercise its obligation to ensure research volunteers are adequately warned o f  
risks and to provide new information as it becomes available. The information will be retained in this 
database for a minimum of 75 years. All information obtained in this database is protected under the 
Privacy Act o f 1974. Personal identifying information may not and will not be released unless the 
subject (or legal guardian) provides written approval o f such disclosure. Each subject on whom data 
are collected, upon written request to Human Subjects Protection Division, Office o f the Deputy Chief 
o f  Staff for Regulatory Compliance and Quality, USAMRMC may have access to their record, and 
only their record, contained in the database.
In the event o f a research related injury, you should contact any o f the investigators at the 
National Medical Laser Centre, Institute o f Surgical Studies, 67-73 Riding House Street, London 
W1W 7EJ.  
 Any questions on subjects rights should be addressed to UCL/UCLH 
Committee on the Ethics o f Human Research, Chairman - Professor A Maclean, UCLH NHS Trust, 1st 
Floor Vezey Strong Building, 112 Hampstead Road, London NW1 2LT.  
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C O N F I D E N T I A L  
PA TIENT CONSENT FORM
OPTICAL BIOPSY FOR DIAGNOSIS OF LESIONS IN THE BREAST
Mr A Lee, Mr M  Keshtgar, Dr M  Hall-Craggs, Prof S G Bown, Mr R Sainsbury,
Dr S Lakhani
Have you read the information sheet about this study? YES/NO
Have you had the opportunity to ask questions and discuss this study? YES/NO 
Have you received satisfactory answers to all your questions? YES/NO
Have you received enough information about this study? YES/NO
My questions concerning the study has been answered by
 (Doctor's name)
I understand that I am free to withdraw from the study at any time without giving a reason 
and withdrawal from the study will not affect my routine care and management. I agree to 
take part in this study.
Patient
signature:.......................................................................... Date......................................................................................
Please print name and 
Address ...................
Witnessed: ....................................................................... Date,
Please print name
(doctor)........................................................................................
Investigator: Date,
